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ABSTRACT 
The role of MRI after preoperative treatment of rectal cancer is unclear. This thesis 
investigates its diagnostic relevance in patient management. 
 
Matching pathology with MR images aimed to characterise post treatment rectal cancer 
appearances on T2 weighted MRI and verify the proposed MRI tumour regression grading 
system(mrTRG). Correlation of post-chemoradiation mrTRG, T stage(ymrT), N 
stage(ymrN) and Circumferential Resection Margin(ymrCRM)  with histopathological T 
stage(ypT), N stage (ypN),  and pathological CRM(pCRM) was investigated. These 
parameters were also compared against survival outcomes.  
  
The alternative response assessment methods of tumour volume and length change/RECIST 
as well as mrTRG and ymrT were evaluated against pathology. The accuracy and 
reproducibility of MRI parameters in assessing rectal cancer response to neoadjuvant 
chemotherapy was also investigated.  
 
Patients with good response to chemoradiation(assessed by mrTRG) were enrolled into a 
deferral of surgery trial. Serial MRI-based monitoring enabled evaluation of quantitative 
imaging methods such as Apparent Diffusion Co-efficient (ADC) measurements in 
distinguishing tumour vs. complete response. 
 
Pathological fibrosis correlated with low signal on MRI, tumour was intermediate signal.  
mrTRG showed good diagnostic accuracy against ypT&pTRG,  ymrT‘s diagnostic 
accuracy was fair but  improved when grouped into favourable and unfavourable 
categories. MRI Length&volume assessment were less consistently related. Negative ymrN 
and potentially clear ymrCRM correlated well with their respective pathological endpoints. 
Importantly, mrTRG and ymrCRM involvement predicted survival outcomes. 
 
mrTRG showed good diagnostic accuracy against pTRG when assessing neoadjuvant 
chemotherapy response, ymrT correlated less well. Overall mrTRG and ymrT were the 
most reproducible parameters. ADC values were significantly lower in patients with tumour 
vs. complete response with ADC measurement of <1.3X10
-3
/mm
2
/sec associated with 
tumour regrowth in 86% of cases. 
 
mrTRG and MRI CRM assessment appear the most important post treatment imaging 
parameters.  Grouped ymrT may also be useful. These parameters could be used by the 
multidisciplinary team to tailor treatment pre-operatively.  
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1 Background and Literature Review 
1.1 Introduction  
Colo-Rectal cancer is the third most common form of cancer in the UK, with 33000 new 
cases every year (accounting for 12% of all new cancers) (Office for National Statistics 
2011). It is the second commonest cause of cancer-related mortality, responsible for more 
than 16,000 deaths per year, or 10% of the total (Koh, Brown et al. 2005). Rectal tumours 
have a relatively poor prognosis due to the high risk of metastases and local recurrence. 
Total Mesorectal Excision (TME) is the surgical treatment of choice  as it gives the best 
chance of a tumour-free circumferential resection. TME involves complete removal of the 
rectum and surrounding mesorectal fat by sharp dissection along the investing mesorectal 
fascia (Heald and Ryall 1986). 
 
High resolution pelvic magnetic resonance imaging is a well validated tool for the baseline 
staging of rectal cancer. The plane for TME excision, the circumferential resection margin 
(CRM), is well demonstrated on MR. Studies have demonstrated that 94% of patients with 
MRI predicted negative CRM had tumour free resection margins on histopathological 
examination (MERCURY 2006). In the 20-30% of patients which have involvement of the 
CRM on baseline MR imaging there is a high likelihood of not achieving curative 
resection. This group of patients is offered preoperative chemo radiation therapy (CRT) in 
many UK centres. This approach has been shown to reduce the recurrence rate from 8.2% 
to 2.4% at 2 years (Kapiteijn, Marijnen et al. 2001). 
 
At present after CRT patients undergo surgery at a date determined at the beginning of each 
case, often without restaging imaging.  However there is increasing interest that imaging 
can be used to restage disease post CRT, and used to tailor treatment.  Histopathologists 
have reported in up to 25% of patients no residual tumour is seen on pathological 
examination. i.e. a complete response of a locally advanced tumour to neo-adjuvant CRT 
(O'Neill, Brown et al. 2007). Identification of such excellent response as well as poor 
response prior to definitive surgery is an important goal- excellent responders may be 
offered less radical treatment, and poor responders could be considered for more radical 
surgery or second line chemo-radiotherapy (Habr-Gama, Perez et al. 2004). 
 
This thesis investigates several approaches to accurately restage residual tumour/ fibrosis 
post CRT. The background for this thesis explores the current standard of care and what is 
known regarding the restaging of rectal cancer: 
 
1.2 Pathological staging of rectal cancer. 
1.3 Baseline MRI staging of rectal cancer with MRI. 
1.4 Surgery. 
1.5 Neoadjuvant treatment.  
1.6 Pathological staging of rectal cancer post chemoradiation. 
1.7 Restaging of rectal cancer post chemoradiation. 
1.8 Clinical importance of restaging rectal cancer. 
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1.2 Pathological assessment of rectal cancer 
1.2.1 Morphological pathological description of rectal cancer 
 
Rectal and rectosigmoid cancer account for up to 50% of all large bowel cancers. The 
majority; 60% of colorectal cancers are moderately differentiated adenocarcinomas with the 
remaining approximately 20% well differentiated and 20% poorly differentiated (Jass, 
Atkin et al. 1986).   
 
Rectal tumours commonly arise from pre-existing mucosal adenomas that develop 
increasing degrees dysplasia from mild to severe. Such adenomas may be polypoid or flat 
and have a tubular or villous configuration. Macroscopically rectal tumours commonly 
appear as an ulcerating tumour with a central depression and raised rolled edges.  When 
these tumours encompass the full circumference of the bowel wall forming an annular 
growth, they produce marked stricturing of the bowel lumen increasing the risk of bowel 
obstruction or perforation. Ulcerating tumours, even when a relatively small size, may 
produce a stricture causing stenosis.   (Cohen, Brown et al. 1981; Bjerkeset, Morild et al. 
1987; Michelassi, Leuthner et al. 1987).  
 
A fairly well circumscribed border is commonly seen when rectal tumours invade through 
the bowel wall into perirectal fat. However, in 25% of cases the pattern of spread is widely 
infiltrative with ill-defined borders. This infiltrative pattern of spread has been shown to 
worsen prognosis (Grinnell 1966; Spratt JA 1967; Jass, Atkin et al. 1986).  Conversely, the 
presence of an inflammatory response at the advancing margin of the tumour has been 
observed as a favourable prognostic feature (Jass, Atkin et al. 1986; Halvorsen and 
Thompson 1989).   
 
Colorectal tumours, unlike upper gastrointestinal tumours, rarely show submucosal or 
intramural spread beyond their macroscopic borders.  This characteristic is important in the 
surgical planning of resection margins (Hughes 1983; Madsen and Christiansen 1986; 
Andreola, Leo et al. 1997).  
 
1.2.2 Mucinous tumours 
 
Pathologically mucinous tumours are defined as a tumour containing >75% mucin and 
form a distinct subgroup of rectal tumours.   Mucinous tumours have a gelatinous 
appearance caused by secretion of mucus by tumour cells causing the formation of pools/ 
lakes of extracellular mucin, lined by columns of malignant cells, cords and vessels. This 
gives an overall meshlike internal structure (Secco, Fardelli et al. 1994). 
 
Mucinous tumours  account for 10% of carcinomas of the large intestine and represent a 
poor prognostic subgroup (Sasaki, Atkin et al. 1987). The 5-year survival for mucinous 
carcinomas has been recorded at 11% versus 57% for nonmucinous carcinomas. The reason 
for this difference maybe because mucinous rectal carcinomas are usually diagnosed at a 
more advanced stage due to a greater tendency to infiltrate diffusely (Pihl, Nairn et al. 
1980). 
 20 
1.2.3 Pathological assessment 
 
Most laboratories  use a similar protocol for specimen processing;  A freshly resected 
specimen is initially opened anteriorly, pinned on to a board, and fixed in 10% formalin. 
Dissection is then performed and generally consists of serial 5-10 mm slicing of the whole 
tumour and the surrounding mesorectum in the transverse plane.  
 
The  maximum  extent  of  tumour  spread  from  the  outer  limit of the muscularis propria  
is  measured  by  ruler, this  measurement is to  the  edge  of  tumour's  greatest  distance  of  
penetration  from  the  muscular wall,  be  it  direct,  discontinuous,  vascular   or  lymph  
node  involvement. Area(s)  of  involvement  can  usually  be  seen  by  naked  eye  and  
any  suspicious areas are sampled  for  histology. The slice containing the most lateral 
spread is identified as the "primary slice" and is selected for division into blocks which are 
all embedded and processed for haematoxylin and eosin (H&E) staining. Sometimes one 
block is sufficient but up to six can be needed in cases with extensive spread. On average 
four blocks suffice for the majority of tumours. Remaining slices are wholly embedded for 
single large-mount sections of the tumour and mesorectum, cut at 10 pxn on a sledge 
microtome, and stained with H&E.  The  circumferential  resection margin  of  the  block  is 
marked  with  India  ink  to  demarcate  it  on  histology  and  rule  out  false  positive  
tumour involvement  of  a  tissue  margin  caused  by  poor  embedding practice (Quirke, 
Durdey et al. 1986). 
 
The rest of the specimen both above and below the tumour is then serially sliced. While 
incising the mesentery and mesorectum, lymph nodes and tumour deposits are identified 
and sampled. Metastases and lymph nodes  adjacent to  the circumferential margin  are  
sampled en-bloc with  the  resection  margin again  identified  by  painting  with  India ink.  
 
1.2.4 Pathological national minimum dataset for colorectal cancer 
 
In the UK the Royal College of Pathologists has developed a national minimum dataset for 
the reporting of colorectal cancer. The dataset has been approved by all the professional 
bodies in the UK concerned with treating colo-rectal cancer. The reporting proforma is 
shown in Figure 1.1. The adoption of a proforma has been shown to increase the 
completeness of the reporting. The following sections give background on the different data 
recorded (Quirke and Morris 2007). 
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Figure 1.1. Minimum pathology reporting dataset 
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1.2.5 Pathological T staging in rectal cancer 
 
Historical perspectives 
 
In 1932 Cuthbert Dukes proposed the first recorded staging system for colo-rectal cancer 
based on analysis of 215 patients. Three stages of disease were defined: 
 
A: Cancer limited to the rectal wall. 
B: Spread of the cancer into extrarectal tissues but no nodal involvement. 
C: Lymph node involvement present. 
 
Later studies showed statistically significant differences in post operative survival with   
three-year survival of 80%, 73% and 7% for groups A, B and C respectively (Dukes 1932.). 
In subsequent years, the Dukes system was further modified, in 1954 Astler and Coller 
noted statistically significant differences in overall survival between different depths of 
tumour penetration. They proposed subdivision of Duke‘s C cases into C1 and C2 to 
underline the importance of the degree of local tumour extension in the presence of 
involved lymph nodes. This is shown in Table 1.1. (Astler and Coller 1954). 
 
Table 1.1. Astler and Coller‘s Modification of the Dukes‘ staging system 
Stage Histopathology definition Five year overall survival 
A Lesion limited to the mucosa 100% 
B1 Lesion involving the submucosa or muscularis 
propria but not beyond it 
66.6% 
B2 Lesion beyond the muscularis propria 53.9% 
C1 B1. With nodal metastasis 42.8% 
C2 B2. With nodal metastasis 22.4% 
 
The TNM staging system 
 
In 1985, a general staging system for solid organ cancers of all sites was jointly proposed 
by the American Joint Committee on Cancer (AJCC) and the Union Internationale Contre 
le Cancer (UICC).  The TNM system maps the anatomical extent of the malignancy using: 
 
Size and extent of the primary tumour (T), 
The absence or extent of regional lymph node metastasis (N),  
The presence or absence of distant metastasis (M).  
 
A higher numerical value (ranging between 0 and up to 4) is given the greater the extent of 
the cancer in each of the TNM categories.   Various TNM groupings are divided into stages 
(Stage I to IV) based on prognosis.  
 
The TNM staging system is revised every five years by a group of experts appraising recent 
clinical trials. In clinical guidelines TNM is linked to treatment approaches, therefore 
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changes to the TNM classification have important implications for patient care. The most 
recent TNM 7 system was released in 2010 and is detailed in table 1.2. 
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Table 1.2. Definitions of TNM components in the 7th edition of the AJCC system for staging cancer 
of the colon & rectum, 2010  
Category Description 
Tx The primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ (intraepithelial or intramucosal carcinoma) 
T1 Tumour invades into the submucosa 
T2 Tumour invades into the muscularis propria 
T3 Tumour invades through the muscularis propria into the subserosa, or into non-
peritonealised pericolic or perirectal tissues 
Optional subdivision of T3: 
 
T3a  Minimal invasion: <1mm beyond the border of the muscularis propria 
 
T3b  Slight invasion: 1-5mm beyond the border of the muscularis propria 
 
T3c  Moderate invasion: ≥5-15mm beyond the border of the muscularis propria 
 
T3d  Extensive invasion: ≥15mm beyond the border of the muscularis propria 
     
T4 Tumour directly perforates the visceral peritoneum (T4a) or invades into other organs 
or structures  (T4b) 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 
 
Metastatic tumour in 1 to 3 pericolic or perirectal lymph nodes 
N1a  Metastasis in one regional lymph node  
 
N1b  Metastasis in 2–3 regional lymph nodes 
 
N1c  Tumour deposit(s) in the subserosa, mesentery, or nonperitonealised pericolic or 
perirectal tissues without regional nodal metastasis  
 
N2 Metastatic tumour in 4 or more pericolic or perirectal lymph nodes 
N2a  Metastasis in 4–6 regional lymph nodes  
 
N2b  Metastasis in 7 or more regional lymph nodes 
Mx The presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis present 
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Table 1.3. Overall 7
th
 Edition TNM staging summary from the American Joint Committee on 
Cancer 
Stage    
0 Tis   N0 M0 
I T1      N0      M0 
 T2       N0 M0 
IIA T3 N0   M0 
IIB T4a   N0       M0 
IIC T4b     N0   M0 
IIIA T1-2           N1/N1c      M0 
 T1   N2a      M0 
IIIB T3-T4a       N1/N1c      M0 
 T2-T3         N2a   M0 
 T1-T2         N2b     M0 
IIIC T4a    N2a      M0 
 T3-T4a       N2b     M0 
 T4b     N1-N2         M0 
IVA Any T         Any N          M1 
 
T staging 
 
The TNM system for staging cancer of the colon and rectum was originally devised to 
correspond directly with the original Dukes system (Dukes 1932.): Stage I, Dukes A; Stage 
II, Dukes B; Stage III, Dukes C with Stage IV corresponding to the presence of distant 
metastases.  However with periodic review and new prognostic outcome data the latest 
(7th) revision, published in 2010 is much changed from this original template.  Current 
TNM staging criteria is shown in Table 1.2. The TNM classification is the standard for 
colorectal cancer staging, recommended in the UK by the Royal College of Pathologists 
and in the USA by College of American Pathologists.  
 
Both T1 and T2 tumours have high 5-year survival rates.  TNM 6&7 suggested an optional 
sub-classification of T3 tumours according to measured depth of extramural invasion. A 
four tiered subclassification was proposed (≤1mm; 1-5mm; ≥5-15mm; ≥15mm). This was 
to address the wide range of survival reported in patients with T3 tumours, which make up 
80% of those seen in clinical practice (Wittekind, Henson et al. 2003).   
 
T3 subdivision is carried out as follows: the sections are first examined microscopically for 
lateral circumferential resection margin involvement. If the margin is clear, the extent of 
extramural spread is measured from the muscularis propria to the outermost part of the 
tumour; if mesorectal tumour or lymph node deposits are present the measurement is made 
to the outer border of the deposit. As well as indicating T substage this enables detection of 
surgical margin involvement (Quirke, Durdey et al. 1986). 
 
A T4a tumour was classified in TNM 5&6 as a tumour directly invading other organs, 
while a T4b tumour invaded the visceral peritoneum. This sub-classification was reversed 
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in TNM 7  and has been suggested to be more intuitive, with the invasion of the peritoneal 
surface- despite the risk of transcoelomic metastasis- representing a less advanced stage 
than direct organ invasion (Doyle and Bateman 2012). 
 
Lymph Node Involvement 
 
Assessment of positive lymph nodes 
 
 Upon retrospective review of 379 histological sections from patients with rectal cancer  
Jass et al identified lymph node involvement as one of four pathological variables that 
independently affected long-term cancer-associated mortality. The other three variables 
included; invasive margin, peritumoural lymphocytic infiltration, and local spread (T stage) 
(Jass, Love et al. 1987). Such studies lead the 5&6 editions of the TNM classification to 
subdivide stage III patients according to the depth of tumour penetration and the number of 
proven lymph nodes; with N1 indicating 1 to 3 involved pericolic or perirectal lymph nodes 
and N2 indicating involvement of 4 or more lymph nodes. 
 
More recently a Surveillance, Epidemiology, and End Results (SEER) analysis of over 
35,000 patients with rectal cancer stratified N1 and N2 disease as follows: N1a/N1b (one 
vs. two-three nodes) and N2a/N2b (four-six vs. seven nodes).  A statistically significant 
difference in 5-year survival was shown between patients with one positive node (N1a) and 
those with two to three positive nodes (N1b). Furthermore patients with four to five 
positive nodes (N2a) have a better prognosis than patients with seven positive nodes (N2b) 
(Gunderson, Jessup et al. 2010). The latest, 7
th
 edition of the TNM staging system (Table 
1.2) incorporates these changes. 
Number of lymph nodes excised 
Detection of metastatic deposits in lymph nodes is improved by examining multiple 
pathological sections (Messerini, Cianchi et al. 2006).  This has been supported by several 
studies concluding that a high nodal harvest is related to improved survival in both stages II 
and III disease (Puppa, Sonzogni et al. 2010).  In the UK, the Royal College of pathologists 
recommends examining a minimum of 12 nodes (Sobin and Greene 2001).  
As well as macrometastatic nodal disease, small deposits of tumour cells, less than 2 mm in 
diameter can also be found in regional lymph nodes. These have been defined as nodal 
micrometastases. Micrometastases are only seen in a small minority of nodes using routine 
H&E stains with immunohistochemical techniques using monoclonal antibodies targeting 
specific proteins shown to be more sensitive (Puppa, Sonzogni et al. 2010). 
 
The significance of micrometastases is debatable with some studies suggesting they may 
not affect survival as they are biologically distinct from macrometastases because they lack 
their own blood supply (Schofield, Mounter et al. 2006). The present TNM 7
th
 edition 
classifies nodal micrometastasis as N1 disease, with the number of lymph nodes involved 
by micrometastasis to be clearly stated  
 
 27 
1.2.6 Controversies between different TNM editions 
 
1.2.6.1 Extramural Tumour deposits 
 
Tumour deposits are discrete nodules of adenocarcinoma deposited in pericolonic and 
perirectal fat. Their prevalence ranges from 6% to 64%. The presence of extramural 
deposits implies that cancer cells have spread discontinuously, presumably via lymphatic 
/venous channels. Such aggressive tumours have a poorer prognosis, irrespective of other 
factors (Ono, Yoshinaga et al. 2002). 
 
1.2.6.2 Extramural Venous invasion 
 
Extramural venous invasion has been demonstrated in 10 to 22% of post operative 
specimens in colorectal cancer (Shirouzu, Isomoto et al. 1991; Saclarides, Bhattacharyya et 
al. 1994). Shirouszu   upon prospectively reviewing postoperative specimens of 645 
patients with  colorectal cancer found the degree of pathological vascular invasion 
influenced the likelihood of liver metastasis and survival.  For example in patients with 
Dukes' stage C, survival was 77% for slight vascular invasion; 56% for moderate, and 44% 
for marked venous invasion.  A similar relationship was seen for Dukes A and B. 
Extramural venous invasion  has also been found to be significantly associated with the 
likelihood of nodal dissemination (Saclarides, Bhattacharyya et al. 1994).  
 
1.2.6.3 Extramural Tumour deposits definition in TNM classifications 
 
Satellites of tumour within the mesorectum have generated a great deal of interest and 
controversy. Extramural/Peritumoural deposits have been recognized as an entity since at 
least 1935, when Gabriel et al noted their existence (Gabriel and Bussey 1935). The source 
of such deposits is uncertain as there is no associated lymph node architecture, making their 
optimum classification unclear. Some authors suggest that they derive from vascular 
metastases that grow through the vessel wall and into the surrounding tissue, while others 
suggest they represent direct extension from the adenocarcinoma or completely replaced 
lymph nodes (Goldstein and Turner 2000). 
 
TNM 4&5 
 
Up to and including the 4th TNM edition in 1992, it was left to the pathologist to determine 
whether peritumoural satellites represented  of T, N or venous invasion (Hermanek 1993).  
The TNM 5 system (1997) defined discrete tumour cell collections in the perivisceral fat 
≤3mm in size as primary tumour and tumour cell collections in the perivisceral fat >3mm 
as nodal disease. This was based on a study that was not subsequently published.  
Extramural vascular invasion was defined as ―tumour present within an extramural 
endothelium lined space surrounded by either a rim of muscle of contains red blood cells‖ 
(Williams, Quirke et al. 2007) 
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TNM 6 
 
Subsequent work by Goldstein et al showed that increasing peritumoral deposit size  was 
associated with decreased survival and  deposits of any size, including those less than 3 mm 
in maximum dimension, had a significantly worse survival relative to the absence of 
deposits (Goldstein and Turner 2000). Therefore in TNM 6 (2002), the size criteria was 
replaced  with shape, with a  nodule in the perivisceral fat considered as venous invasion if 
the nodule was irregular in contour and as lymph node metastasis if the nodule was smooth 
in contour. Venous invasion was coded as an extension to T stage. 
 
The TNM 6 definition has been shown to be poorly reproducible. A study by Howarth et al 
asked 23 pathologists to assess extramural nodules in 80 cases according to TNM 6. The 
interobserver agreement was marginal at 0.36. Importantly 5 of the 80 cases were upstaged 
from N0 to N1 and would therefore have been offered adjuvant chemotherapy (Howarth, 
Morgan et al. 2006). Furthermore recent data has shown that the shape of tumour deposits 
is not related to their origin, and that the use of this criteria has less prognostic value than 
the 3 mm rule (Nagtegaal, Tot et al. 2011). 
 
TNM 7 
 
Further changes were proposed in TNM 7 (2010); with lymph node metastasis defined by 
the reporting pathologist as a node completely replaced with tumour (generally having a 
smooth contour) while nodules  with an irregular contour are placed in a new N1c category, 
(stage III disease) (Quirke, Cuvelier et al. 2010). Given these distinctions are at the 
discretion of the reporting pathologist the definition has been suggested to essentially revert 
back to the TNM 4 criteria (Sobin, Compton et al. 2010). As noted by Ricci, some 
inconsistencies ensue; for example, the N status of a patient with tumour deposits only 
would be N1c, whereas a case with tumour deposits and 1 to 3 positive “true” lymph 
node(s) would paradoxically “regress” to N1a/b (Ratto and Ricci 2011).  
 
The TNM 7 definition has been considered by some to be poorly reproducible (Nagtegaal 
and Quirke 2010) and shown to offer no significant improvement in prognostic value over 
TNM5 (Ueno, Mochizuki et al. 2012). This has lead to several leading pathologists to 
continue to use the TNM 5 criteria (Nagtegaal and Quirke 2010). For example the UK 
Royal College of pathologists use TNM 5 in the in the minimum dataset, stating this 
criteria  is quantitative and can be used as a starting point to test  hypotheses in clinical 
trials (Quirke, Cuvelier et al. 2010). 
 
New proposals 
 
A study by Ueno investigating the impact of peritumoural deposits on survival has 
suggested a revised classification based on peritumoral deposit origin. On retrospective 
review pathological samples of 1027 patients, 205 patients were found to have peritumoural 
deposits.  Deposits were classified as according to contour (TNM 6 criteria) as well as 
vascular invasion (confined to a vascular space), non vascular invasion, or aggressive non 
vascular invasion (defined as invasion by a tumour deposit into adjacent vessel/nerve). The 
hazard ratios for patients with smooth and irregular contour deposits were 3.5 and 3.9 
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respectively.  Vascular invasion, non vascular invasion and aggressive non vascular 
invasion had hazard ratios of 2.5, 4.7 and 8.0 respectively (Ueno, Mochizuki et al. 2007).   
 
By using the Akaike information criterion, N staging was found to predict survival outcome 
with the highest accuracy when both nodal involvement and non-vascular deposits were 
combined together as an N factor and vascular invasion was treated as a T factor (Ueno, 
Mochizuki et al. 2007). Given the poor prognosis of patients with aggressive non vascular 
deposits Puppa et al has proposed  assigning these lesions to the M category as in-transit 
metastases of colorectal cancer  (Puppa, Sonzogni et al. 2010). 
 
1.2.7 Tumour involvement of the Circumferential Resection Margin (CRM) 
 
When the surgically excised specimen is sectioned transversely, the lateral border of the 
specimen is termed the circumferential resection margin. One of the main predictors of 
postoperative recurrence is involvement of the operative circumferential resection margin 
due to lateral spread of the tumour.  A positive circumferential resection margin (CRM) is 
defined as tumour within 1mm of the edge of the resected specimen. 
 
The importance of CRM involvement was first described by Quirke et al in a study of 52 
patients. Spread to the lateral resection margin was noted in 14 /52 patients and 12 of these 
proceeded to local pelvic recurrence (Quirke and Dixon 1988). In a further prospective 
study of 190 patients with rectal cancer, Cox's regression analysis showed tumour 
involvement of the circumferential margin (tumour within 1mm of the CRM) 
independently influenced both local recurrence (HR=12.2 (4.4-34.6)) and survival (HR=3.2 
(1.6-6.53)), (Adam, Mohamdee et al. 1994).  
 
In Quirke et al‘s initial study, each tumour was embedded in its entirety with preparation of 
multiple wholemount blocks.  Quirke later showed that visual inspection of the 
macroscopic slices was sufficient to select sections with suspected CRM involvement 
(Quirke and Dixon 1988; Adam, Mohamdee et al. 1994). This has also proved to be 
reproducible in other institutions (de Haas-Kock, Baeten et al. 1996). Therefore, CRM 
involvement became an important addition to the pathological staging of rectal cancer. 
 
There is a relationship between the CRM status and the height of the tumour, with low 
rectal cancers having higher risk of positive CRM (25.9% versus 16.5% in a series by 
Kapiteijn et al) (Kapiteijn, Marijnen et al. 2001), with subsequent significant increase in 
local recurrence (Nagtegaal, van de Velde et al. 2002).  Currently, a distal resection margin 
of at least 2 cm from the cancer is regarded as standard, though given the relative rarity of 
distal intramural spread, a 1 cm margin as standard has also been proposed (Pricolo, 
Abodeely et al. 2010).  This is important in surgical planning for low rectal cancer, where 
options include a low anterior resection (with an anastomosis potentially in the anal canal) 
or an abdominoperineal excision with stoma formation. 
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1.3 Baseline staging of rectal tumours with MRI 
Two main imaging techniques have been investigated for staging rectal cancer pre-
operatively. They are endoluminal ultrasound (EUS) and MRI. Both techniques can 
differentiate tumour from the normal rectal wall (unlike CT). Studies have shown that MRI 
depicts anatomy beyond the immediate vicinity of the rectum more accurately than EUS 
(Blomqvist, Machado et al. 2000; Brown, Davies et al. 2004). 
 
1.3.1 Normal bowel wall 
The rectal wall in anatomical cross section comprises the mucosal layer, the muscularis 
mucosa, submucosa and muscularis propria which is turn comprises the circular and 
longitudinal layers. 
 
T2-weighted imaging sequences depict the rectal wall anatomy clearly. The MRI 
appearances of the bowel wall show the mucosal layer as a fine low signal line on T2 
weighted imaging, beneath the mucosa lies the thicker higher signal submucosal layer. The 
muscularis propria is represented by an intermediate hypointense layer. The outer 
longitudinal muscle layer of the muscularis propria can have an irregular grooved 
appearance with interruptions due to vessels entering the rectal wall. The perirectal fat 
appears hyper intense (Brown, Richards et al. 1999). 
 
1.3.2 MRI  morphological description 
Rectal tumours have two common macroscopic appearances on MRI. One appearance is 
that of an ulcerating tumour with raised rolled edges and a central depression (figure 1.2).  
If these tumours grow to involve the full bowel wall circumference, they produce marked 
stricturing - increasing the risk of bowel obstruction.  Exophytic or polypoidal tumours 
have a distinctive protuberant morphology with a tumour mass projecting into the lumen 
(figure 1.3). Several studies have indicated that polypoidal lesions are often of a relatively 
low grade of malignancy (Cohen, Wood et al. 1980; Michelassi, Ayala et al. 1991). 
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Figure 1.2. Semi-Annular tumour 
Axial T2 weighted fast spin-echo image (A) and corresponding histological (H&E stained) 
wholemount section (B) demonstrating a semiannular plaque of tumour with central 
ulceration (arrowhead) and raised rolled edges (arrows). 
 
A)                                    B) 
 
 
Figure 1.3. Polypoid tumour 
High resolution T2 weighted fast spin-echo image (A) and corresponding histological 
(H&E stained) wholemount section (B) demonstrating a T1 polyp (long arrow). There is 
partial preservation of the submucosal layer (short arrow) seen as a thin rim of high signal 
intensity deep to the tumour.  
 
A)                          B) 
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1.3.3 Mucinous versus non mucinous tumours 
 
As previously mentioned, mucinous tumours form a distinct subgroup of tumours. Non 
mucinous rectal tumours are generally intermediate signal intensity on T2 weighted 
imaging, with higher signal intensity than the circular and longitudinal muscle layers but 
lower signal intensity than the submucosa.  
 
Mucinous rectal tumours have much higher signal intensity on the T2-weighted images 
compared to both muscle and fat as shown in figure 1.4. This was quantified by Hussain et 
al, showing that 9 patients with pathologically proven mucinous rectal tumours had 
significantly higher tumour to muscle, tumour to fat, and tumour to urine signal intensity 
ratios compared with the 17 patients with nonmucinous tumours (Hussain, Outwater et al. 
1999). 
 
Figure 1.4. Mucinous tumour 
High resolution axial T2 weighted fast spin-echo image demonstrating an advanced 
predominantly high signal mucinous tumour (long arrow). Short arrows show the potential 
circumferential resection margin.  
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1.3.4 MRI prediction of extramural spread / T-Stage 
 
MRI based T staging is based on the degree to which intermediate tumour signal invaded 
the different layers of the bowel wall. MRI based T staging is summarised in Table 1.4 
(Iafrate, Laghi et al. 2006). 
 
Table 1.4. MRI based T staging of rectal tumours 
 
Tumour 
stage. 
Imaging criteria. 
T1 Tumour signal intensity is confined to the submucosal layer. The signal 
intensity is low compared to the high signal intensity of the adjacent 
submucosa. 
T2 Tumour signal intensity extends into the muscle layer, with loss of 
interface between the submucosa and circular muscle layer. 
T3 Tumour signal intensity extends through the muscle layer into the 
perirectal fat, with obliteration of the interface between muscle and 
perirectal fat. 
T4 Tumour signal intensity extends into an adjacent structure or viscus. 
 
A T3 tumour is characterised by the muscularis propria being totally disrupted, with tumour 
invading through the muscular layer and into the perirectal fat. Early T3 tumours, T3a and 
T3b extend less than 1mm and 1-5mm beyond the border of the muscularis propria 
respectively.  More advanced T3 tumours, T3c and T3d, extend 5-15mm or greater than 
15mm beyond the muscularis propria, these tumours carry a far worse prognosis than 
T3a/T3b tumours and are associated with high rate of both local and systemic failure. The 
T3 subdivision is illustrated in figure 1.5. The subdivision matches the pathological 
subdivision of T3 tumours proposed by Herminak (Hermanek, Henson et al. 1993.). 
 
Baseline T staging of rectal tumours using the MRI criteria above has shown good 
correlation with pathology. In a prospective study by Brown et al 98 patients undergoing 
surgical excision were assessed by preoperative high-resolution MRI for T N stage and 
depth of extramural tumour spread. The MR images were compared with histopathological 
findings by carefully matching whole-mount sections of the surgical specimen.  Good 
agreement between pathology and MRI assessment of T-stage (weighted κ=0.67), as well 
as between MRI assessment of nodal status (weighted κ =0.68) was observed (Brown, 
Radcliffe et al. 2003).  
 
 
 
 
 
 
 
 34 
Figure 1.5. Summary diagram of T staging 
 
 
 
T1 - Tumour signal intensity confined to the submucosal layer.  
T2 - Tumour signal intensity extends into the muscle layer. 
T3 - Tumour signal extending beyond the muscularis propria.  
T4 - Tumour signal extending through the peritoneum of into an adjacent organ. 
 
Figure 1.6. T3a tumour 
A) Thin section T2 weighted axial MR image shows a T3a rectal cancer, with extension of 
less than 1mm beyond the muscularis propria (curved arrow).  
The invasive margin is at the 11‗o‘clock position. 
B) Photograph of a section of the explanted rectum shows tumour invasion at the 11 ‗o‘ 
clock position (curved arrow). 
 
A)                                                         B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 35 
Figure 1.7. T3b tumour 
 
A) Thin section T2 weighted axial MR image shows a T3b rectal cancer (curved arrow), 
with extension of approx 3mm beyond the muscularis propria.  
B) The invasive margin is at the 4 ‗o‘clock position. Photomicrograph (Original 
magnification X 0.4, haematoxylin-eosin (H-E) stain) shows tumour (curved arrow) 
extending beyond the muscularis propria (arrowheads). 
 
A)                    B) 
 
 
Figure 1.8. T3c tumour 
 
Thin section T2 weighted axial MR image shows baseline images of a T3c rectal cancer 
with tumour invasion at the 6 ‗o‘clock and 10 ‗o‘clock positions (curved arrows).  
There is 10 mm and of 8mm invasion from the muscularis propria respectively. 
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Figure 1.9. T3d tumour 
 
A) Thin section T2 weighted axial MR image shows baseline image of a T3d rectal cancer 
with tumour invasion at the 7 ‗o‘clock position (curved arrow). The arrowhead indicates the 
muscularis propria. There is greater than 15 mm of invasion beyond the muscularis propria.  
B) Photomicrograph (Original magnification X 0.4, haematoxylin-eosin (H-E) stain) shows 
tumour (arrow) extending beyond the muscularis propria (arrowheads). 
 
A)                   B) 
 
 
 
 
 
1.3.5   Tumour height and MRI assessment of the potential circumferential resection 
margin (CRM) 
 
The mesorectum is a discrete anatomical unit composed of the rectum, perirectal fat, blood 
vessels, nerves and lymphatic vessels. A layer of fibroareolar tissue called the mesorectal 
fascia surrounds the mesorectum and forms the potential operative circumferential resection 
margin (CRM) (Heald 1988). On MRI imaging the CRM is a fine linear structure 
enveloping the mesorectal compartment harbouring the rectum and perirectal fat which 
appears hypointense on T2 weighted MR images.  
 
Knowledge of tumour extension to the potential circumferential resection margin (CRM) is 
important as the multidisciplinary team may offer preoperative chemoradiation   in an 
attempt to bring about tumour regression away from the margin. The plane of surgical 
excision may also be widened. 
 
Studies have proposed different cut-off values for the distance of tumour to the mesorectal 
fascia which best predicts CRM status. Original studies suggested that CRM status could be 
predicted with a high degree of accuracy and consistency when a cut-off of 5mm measured 
distance to the CRM was used (Beets-Tan, Beets et al. 2001). Larger, more recent studies, 
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have shown a smaller distance. Brown et al's prospective study involving 98 patients 
undergoing pre-operative MRI staging, predicted positive CRM status when tumour was 
identified by MRI within 1mm of the mesorectal fascia. Comparison with histology showed 
excellent (92%, κ=0.81) agreement. (Brown, Radcliffe et al. 2003). Figure 1.4 shows a 
mucinous tumour with potential CRM involvement at 12‘o‘ clock. 
 
The height of a tumour is given using sagittal images, with the distance from the anal verge 
to the lower edge of the tumour recorded. The rectum is divided into low tumours (≤5cm 
from the anal verge) (figure 1.10), mid rectal tumours (5-10cm from the anal verge) and 
high tumours (10-15cm from the anal verge). The length of a tumour is also measured on 
sagittal images. 
 
Assessment of tumour height is important as low rectal tumours lie below the puborectalis 
sling and at this level the total mesorectal excision plane is defined as the space between the 
muscle coat of the rectum becoming the internal sphincter and the fibres of the puborectalis 
sling which merge with the external sphincter fibres. Therefore at this level tumour 
invading the intersphincteric plane (figure 1.11) or extending to within 1mm of the levator 
muscle is considered to potentially involve the CRM (Shihab, Moran et al. 2009) (Figure 
1.12). 
 
Figure 1.10. Low rectal tumour 
  
A) Axial T2 weighted MRI image at the level of puborectalis (arrowhead). A T1 tumour 
(arrow) is shown. The tumour is predominantly intramural with likely invasion of the 
submucosa.  
B) Axial T2 weighted MRI post treatment. There is a low signal scar at the 12 ‗o‘clock 
position (arrow), with normal submucosa seen. The puborectalis is indicated by arrowhead.  
 
A)                 B) 
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Figure 1.11. Low rectal tumour with potential resection margin involvement 
 
A) Baseline Axial T2 weighted baseline MR image shows a semiannular infiltrating tumour 
between 7‘o‘clock-9‘o‘clock. The tumour extends extramurally (arrow)  and extends up to 
the left levator muscle (arrowhead). The potential resection margin is therefore threatened. 
B) Same patient as A, Baseline Coronal T2 weighted image shows extramural tumour 
extension (arrow) up to the left levator muscle (arrowhead). 
 
A)                  B) 
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1.3.6 Peritoneal reflection involvement 
 
The anterior wall of the upper rectum is covered by the peritoneal reflection. On sagittal 
MRI images the peritoneal reflection appears as a low signal intensity linear structure that 
extends over the surface of the bladder and can be traced posteriorly to its point of 
attachment onto the rectum. On axial images the peritoneum attaches in a V-shape onto the 
anterior aspect of the rectum. This appearance has been characterised as the ―seagull‖ sign 
(Taylor, Swift et al. 2008). 
 
The typical appearance of peritoneal reflection involvement on MRI is one of nodular 
intermediate signal intensity extending into the fine low signal intensity peritoneal 
reflection at or above the level of its attachment to the anterior rectum surface.(Smith, 
Barbachano et al. 2008). Such tumours are staged as T4a (figure 1.12).  
 
Figure 1.12. Peritoneal infiltration 
 
A) Axial T2 weighted MR images shows tumour (open arrow) demonstrated on the surface 
of the peritoneal attachment (white arrow)  
B) Corresponding histological (H&E stained) wholemount section demonstrating  tumour 
(open arrow), infiltrating the peritoneal reflection (not shown). 
 
A)                                                               B) 
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1.3.7 MRI assessment of lymph nodes 
 
The identification of tumour infiltration into lymph nodes is important for two main 
reasons: Firstly, the number of involved lymph nodes at baseline predicts postoperative 
survival (Gunderson, Jessup et al. 2010).  Secondly, defining an involved lymph node near 
the mesorectal fascia will often lead to change of treatment approach to ensure adequate 
tumour clearance. For example, the multidisciplinary team may offer neoadjuvant 
preoperative therapy to induce nodal regression or the standard potential circumferential 
resection plane could be altered.   
 
The ability to predict lymph node status prior to surgery is a major challenge for 
radiologists as involved nodes may be normal sized and only contain microscopic tumour. 
Initial investigations focused on defining nodal size criteria with cut-off values for nodal 
positivity ranging from 3mm to 10 mm (Zerhouni, Rutter et al. 1996; Vogl, Pegios et al. 
1997).  More recent investigations have shown no particular size cut-off is useful in 
predicting nodal status.  Brown et al carefully matched and compared the axial pre-
operative MRI images with transversely sectioned histopathology specimens in an analysis 
of 437 lymph nodes harvested from 42 post operative specimens. This study showed  the 
diameters of benign and malignant nodes were similar (Brown, Richards et al. 2003). 
 
The same study also demonstrated that intranodal signal heterogeneity (mixed signal) was a 
highly specific discriminant and also reported a very high specificity (98%), and moderate 
sensitivity (75%) of lymph node border characteristics in MR images. Combining the two 
measures, with suspicious lymph nodes defined having an irregular border or mixed signal 
intensity (figure 1.13), greater accuracy was achieved, with sensitivity of 85% and 
specificity of 97% (Brown, Richards et al. 2003). 
 
MR imaging using ultra-small particles of iron oxide (USPIO) contrast agent has shown 
promise in identifying very small (>1mm) tumour foci within lymph nodes. Following 
administration of USPIO malignant nodes (confirmed by pathological correlation) had an 
eccentric and uniform high signal intensity, while benign/ reactive nodes showed uniform 
or central low signal intensity patterns (Koh, Brown et al. 2004).  
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Figure 1.13.  Morphological criteria for nodal assessment at MR imaging 
 
A) T2-weighted MR imaging showing a node (circled) with irregular outline and 
heterogeneous signal intensity.  
B) H&E histological slide confirms the lymph node is infiltrated by malignancy with 
extracapsular extension of disease.  
 
A)                     B) 
 
1.3.8 MRI assessment of extra mural venous invasion (EMVI) 
 
Extramural venous invasion is defined by the
 
presence of malignant cells within endothelial 
cell lined
 
blood vessels beyond the muscularis propria. On T2 weighted MRI EMVI is 
characterised as causing expansion and irregularity of venules adjacent and contiguous to 
the primary tumour. A similar T2 signal intensity as the primary tumour is seen in the 
involved vessels  (Brown, Radcliffe et al. 2003).  
 
A recent EMVI scoring system has been developed, with 0, indicating no features 
suggestive of extramural vascular invasion and the
 
maximum score of 4 assigned when 
overt features such as irregular vessel border are seen.  The system  predicts  survival, with 
Smith et al‟s  univariate analysis  showing a 35% 3 year relapse free survival  for  patients 
with an MRI EMVI score of 3-4, compared with 74 per cent for those with a score of 0-2 (p 
< 0.001) (Smith, Barbachano et al. 2008).  
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1.4 Rectal cancer surgery 
1.4.1 Total mesorectal excision 
 
Total mesorectal excision (TME)  involves sharp dissection along the plane that separates 
the visceral from the parietal layer of the perirectal pelvic fascia. This allows the radical 
removal of the rectum within the surrounding mesorectum (Heald, Husband et al. 1982). 
 
Mid to low rectal tumours undergo total mesorectal excision with division of the rectum 
within centimetres of the anal canal. After the rectum has been removed circular staples are 
used to anastomose the anus to the sigmoid.  Very low resections with primary anastomosis 
are generally covered by a defunctioning loop ileostomy or colostomy. The surgery enables 
en bloc removal of rectum and its draining lymph nodes while enabling anal sphincter and 
autonomic nerve preservation. 
 
Given most rectal tumours are limited to within the mesorectal ‗packet‘, the rate of CRM 
positivity and local recurrence is much lower when TME is performed.  However, if   
tumour grows up to or through the mesorectal fascia the CRM may still be positive. 
Therefore the significance of CRM status as a prognostic factor is not diminished by TME. 
 
1.4.2 Abdominoperineal excision 
 
Abdominoperineal excision is used for very low rectal cancers when the distal resection is 
insufficient to allow re-anastomosis. The same dissection in the mesorectal plane is 
performed from above with perineal dissection (excision of the anus) being carried out 
from below. A permanent end colostomy is created in the left iliac fossa from the proximal 
sigmoid colon. Recent muscle flap techniques using  gluteal, gracilis and vertical rectus 
abdominis flaps have  improved perineal wound healing rates when compared with primary 
closure of the perineal wound (Palmer, Vernon et al. 1983; Chessin, Hartley et al. 2005).  
 
1.4.3 Timing of surgery 
 
The Lyon R90-01 trial compared surgery at 2 vs. 6 weeks post radiotherapy completion. 
The longer interval group (6 weeks) had better tumour response (53. 1% in the 2 week 
group vs. 71.7% in the 6 week group, p=0.007)  and pathological downstaging (10.3% in 
the 2 week group v 26% in the 6 week group, p=0.005)   
 
As a consequence, surgery at 6 weeks after completion of radiotherapy has become the 
standard of care (Francois, Nemoz et al. 1999). Extending the interval to surgery beyond 6 
weeks has been speculated to increase the proportion of tumours downstaged by 
preoperative treatment, and is the subject of debate (Evans, Tait et al. 2011). 
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1.5 Neo Adjuvant treatment 
1.5.1 Importance of local recurrence 
 
Patients with rectal cancer have a relatively poor survival when compared to those with 
colonic tumours. This has been attributed to both metastatic disease and the increased 
tendency for local recurrence. In the 1970-1980s the rate of recurrent disease in the surgical 
bed or in adjacent pelvic organs was as high as 25-40%. (Chung, Stryker et al. 1983). The 
incidence of local recurrence in more recent trials is far lower (5-15% in the Swedish rectal 
cancer trial). This is due to improved surgical techniques such as TME and targeted 
radiation/chemoradiation to reduce local recurrence (Swedish Rectal Cancer Trial 1997). 
 
1.5.2 Pre versus Post operative treatment 
 
Radiation therapy seeks to eradicate peripheral microscopic tumour foci in the peritumoural 
tissue. The addition of chemotherapeutic agents such as fluorouracil and leukovuerin to 
preoperative radiotherapy has been shown to increase the proportion of tumours 
downstaged, as well as reduce local recurrence rates (Gerard, Conroy et al. 2006). Current 
British Medical Journal guidelines recommend Fluorouracil / Fluorouracil and Folinic acid 
/ Capecitabine (BMJGuidelines 2012) 
   
An important study Sauer et al randomised patients with locally advanced (T3/greater 
and/or Node positive) rectal cancer between pre and post operative chemo-radiotherapy. 
Improved local control and decreased toxicity was found in the preoperative chemo-
radiotherapy group, but no survival difference was seen (Sauer, Becker et al. 2004). 
Therefore preoperative treatment is used in most centres in preference to postoperative 
therapy. 
 
1.5.3 Selection of patients for neoadjuvant treatment 
 
1.5.3.1 Surveillance, Epidemiology, and End Results (SEER) data 
Many centres in the United States offer preoperative CRT to patients with T3 or Node 
positive disease (i.e. AJCC stage II and III disease). This approach is based on SEER data 
detailing decreased overall survival with increasing T stage and nodal stage; T stage results; 
5 year OS: T2N0, 78% vs. T3N0 64%; N stage results; 5 year OS T3N0, 64% vs. T3N1, 
52.4% vs. T3N2, 37.5% (Gunderson, Jessup et al. 2010). MRI based staging is not 
widespread in the USA, with many centres preferring a combination of endoscopic 
ultrasound and clinical assessment. 
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1.5.3.1 MRI based selection –Poor prognosis tumours 
 
MRI staging has enabled the development of criteria for pre-operative therapy based on 
imaging findings. An example of selection criteria for poor prognosis tumours is found in 
the recent UK based EXPERTc trial (Comparing Oxaliplatin (Eloxatin), Capecitabine 
(Xeloda) and pre-operative radiotherapy with or without Cetuximab followed by total 
mesorectal excision).  The MRI based inclusion criteria was: CRM involved or threatened, 
T3 low lying tumour at or below the levators (i.e. low rectal tumours, where the resection 
margin is closer to the rectum), tumour extending 5 mm or more into perirectal fat (T3c or 
above), tumour invading surrounding structures or peritoneum (T4), and T1-4 N2 tumours 
(Chau, Brown et al 2006). 
 
1.5.3.1 MRI based selection –Intermediate  prognosis tumours 
Intermediate tumours do not show potential CRM involvement on baseline MRI, several 
other parameters are used to define this group. Parameters include the presence of 
extramural venous invasion (3 year relapse-free survival, 35% vs. 74.1%;  p< 0.001), as 
well as extramural spread of tumour beyond 5 mm (5 year disease specific survival, 54.1% 
vs. 85.4%;  p< 0.0001) (Smith, Barbachano et al. 2008). In the United Kingdom The 
National Institute of Clinical Excellence has suggested  >T3b / Nodal involvement / 
Vascular invasion as  criteria for intermediate prognosis, see Table 1.5 (NICE 2011).  
1.5.4 Short course radiation Vs. Long course chemoradiation 
While few would disagree with maximal preoperative long course chemoradiation therapy 
for tumours invading local structures and most consider neoadjuvant therapy unnecessary 
for very early T1 or T2 cancers, there is considerable variation in treatments offered to 
intermediate prognosis patients.  
In general, intermediate risk rectal cancer patients are offered either preoperative short 
course radiotherapy or long course chemoradiotherapy (CRT) followed by TME surgery. 
Short course radiotherapy uses 25 Gy in 5 fractions while long-course treatment uses a 
higher dose of 50.4 Gy in 28 fractions and is combined with chemotherapy. Both long 
course chemoradiation and short-course radiotherapy has been shown to reduce local 
recurrence versus surgery alone (Kapiteijn, Marijnen et al. 2001; Sauer, Becker et al. 2004).   
 
The choice between preoperative CRT and short course radiation is a subject of debate. 
Two randomised studies have compared preoperative CRT with preoperative short course 
radiation using the inclusion criteria of T3 or node positive disease. Bujko et al randomised 
316 patients with adenocarcinomas above the anorectal ring.
 
Over a median follow-up of 48 
months no significant differences in local control or survival were observed (Bujko, 
Nowacki et al. 2006).  Similarly, Ngan et al randomised 326 patients with T3 any N rectal 
cancer to short course versus CRT. Again no significant differences in 3 year local 
recurrence (8% vs. 4%) or 5 year survival (74% vs. 70%) were seen (Ngan 2010). Sphincter 
function results were not presented in either trial.  
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Interim results from the ongoing Stockholm III trial are similar, with no significant 
difference between pathological response rates between short course radiotherapy with 
surgery after 4-8 weeks and long-course radiotherapy with surgery after 4-8 weeks. The full 
results of this study are awaited (Pettersson, Cedermark et al. 2010). 
 
The data has lead to some UK, Northern European and Scandinavian centres using short 
course treatment for intermediate risk rectal cancer patients. For example, the UK NICE 
guidelines recommend short course treatment in intermediate risk rectal cancer, but long 
course treatment in those with intermediate/high risk tumours (NICE 2011). However, 
many centres in the United States use CRT, as short course treatment ―cannot be safely 
combined with adequate doses of systemic concurrent chemotherapy, and, as currently 
designed, it does not increase sphincter preservation.‖ (Minsky 2011).  
 
Table 1.5. Treatment of rectal tumours, NICE guidelines (NICE 2011) 
 
Prognosis Characteristics of rectal 
tumours predicted by MRI 
Treatment recommendations 
Poor 
prognosis. 
High risk of 
local 
recurrence. 
A threatened (< 1 mm) or 
breached resection margin or 
Low tumours encroaching 
onto the inter-sphincteric 
plane or with levator 
involvement 
Offer preoperative chemoradiotherapy 
with an interval before surgery to 
allow tumour response and shrinkage 
(rather than short course 
radiotherapy), to patients with high-
risk operable rectal cancer. 
 
Intermediate 
Prognosis. 
Moderate risk 
of local 
recurrence. 
Any T3b or greater, in which 
the potential surgical margin 
is not threatened or 
Any suspicious lymph node 
not threatening the surgical 
resection margin or 
The presence of extramural 
vascular invasion 
Consider Short Course Preoperative 
Radiotherapy then immediate surgery 
for patients with moderate-risk 
operable rectal cancer.  
Consider preoperative 
chemoradiotherapy with an interval to 
allow tumour response and shrinkage 
before surgery for patients with 
tumours that are borderline between 
intermediate and poor prognosis. 
 
Good 
prognosis. 
Low risk of 
local 
recurrence. 
T1 or T2 or T3a and 
No lymph node involvement 
Do not offer short-course preoperative 
radiotherapy or chemoradiotherapy to 
unless as part of a clinical trial. 
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1.5.5 ―Good‖ prognosis tumours 
―Good‖ rectal tumours have very low local recurrence rates and high cure rates after TME 
surgery. A recent analysis of patients treated by TME surgery classified good prognosis 
tumours as T1-T3b, irrespective of nodal status. Such patients had a 5 year overall survival 
of 68%, disease free survival of 85% and local recurrence rate of 3% (Taylor, Quirke et al. 
2011).  NICE has adopted a more selective definition of T1-T3a with no lymph node 
involvement.  
Experimental treatments for early stage tumours are aimed at rectum preservation with 
subsequent improved quality of life. Such treatments include transanal local excision and 
transanal endoscopic microsurgery (TEM) with or without preceding chemoradiotherapy 
(Zeestraten, Kuppen et al. 2012).  In TEM surgery, the margin of excision around the 
tumour is marked using cautery, the lesion excised and the wound sutured. Most local 
excision procedures are carried out on tumours <3 cm in diameter, involving <30% of the 
bowel circumference and histologically moderately or well differentiated. 
A meta-analysis conducted in 2011 of the available trials suggests TEM has fewer 
complications but a higher local recurrence rate (12%) compared with standard surgery 
(0.5%) with no difference in survival advantage (Wu, Wu et al. 2011).   The local failure 
rate for TEM is likely to be due to false negatives from both MRI and endoscope ultrasound 
in the identification of involved mesorectal lymph nodes. Furthermore endoscopic 
ultrasound evaluation of tumour invasion depth in villous lesions has been reported at 60% 
due to difficultly in assessment of large villous lesions (≥20 mm wide, ≥5 mm high) 
(Konishi, Akita et al. 2003).  Therefore, at present TEMS surgery is considered if the 
patient is unfit for TME surgery or chooses TEMS while understanding the risks of 
recurrence (BMJGuidelines 2012). 
 
Several pathological studies have shown pT1 and pT2 tumours which show deeper invasion 
into the submucosa (SM3), lymphovascular invasion (Nascimbeni, Burgart et al. 2002) or 
poor differentiation
 
 carry a significantly greater rate of lymph node involvement 
(Tominaga, Nakanishi et al. 2005). Therefore if post procedure pathology shows a poorly 
differentiated tumour/lymphovascular invasion or tumour 1mm from the margin (i.e. pT2 
tumour) then further surgery/radiotherapy/CRT is necessary.  
A further alternative approach for this group of patients is to perform a local excision 
intended as a ―full-thickness excisional biopsy,‖ which allows complete pathologic 
examination of the entire specimen. If histological findings are favourable (low risk T1), 
close observation by endoscopy and endorectal ultrasonography can be offered, while a 
deeper stage or any unfavourable pathologic features (high risk T1), could prompt radical 
resection,
 
 or neoadjuvant CRT (Pricolo 2011). 
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1.5.6 Adjuvant chemotherapy 
 
Current UK guidelines recommend patients with high risk stage II disease (presence of T4 
disease, high grade tumour or extramural vascular invasion) and all stage III disease (T1-4 
N1/2 M0) are offered adjuvant chemotherapy. This approach is based on studies such as the  
QUASAR trial, which showed a  small significant 5 yr survival benefit of  3–4% for those 
patients with pathological stage II (T1-4 N0) rectal cancer treated with adjuvant 5-FU-
based chemotherapy (Gray, Barnwell et al. 2007).  A recent Cochrane meta-analysis of 21 
randomised controlled trials comparing patients receiving adjuvant chemotherapy (n=4854) 
to those observed (n=4367) supported the use of 5-FU based postoperative adjuvant 
chemotherapy. A significant reduction in the risk of death (17%) among patients 
undergoing postoperative chemotherapy as compared to those undergoing observation was 
found (HR=0.83, CI: 0.76-0.91) (Petersen, Harling et al. 2012).  
 
Chemotherapy options include fluorouracil/folinic acid/ FOLFOX 4 (Oxaliplatin, Folinic 
acid, bolus Fluorouracil) /Capecitabine. The use of FOLFOX 4 and Capecitabine in this 
setting is based on extrapolation of data from colon cancer studies (BMJGuidelines 2012). 
 
1.5.7 Patient selection for neoadjuvant treatment in The Royal Marsden Network 
 
The treatment algorithm presented in figure 1.14 is the current the standard of care in The 
Royal Marsden cancer network. This algorithm classifies patients according to the presence 
of four factors on baseline staging MRI:  the extent of extramural spread of tumour, the 
relation to the mesorectal fascia, the presence of 4 or more lymph nodes and the presence of 
extramural vascular invasion.   The inclusion criteria used for preoperative treatment in the 
4 studies used in this thesis vary and are detailed in the relevant chapter. 
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Figure 1.14.  Selection of patients for neoadjuvant treatment at The Royal Marsden 
Colorectal network 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjuvant chemotherapy if pathological stage III or high risk selected stage II patients. 
 
1.5.8 Neoadjuvant chemotherapy prior to chemoradiation 
There are several potential uses for neoadjuvant chemotherapy in the treatment of rectal 
cancer.  
The first approach is neoadjuvant chemotherapy pre/post chemoradiation. A recent 
systematic review included 16 studies using chemotherapy as induction to CRT and 5 
studies investigating chemotherapy post CRT as consolidation.  The addition of 
neoadjuvant chemotherapy as induction to chemoradiation did not appear to increase 
pathological complete response rate, or negative pathological CRM rates (Glynne-Jones, 
Anyamene et al. 2012).  However, in some of the included studies rates of grade 3 or 4 
toxicity were significantly different (19% induction arm vs. 54% adjuvant arm, p= 0.0004)  
(Fernandez-Martos, Pericay et al. 2010). Therefore neoadjuvant chemotherapy appears 
Primary surgery (TME) 
Consider local excision 
if unsuitable for 
surgery. 
T3c or greater >5mm 
OR N2 
OR EMVI + 
AND CRM clear. 
 
T1-T3b AND 
N0/N1 AND 
EMVI – AND 
CRM clear. 
 
Rectal cancer assessed by MRI. 
Good risk. 
 
 
 
 
Locally advanced.  
High risk of distant 
failure.  
Low risk of local 
recurrence. 
 
 
High risk of local 
recurrence +/- distant 
failure. 
 
 
Potential CRM + 
disease. 
Neoadjuvant chemoradiation.  
With TME surgery 6 weeks after completion of 
chemoradiation. 
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better tolerated than adjuvant treatment and may improve upon the moderate levels of 
compliance observed to adjuvant chemotherapy (Fernandez-Martos, Pericay et al. 2010).  
Few studies to date have used imaging to evaluate response to induction neoadjuvant 
chemotherapy regimes. Measuring MRI length change, using RECIST (Response 
Evaluation Criteria In Solid Tumours) criteria Chau et al observed radiological response in 
60/68 patients (88%) (Chau, Allen et al. 2003). A smaller study of 10 patients showed that 
all patients responded to induction chemotherapy MRI volume reduction criteria (Seierstad, 
Hole et al. 2009). 
There is increasing interest in the use of  neoadjuvant chemotherapy for the treatment of a 
subgroup of MRI defined „intermediate risk‟ patients, which have a high risk of distant 
metastatic relapse but a low risk of local recurrence as the CRM is not threatened (Hunter, 
Garant et al. 2012).  The use of chemotherapy at systemically effective doses may improve 
survival in this subgroup of patients as neoadjuvant chemotherapy theoretically allows 
early treatment of micrometastases and enables delivery of chemotherapy at full systemic 
doses. There are few trials in this area but “Overall, there  appears to be sufficient 
preliminary evidence to support the view that in less locally advanced patients selected by 
initial MRI, the role of neoadjuvant chemotherapy alone, without radiation, should be 
evaluated” (Glynne-Jones, Anyamene et al. 2012).  
Which of the available MRI imaging assessment methods can identify good versus 
poor responders to neoadjuvant chemotherapy compared with histopathological 
reference standards is presently unknown. The ability of MRI to select intermediate 
risk patients is also uncertain. 
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1.6 Pathological restaging of rectal cancer post chemoradiation 
1.6.1 Morphological changes post chemoradiation 
 
Surgical specimens post chemoradiation show; collagen, desmoplasia, fibrosis, 
inflammatory change as well as submucosal oedema, mucin and necrosis.    
 
Fibrotic stroma consists of matrix components such as collagen as well as cells responsible 
for matrix production such as  fibroblasts and histiocytes (Knutsen, Adell et al. 2006).  Fine 
and elongated collagen fibres stratified into layers makes up mature fibrotic stroma while 
immature fibrotic stroma consists of randomly orientated collagen bundles (Ueno, Jones et 
al. 2004).  
 
Desmoplastic reaction is also called reactive fibrosis. Pathologically this process involves 
the deposition of collagen as a stromal response, anatomical distortion may result. Mature 
desmoplastic reaction does not contain tumour (Puppa, Sonzogni et al. 2010). 
 
As well as residual mucin producing tumour cells, the presence of acellular mucinous lakes 
has been reported in 20-55% of patients post chemoradiation. Shia et al analysed the pattern 
and significance of mucin pools in 108 consecutive, prospectively collected resection 
specimens from patients with rectal cancer treated with preoperative long course CRT. 
Mucin pools were identified in 33/108 specimens; in 16/108 they were acellular. The 
presence of mucin pools had no impact on 3 year recurrence free survival (Shia, McManus 
et al. 2011). Therefore pathologists do not upstage tumours due to mucinous degeneration 
(Nagtegaal 2008). 
 
1.6.2 Pathological T stage post chemoradiation (ypT) 
 
T staging post chemoradiation has been shown to predict outcome. For example Kim et al 
retrospectively reviewed 114 patients who had undergone neoadjuvant chemoradiation for 
advanced rectal cancer (T3 or T4 and node positive) using TMN 6 criteria. This study 
showed 5 year survival rates according to pathologic stage were: 100% in pathologic 
complete remission (n = 10), 80% in stage I (n = 23), 56.8% in stage II (n = 34), and 42.3% 
in stage III (n = 47) (p= 0.00001) (Kim, Baik et al. 2006). Other groups have shown similar 
results (Janjan, Crane et al. 2001; Theodoropoulos, Wise et al. 2002).  
 
Applying T stage criteria to post treatment specimens has been noted by several authors to 
lead to difficulty in assessment of residual tumour (Puppa, Sonzogni et al. 2010). There is 
uncertainty how small microfoci of tumour post chemoradiation should be recorded.  Some 
groups have suggested such foci with a smooth contour should be considered as lymph 
nodes as the TNM 6 criteria. However other pathologists believe such rules should not be 
applied post CRT and the presence of microfoci should be recorded in ypT stage rather than 
ypN stage. (Quirke, Williams et al. 2007). This is a similar discussion as the classification 
of extramural tumour deposits discussed in 1.2.6. 
It is important to note that the current TNM 7th edition states in its supplement booklet that 
only viable tumour cells should be used for TN staging purposes. Findings of regressed 
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tumour tissue such as scars, fibrosis and mucin lakes in either intestinal wall, perivisceral 
fat, or regional lymph nodes are not recorded (Sobin and Wittekind 2009) .  This view has 
changed since 2nd edition of the TNM Supplement, where  ―ypTNM considered not only 
viable tumour cells but also signs of regressed tumour tissue such as scars, fibrotic areas, 
fibrotic nodules, granulation tissue, mucin lakes (Wittekind, Henson et al. 2002).‖  
1.6.3 Definition of tumour stages – Pathological complete response 
 
Pathological complete response (pCR) has been used as an endpoint in many clinical trials 
investigating chemotherapy regimes in rectal cancer.  Approximately 10–20% of patients 
are downstaged to pCR in most trials (Hartley, Ho et al. 2005). There has been some 
confusion as to what constitutes a pCR: ypT0 alone or ypT0 plus ypN0. This is important 
as lymph node metastasis are found in 7.1% of ypT0 cases. Most current trials use ypT0N0 
to define complete pathological response (Nagtegaal 2008).  
 
Patients with pCR group have been shown to have a survival advantage in several clinical 
trials. For example Capirici et al reported a retrospective review of 566 patients treated at 
multiple European centres who achieved a pCR after receiving a variety of long course 
CRT regimens. With a median follow-up of 46 months, the local recurrence rate was only 
1.6%, and the 5 year disease free and overall survival rates were 85% and 90% respectively 
(Capirci, Valentini et al. 2008). 
 
1.6.4 Pathological Tumour regression grading 
 
Some pathologists believe ―T-downstaging‖ does not entirely reflect cancer regression 
following neo-adjuvant therapy as, for example, a small focus of residual extramural 
tumour surrounded by fibrous tissue is classified as a T3 tumour despite a good response.  
Pathological TRG systems have been developed to overcome this issue. Dworak et al 
reviewed 17 surgical specimens post CRT and described varying degrees of replacement of 
tumour with fibrous or fibroinflammatory tissue. The degree of fibrosis versus degree of 
residual tumour is used as the basis for the Dworak tumour regression system (Dworak, 
Keilholz et al. 1997) as well as the modified Mandard tumour regression system used in 
oesophageal cancer (Mandard, Dalibard et al. 1994). Such systems provide  information 
about the grade of tumour regression/ response to chemoradiation which is not readily 
available from T staging (figure 1.15).   
 
The usefulness of Dworak system was investigated by Rodel et al, in 385 patients, it was 
found that  complete  and intermediate tumour regression response  had improved disease 
free survival after preoperative CRT compared to poor response (Rodel, Martus et al. 
2005). 
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However  pathological TRG has several limitations;  
 
As the definition of each grade is subjective, this leads to a lack of reproducibility as 
reported by Nagtegaal (Nagtegaal 2008). A more quantitative definition to include the 
percentage of regression cannot be employed as there is no baseline pathology. 
 
Simpliﬁed TRG systems with three or four grades have also been employed and have 
different cutoffs between favourable and unfavourable groups, however, there is no 
accepted cutoff.  The lack of an accepted classification system has resulted in the studies 
investigating correlation between pathological TRG and survival grouping tumour 
regression grades differently. For example Rodel et al showed 63% disease free survival for 
TRG0+1,  75% DFS for intermediate TRG groups 2+3 and 86% DFS for favourable  TRG 
4, while Suarez reported 74% DFS for TRG 1+2  and 100% DFS for TRG 3+4+5 (Rodel, 
Martus et al. 2005; Suarez, Vera et al. 2008). Importantly both these studies showed TRG 
to be a significant prognostic factor on univariate analysis, and as Chetty et al recently 
noted TRG ―has not been established to be an independent prognostic value that is superior 
to ypTNM in predicting clinical outcome‖ (Chetty, Gill et al. 2012). 
 
1.6.5 Pathological lymph node assessment post chemoradiation 
 
Studies have shown the presence of lymph node metastases after neoadjuvant therapy is a 
major prognostic factor (Lee, Jang et al. 2012).
 
However, areas of discussion remain; TNM 
criteria considers 12 lymph nodes an adequate pathological sample for assessment. 
However several large studies have found that such numbers of lymph nodes are often not 
obtained post chemoradiation, with mean numbers of lymph nodes reported as 7, 8.4 and 
10.8. It is not clear if the minimum acceptable harvest of 12 lymph nodes still applies to 
these cases, with some authors currently advocating that if no positive nodes are identified 
in a lower yield post chemoradiation sample, a stage of N0 is reported (Nagtegaal 2008). 
 
A further issue to consider is that neoadjuvant therapy is likely sterilise a number of 
initially positive nodes. Therefore ypN0 is a heterogeneous group of patients with initially 
node-negative disease and patients with sterilised metastatic nodal deposits. It is uncertain 
if this is of significance.(Puppa, Sonzogni et al. 2010; Marzouk O. 2011).  
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Figure 1.15.  Pathological Tumour regression grading 
A) TRG 4. Total regression. No viable tumour cells, only fibrotic mass.  
B) TRG 3.Very few, difficult to find microscopically, tumour cells in fibrotic tissue   
with or without mucus substance. 
C) TRG 2. Dominant fibrotic changes with few tumour cells (easy to find). 
D) TRG 1. Dominant tumour with obvious fibrosis.  
TRG 0. Complete tumour, No regression. (Not illustrated).   
 
 
 
1.6.6 Pathological CRM assessment post chemoradiation 
 
The same criteria are applied to CRM assessment regardless of whether the patient has 
undergone neoadjuvant treatment. Microscopic tumour foci within 1mm of the CRM is 
regarded as a R1 margin and macroscopic tumour within 1mm of the CRM regarded as an 
R2 resection (Puppa, Sonzogni et al. 2010). 
 
CRM is an important post treatment prognostic factor, with a recent review of data from 
17,500 patients demonstrating that the prognostic value of an involved CRM for local 
recurrence is stronger for those patients undergoing neoadjuvant therapy compared to 
patients treated with surgery alone (HR=6.3; 95% CI, 3.6-16.7 Vs HR=2.2; 95% CI, 1.5-
3.2) (Nagtegaal, Gosens et al. 2007). 
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1.6.7 Summary 
 
Histopathologists grade tumour response in three ways: firstly assessment of the status of 
the circumferential resection margin (CRM), secondly, the depth of tumour spread and 
nodal status (ypT and ypN stage) and thirdly by evaluating tumour regression grade 
(pTRG) (Kapiteijn, Marijnen et al. 2001; Sauer, Becker et al. 2004; O'Neill, Brown et al. 
2007; Guillem, Diaz-Gonzalez et al. 2008; Suarez, Vera et al. 2008).   
 
A number of studies have shown that both ypT, ypN and pCRM stage are independent 
predictors for outcome and in several retrospective studies a link between outcome and 
histopathology assessment of tumour regression after CRT has been shown 
(Theodoropoulos, Wise et al. 2002; Valentini, Coco et al. 2002; Kuo, Liu et al. 2007).  
 55 
1.7 MRI Restaging post chemoradiation 
1.7.1 T stage on MRI post chemoradiation 
 
The first study to conduct MR imaging in patients with rectal carcinoma treated with 
radiation was undertaken by Sugimura et al in 1990. Ten of the 51 patients irradiated in this 
study had rectal and anal carcinoma, remaining patients had malignancies of other pelvic 
organs.  Pathological correlation was available in 16/51 cases. The imaging appearances of 
the rectal tumours post chemoradiation was not fully commented on, however difficulties in 
the interpretation of post chemoradiation images was noted; for example in 1 patient 
imaging demonstrated extensive submucosal thickening and increase in the muscularis 
signal intensity, which was interpreted as post radiation change, but an  invasive rectal 
tumour was found pathologically (Sugimura, Carrington et al. 1990). 
 
In 1991 de Lange et al further evaluated the role of MR imaging in assessing the effect of 
preoperative irradiation in 11 patients with primary rectal carcinoma. Findings on MR 
images obtained at baseline and 5-6 weeks post treatment were correlated with 
histopathological findings (9 patients) or findings at laparotomy (2 patients). The study 
reported a relatively low incidence of tumour downstaging on MRI, with no change in the 
MR tumour stage in 9 of the 11 patients. There was agreement between MR T stage and 
subsequent pathology in 9/11 cases, with 1 patient overstaged and 1 patient understaged.  
Difficulties in interpreting post CRT MR images was noted, with extensive streaks of tissue 
from the bowel wall into the perirectal fat interpreted as tumour invasion on MR, but found 
to be linear areas of fibrous tissue/ desmoplastic reaction pathologically (de Lange, Fechner 
et al. 1992) 
 
The correlation between MR imaging in advanced rectal carcinoma after preoperative 
radiotherapy and histopathology was investigated in a larger series of 35 patients by 
Hoffman et al. Post CRT MRI and pathological T stage matched in 19/35 patients, leading 
to the conclusion that  ―MRI proved independent of  response status and is not suitable to 
restage locally advanced rectal carcinoma after preoperative radio chemotherapy‖ 
(Hoffmann, Rau et al. 2002). 
 
Subsequent trials in 2005 by Kuo et al (n=36) and Chen et al (n=50) found MRI  T stage 
had an accuracy of 47% and 52% respectively when compared to pathological T stage  
(Chen, Lee et al. 2005; Kuo, Chern et al. 2005). Allen et al recorded similar results, with, 
18 of 30 (60%) tumours correctly T staged after treatment. Concordance between 
postchemoradiation therapy MRI T stage and histological T stage was fair to moderate (κ = 
0.40; 95% CI, 0.10–0.66) (Allen, Padhani et al. 2007). The main reason given for the 
relatively poor accuracy was that MRI could not completely differentiate the changes of 
post chemoradiation fibrosis from residual tumour. 
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1.7.2 N stage on MRI post chemoradiation 
 
As noted during pathological evaluation CRT often reduces the size and number of benign 
and malignant lymph nodes. Frequently nodal downstaging is accompanied by tumour 
downstaging, while malignant nodes are often identified in those with significant residual 
disease (Taylor, Swift et al. 2008).  
 
As with baseline imaging determining a node to be benign or malignant uses morphological 
rather than size criteria, with a malignant node showing irregular outline or internal signal 
heterogeneity. High signal mucinous degeneration can also occur within lymph nodes and 
is a sign of treatment response (Koh, Chau et al. 2008). Using this criteria Koh et al (Koh, 
Chau et al. 2008) showed a 80% positive predictive value, 90% negative predictive value 
and 88% accuracy in detecting nodal disease after neoadjuvant treatment. 
 
Several studies have shown that lymph node specific contrast agents such as ultra small 
super paramagnetic iron oxide particles may aid in the detection of small tumour deposits 
and lymph node characterisation (Koh, Brown et al. 2004). These particles are 
phagocytosed by nodal macrophages, producing susceptibility effects which result in signal 
loss in normal nodes on T2 weighted MR images. In nodes that are totally or partially 
replaced by tumour macrophage numbers are depleted and little susceptibility artifact and 
relatively high signal intensity are demonstrated. Nodal staging with ultra small super 
paramagnetic iron oxide particles has a sensitivity and specificity of approximately 95% for 
detecting malignant lymph nodes in patients with primary rectal cancer (Koh, Brown et al. 
2004; Koh, Brown et al. 2006). However, there is limited commercial availability of ultra 
small super paramagnetic iron oxide particles with the application for marketing 
authorisation recently been withdrawn in Europe, and approval declined by the Food and 
Drug Administration in the United States (Magnetic Resonance Technology Information 
Portal2007). 
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1.7.3 Refinement of T and N restaging post chemoradiation 
 
Brown et al have proposed refined criteria for interpretation of post treatment MRI. 
 
In this study 78 patients with MRI defined locally advanced rectal cancer were treated with 
long course chemoradiation. Sixty four patients had an evaluable restaging MR imaging 4 
weeks after completing CRT (Brown, Chau et al. 2003); 
 
The following criteria were used for post treatment assessment: 
 
1. Tumour- Persistent intermediate signal intensity was classified as indicating residual 
tumour following therapy.  Intermediate signal was interpreted in relation to the bowel 
wall as well as mesorectal fascia for assessment of T stage and potential CRM 
involvement respectively. The potential CRM was considered involved on post 
treatment MRI if the shortest distance from the outermost part of the tumour to the 
adjacent mesorectal fascia was <1mm.   
 
2. Mucinous tumour- Intermediate signal intensity foci seen within pools of much higher 
signal intensity material was classified as representing mucinous tumour. Regression of 
such intermediate areas post chemoradiation was classified as treatment response.   
 
3. Treatment response- Low signal intensity of the muscularis propria with thickening of 
the muscularis propria was classified as representing fibrosis following tumour 
necrosis.  
 
4. Treatment effects- Low signal intensity stranding was classified as desmoplastic 
changes following extramural tumour necrosis.   As pathological desmoplastic reaction 
does not contain tumour, linear low signal spiculations seen on MRI were interpreted as 
desmoplastic reaction not containing tumour cells.  
 
5. Lymph node assessment: A node was classified as malignant if it contained either 
mixed signal intensity or had an irregular contour as described by Koh et al (Koh, Chau 
et al. 2008).  
 
Using this criteria favourable post treatment MRI T staging was 81% predictive of 
favourable T stage pathology, while an unfavourable MRI T stage was 90% predictive of 
an unfavourable pathological T stage.  Post treatment MRI nodal positivity was 77% 
predictive of pathological nodal disease while post treatment node negativity was 73% 
predictive of pathological N0.  MRI predicted post treatment CRM involvement correctly 
in 69% while MRI predicted a potentially clear CRM correctly in 73%. 
 
Therefore, the definitions of residual tumour, treatment response and treatment 
effects used in this study show promise, but need further characterisation by for 
example matching imaging appearances to pathology. 
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Furthermore, The accuracy of the proposed refined system of T, N and CRM 
assessment have  yet not been assessed against pathology or survival endpoints in 
multicentre multireader studies.  
 
1.7.4 MRI Tumour regression grading 
 
It has been noted that the TNM classification does not make allowances for microscopic 
foci of tumour cells within a stroma of extensive fibrosis and necrosis. Such pat ients are 
staged as pT3 despite only microscopic residual disease present and may not have the same 
prognosis as a large volume T3 tumour (Mehta, Johnson et al. 1994; Wheeler, Warren et al. 
2002). Therefore, an alternative staging classification has been proposed that incorporates 
the initial MR imaging findings to give the true degree of downstaging in these patients 
(Brown, Chau et al. 2003). Such a classification is based on the degree of tumour and 
fibrosis on the post treatment MRI, with patients categorised in a similar way to the 
Dworak tumour regression grading system (Dworak, Keilholz et al. 1997). Importantly 
while Dworak TRG 2 is defined as dominant fibrotic changes with few tumour cells, the 
related MRI TRG grade 3 is defined as ~50% fibrosis/acellular mucin with remaining 
intermediate signal representing residual tumour. 
 
MRI based tumour regression grading system proposes that firstly, the entire tumour is 
assessed to determine whether fibrous signal intensity or tumour signal intensity 
predominates. This requires a comparison of the high resolution oblique images with the 
baseline scans to determine the proportion of tumour that has become  fibrotic low signal 
intensity/featureless high signal mucinous response and the proportion of remaining 
residual intermediate signal intensity. If there is a predominance of fibrosis/acellular mucin 
with no or minimal residual intermediate tumour signal this is classified as TRG 1 and 2 
respectively. If there is substantial tumour signal present but this does not predominate the 
fibrosis/acellular mucin this is classified as TRG3. If there is a predominance of tumour 
with minimal low signal fibrosis/high signal mucin this is classified as TRG 4.  If the 
tumour appears unchanged from baseline this is classed as TRG 5.   
 
The accuracy of post chemoradiation MRI tumour regression system has not been 
assessed against histopathological or survival endpoints or compared against the 
existing standard of T staging.  
 59 
Table 1.6. Tumour regression grading of rectal cancer on MR imaging 
mrTRG grade Response  Description 
Grade 1. Complete 
radiological response 
Absence of any tumour signal. 
Grade 2. Good response. Dense hypointense fibrosis/acellular mucin. 
Minimal residual tumour. 
Grade 3. Moderate response. Mixed areas of low signal fibrosis and 
intermediate signal intensity present but 
without predominance of tumour 
Grade 4. Slight response. Minimal fibrosis/acellular mucinous 
degeneration, mostly tumour. 
Grade 5. No response. Tumour has same appearance as baseline. 
 
1.7.5 Volumetric Analysis using MRI 
 
MR volumetry performed before and after neoadjuvant chemoradiation has been 
investigated as a method of predicting treatment response. Torkzad et al selected a single 
axial slice where a tumour was at its largest dimensions and measured tumour width and 
thickness. Tumour length was then measured, defined as the distance between the extremes 
of the tumour in sagittal plane. Tumour volume was calculated by width multiplied by 
length and thickness of the tumour. Using this method tumour volume was calculated at 
baseline and post CRT.  A statistically significant correlation was shown between 
percentage of residual tumour at second MR (tumour volume post CRT / tumour volume at 
baseline) and ypT.  All ypT0-T1 cases had a residual volume of less than 44%, 5/7 ypT2 
cases had a residual volume of less than 44%, while 11/14 ypT3-4 cases had a residual 
volume of greater than 44% (Torkzad, Lindholm et al. 2007). 
 
1.7.6 MRI Length assessment /modified MRI RECIST 
 
Change in tumour length on sagittal images has been investigated as a tool to evaluate 
tumour response to treatment.  (Chau, Brown et al. 2006).  At the time of starting this 
thesis, data from the EXPERT-C trial had shown a decrease in maximum tumour length 
between baseline and post treatment sagittal images. Favourable pathology (ypT0-2) 
outcome was seen in 35/67 patients post TME. Although the data correlating change in 
tumour length and pathology was not presented it appears a relationship may exist (Chau, 
Brown et al. 2006). 
 
As yet no studies have compared the diagnostic accuracy of post chemoradiation 
volume reduction post treatment and modified RECIST length measurement with 
more established techniques such as T staging or other proposed approaches such as 
MRI tumour regression grading. 
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1.7.7 Diffusion weighted MR Imaging 
 
1.7.7.1 Introduction to technique 
 
Diffusion weighted imaging (DWI) explores the random motion of water molecules in the 
body. The degree of restriction of water diffusion in biologic tissue
 
is inversely correlated 
to the tissue cellularity and the integrity
 
of cell membranes. Therefore tissue contrast in 
DWI is derived from differences in the diffusion of water between tissues.   
 
By applying a pair of strong magnetic field gradient pulses within the imaging sequence, 
imaging is sensitised to random spin displacements of diffusing free water molecules. The 
apparent diffusion coefficient (ADC) can be calculated from DWI measurements. The  
ADC  is  a  measure  of restriction  to  diffusion  of molecules  by  structures  such  as cell  
membranes,  allowing  inferences  to  be  made  about microstructure of  the cellular 
environment. Therefore, diffusion-weighted MRI has been suggested as a tool to 
distinguish different tissue compartments  and to detect changes in cellular tissue structure, 
which could be used to monitor effects of radiation in tumour tissue (Koh and Padhani 
2006) 
 
1.7.7.2 Studies to date 
 
The first study assessing the correlation of tumour ADC values with response to 
chemoradiation was carried out by Dzik-Jurasz et al in 2002. Tumour ADC values were 
measured before and after chemotherapy in 14 patients.  Patients showing a greater than 
50% reduction in tumour size between baseline and post treatment MR imaging were 
classified as responders (n=7), while non-responders (n=7) showed less than a 50% 
decrease. The ADC of responders fell after chemotherapy and increased after 
chemoradiation, while non-responders maintained a high ADC throughout treatment. A 
significant difference between mean ADC of responders and non-responders was shown 
before (p=0.03) and after chemotherapy  (p=0.03),  but  not  after  the  end  of 
chemoradiation (p=0.20) (Dzik-Jurasz, Domenig et al. 2002). 
 
Conversely a subsequent study by Kremser et al showed high ADC values in pathological 
responders, while lower ADC values are seen in pathological nonresponders. DWI was 
used in 8 patients with primary advanced rectal carcinoma undergoing preoperative 
chemoradiation. Mean tumour ADC values were determined weekly during therapy and 
correlated with pathology. In the four patients with T-downstaging (ypT0–2) there was a 
significant increase in ADC value during week 1 of therapy, followed by a steady decrease, 
while in four patients with no downstaging (ypT3) no initial increase of ADC values was 
observed (Kremser, Judmaier et al. 2003) 
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1.8 Clinical importance of MRI Restaging post chemoradiation 
At present after CRT patients undergo surgery at a date determined at the beginning of each 
case, often without restaging imaging.  Accurate preoperative assessment of response to 
therapy may permit the clinical teams to modify definitive treatment in different ways. 
 
1.8.1 Good response 
 
Histopathologists have reported no residual tumour is seen on pathological examination in 
up to 25% of patients, i.e. a complete response of a locally advanced tumour to neo-
adjuvant CRT (O'Neill, Brown et al. 2007).  There is potential for deferral of surgery in this 
subgroup of excellent responders to CRT. A landmark study in this area was carried out by 
Habr Gama et al.  Two hundred and sixty five patients with distal rectal adenocarcinoma 
considered resectable were treated by neoadjuvant chemoradiation between 1991-2002. 
Complete clinical response was observed in 71 patients (26.8%) following chemoradiation 
(Observation group), 22 patients (8.3%) showed incomplete clinical response and 
subsequent pT0N0M0 pathology (Resection group). No difference was observed in the 5 
year overall and disease free survival rates in these 2 groups (Resection Group,  5 yr OS 
and DFS; 88% and 83% respectively, Observation group, 5 yr OS and DFS; 100% and 92% 
respectively). Patients in this study were selected by digital rectal examination, pelvic CT 
and proctoscopy, the ability of MRI to select patients and monitor patients was not 
evaluated (Habr-Gama, Perez et al. 2004).  
 
Habr Gama et al‘s group recently published updated results of their deferral of surgery 
cohort. Data from 173 patients recruited between 1991-2009 from one of the two original 
centres was presented. Trends from the original dataset have continued, with overall, 67 
(39%) of patients developing complete clinical response. Sigmoidoscopy was the main 
modality used for surveillance, MRI was not available. Overall survival and disease free 
survival rates at 5 years in the observation group were 96% and 72%, respectively. Fifteen  
patients developed disease recurrence; 8 developed local recurrences while 7  developed 
distant metastases (Habr-Gama, Perez et al. 2011).  All local recurrences were potentially 
amenable to salvage therapy. 
 
Smaller studies have shown less favourable results, Nakagawa et al recruited 52 patients 
with mid or low rectal tumours. Post CRT 10 patients had biopsy confirmed complete 
response. Of the 10 cases with pCR, 8 presented with local recurrence between 3.7-8.8 
months. MRI was not used for selection or during surveillance (Nakagawa, Rossi et al. 
2002).   
 
Therefore the criteria to enrol patients into a deferral of surgery programme are 
uncertain, as is the approach to monitor such patients to detect tumour regrowth. As 
discussed in section 1.7.7.2, diffusion weighted imaging indices appear to change 
during treatment, therefore there may be a role for diffusion weighed imaging in 
surveillance. 
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1.8.2 Poor response 
 
The subgroup of patients with unfavourable post treatment MRI parameters appears to be at 
higher risk of local or systemic failure following a standard TME resection. The surgeon 
may be warned of this preoperatively, and direct dissection accordingly. In future studies, 
this group could be considered for further  therapy such as intensified or extended systemic 
chemotherapy, a radiotherapy boost or more intensive postoperative follow up (O'Neill, 
Brown et al. 2007) . Such approaches have not yet been studied in clinical trials. 
 
1.9 Conclusion 
MRI is a validated technique for the baseline staging of rectal cancer. Those patients with 
MRI defined locally advanced disease often undergo preoperative chemoradiation prior to 
total mesorectal excision.  
 
Although post operative pathological staging of rectal tumours gives useful prognostic 
information about survival and can be used to plan adjuvant therapy, it is clear that the 
availability of this information preoperatively could influence treatment substantially. For 
example those with good response on MRI could enter a deferral of surgery programme- 
however the use of MRI in a surveillance setting has not been evaluated. 
 
Overall, from the literature, the precise role, importance and validity of restaging rectal 
cancers after preoperative therapy (chemoradiation/ chemotherapy) is uncertain. Many 
studies to date evaluating the T restaging of rectal cancer post chemoradiation have been 
disappointing with radiologists unable to reliably differentiate the changes of post 
chemoradiation fibrosis from residual tumour. Other groups have suggested novel criteria 
using the degree of fibrosis and residual tumour (mrTRG), volumetric tumour reduction 
and the use of diffusion weighted imaging.  These approaches are not well validated against 
pathological endpoints.  Moreover, no present study has investigated the relationship 
between any MRI parameter and survival endpoints. 
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2 Aims 
2.1 Overall Hypothesis 
A validated approach for rectal cancer assessment following preoperative therapy using 
MRI can be developed and validated against histopathological and survival outcomes.   
 
2.2 Aims 
1. To characterise the imaging appearances of treatment response/fibrosis and residual 
mucinous and non-mucinous tumour by matching post neoadjuvant therapy high 
resolution MR images with histological specimens. 
 
2. To evaluate the accuracy of post chemoradiation MRI based tumour regression 
system, T staging, N staging and CRM against with histopathological endpoints (T 
stage, N stage, and Circumferential Resection Margin). 
 
3. To compare the post chemoradiation diagnostic accuracy of MRI tumour regression 
grading, T staging, volume reduction post treatment, and modified RECIST length 
measurement; with the histopathological standards of T stage and tumour regression 
grading.  
 
4. To evaluate the prognostic relevance, as judged by overall survival, disease free 
survival and local recurrence of  post chemoradiation  MRI tumour regression 
grading, T staging, N stage and post treatment MRI CRM status. 
 
5. To identify which of the available MRI imaging methods, MRI tumour regression 
grading, T staging, and modified RECIST length measurement can identify good 
versus poor responders to neoadjuvant chemotherapy compared with the 
histopathological reference standard of tumour regression grade.   
 
6. To determine, in a group of rectal cancer patients with MRI determined good 
response to chemoradiation and enrolled in a deferral of surgery programme, 
whether ADC values differ between patients with residual/recurrent tumour and 
those patients in clinical, radiological and biopsy confirmed complete response. 
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3 Materials & Methods 
An overview of the materials and methods used to evaluate the aims of this thesis are 
presented. Further details particular to the specific aims of each study are described in the 
individual chapters.  
 
3.1 Patients 
3.1.1 Patient Databases 
 
The clinical material for this thesis came from four prospective studies: (a) Magnetic 
Resonance Imaging and Rectal Cancer European Equivalence Study, (MERCURY Study)   
[Project number MREC 02/01/01], (b) Capecitabine Oxaliplatin Radiation Excision Trial 
(CORE Trial) [Project Number C86-01], (c) Groupo Espanol Multidisciplinario del Cancer 
Digestivo (GEMCAD study) [EudraCT Project Number 2008-006974-14], and  (d) 
Deferral of surgery study [LREC Project Number UKCRN ID 8565]. The studies were 
approved by either local or multi-centre research and ethics committees. Written consent 
was obtained from all patients prior to inclusion into the studies.  
 
3.1.2 MERCURY study patients & statistical considerations 
 
The MERCURY study was a prospective multi-centre study evaluating the equivalence of 
MR imaging in the evaluation of rectal cancer between centres. Eleven specialist colorectal 
units in 5 European countries participated in the trial. Over 700 patients were enrolled into 
the study between February 2002 and October 2003.  Five year follow up was completed in 
December 2008.The MERCURY group has developed a unique pathological and imaging 
database that has been integrated to form an important teaching and research resource for 
radiologists and pathologists. This database of radiological pathological correlated cases of 
rectal cancer is the most comprehensive and largest in the world (MERCURY 2007).     
 
Using this database, an observational study was performed to match the appearance of 
rectal tumours, fibrosis and treatment effects after neo-adjuvant chemoradiation treatment 
to  histopathology (Aim 1).    
 
Using this information; the accuracy of post chemoradiation  MRI based tumour regression 
system, T staging, N staging and CRM  was assessed against histopathological endpoints (T 
stage, N stage,  and Circumferential Resection Margin) (Aim 2). 
 
To validate the interpretation principles developed from the radiology pathology matching 
study,  a prospective study of the 111 patients with rectal cancer treated by neoadjuvant 
therapy in this cohort was performed. Patients were assessed for response by both MR and 
pathology T, N staging and CRM status. MRI tumour regression grade was also assessed. 
Overall survival was estimated using the Kaplan-Meier product-limit method. A Cox 
proportional hazard model was used to determine the association between good and poor 
responders on MRI/ Pathology and survival outcomes after controlling for patient 
characteristics (Aim 4).    
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3.1.3 CORE study patients & statistical considerations 
 
The CORE (Capecitabine, Oxaliplatin, Radiation, Excision) study was a prospective phase 
II trial evaluating if treating patients with Oxaliplatin and Capecitabine with concomitant 
pelvic radiotherapy reduced distant recurrence and increased tumour resectability. 
Enrolment was between July 2003-December 2004. Eleven specialist colorectal units in 6 
European countries took part in the trial (Rutten, Sebag-Montefiore et al. 2006). 
 
 
Eighty-six patients underwent chemoradiotherapy for MRI defined locally advanced rectal 
cancer. Eighty-three patients had evaluable imaging and 78 had final pathology.  
MRI tumour regression grade and post treatment MRI T stage were assessed alongside the 
parameters of MRI volume change and MRI length change/mrRECIST by two independent 
readers in all 78 patients. Parameters were analysed against both T stage pathology and 
pathological tumour regression grading. Several statistical tests were used, (Receiver 
operating curve analysis, Kappa Calculation, Mann-Whitney U test, Kruskal Wallis 
analysis of variance and  univariate logistic regression), to enable calculation of the 
diagnostic accuracy for each MRI parameter (Aim 3). 
3.1.4 GEMCAD study patients 
The GEMCAD (Groupo Espanol Multidisciplinario del Cancer Digestivo) study is a 
prospective phase II trial evaluating the safety and efficacy of neoadjuvant Capecitabine, 
Oxaliplatin and Bevacizumab in intermediate-risk rectal cancer patients defined by MRI. 
Twenty eight eligible patients were enrolled between July 2009-May 2011.  Twenty four 
patients had evaluable imaging and pathology. 
The reproducibility of different post treatment assessment methods was investigated by 
7 radiologists independently assessing baseline and post treatment MRIs for: MRI T stage, 
MRI tumour regression grade, and MRI length change. Parameters were analysed against 
pathological tumour regression grading using Receiver operating curve analysis and the 
Mann-Whitney U test as well as univariate logistic regression. Agreement between the 7 
radiologists for each parameter was assessed by Krippendorff's alpha. Krippendorff‘s alpha 
is applicable to any number of readers, can compensate for missing data and can adjust 
itself to small sample sizes (Aim 5).   
 
3.1.5 Deferral of surgery patients 
 
This is an ongoing multicentre prospective phase II trial studying patients undergoing 
imaging and clinical surveillance following a good response to preoperative CRT. The 
primary endpoint of the trial is to demonstrate that surgery can be deferred and even 
permanently deferred in patients that show complete response.  The follow-up protocol 
includes serial MRI, sigmoidoscopies and biopsies. Forty one patients have been enrolled 
between 2006-2012,  
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The ability of serial MRI diffusion weighted imaging to identify and monitor patients likely 
to be in complete response versus those with tumour is investigated in this thesis (Aim 6). 
  
Two radiologists independently drew a region of interest over the treated tumour/scar on a 
single slice of the MRI ADC map. Scans were coded as showing complete response or 
tumour according to biopsy and MRI T2 imaging findings. Linear mixed effects modelling 
was used to test for significant differences in ADC values, which were regressed as a factor 
of time and presence/ absence of tumour regressed as an independent variable. Receiver 
operating curve (ROC) analysis was also used to define the mean ADC cut-off value in 
discriminating the tumour group from complete response group and to investigate the level 
of agreement between the two observers. 
 
In each statistical test employed a p-value of <0.05 was considered statistically significant. 
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3.2 High-resolution MRI scanning protocol 
3.2.1 MR technique 
3.2.1.1 Background 
 
Preoperative thin section MR imaging was first shown to improve staging in rectal cancer 
and demonstrated accurate measurement of depth of extramural tumour infiltration in 1999 
(Brown, Richards et al. 1999). The details of the MRI technique published in 2005 and its 
accurate reproducibility confirmed in 2007 (Brown 2005) (Koh, Brown et al. 2007). This 
high resolution technique is recommended for optimal visualisation of rectal and 
mesorectal anatomy  (Brown, Kirkham et al. 2004), and for characterisation of mesorectal 
lymph nodes (Brown, Richards et al. 2003).  
 
3.2.1.2 Protocol 
 
Each trial employed a similar imaging protocol; Patients were placed supine on the table 
with the flexible multi-element phased array body/ pelvic coil placed firmly around the 
pelvis to minimise motion.  A full bladder and purgatives were not necessary and anti-
peristaltic agents were not needed as small bowel movement was not a problem.  
 
The same technique was used both for baseline and post treatment imaging, with images 
acquired using same angles. This enabled direct comparison. Baseline images were also 
used to help locate the treated tumour – which was difficult to visualise in some patients 
that had a good response (Brown 2005). Full MR parameters for both Siemens and Philips 
systems are detailed in tables 2.1 and 2.2. 
 
After initial localisation imaging, initial large field of view sagittal and axial images were 
acquired (Brown 2005). These first two sequences allowed an overview of the treated 
tumour, potentially involved lymph nodes and direction of the rectal wall. This enabled 
planning of high resolution sequences, which were vital for the visualisation of the tumour 
and post treatment fibrosis. Besides the imaging plane, these sequences were obtained with 
the same imaging parameters (figure 3.1). 
 
First sequence planned axial to the plane of the tumour and rectal wall; Figure 3.1A 
Thin-section (maximum 3 mm) axial T2 weighted images through the treated rectal cancer 
were planned using the sagittal T2 weighted images.  These images were performed 
perpendicular to the long-axis of the rectum, using a 16 cm field of view. 
  
Second sequence for oblique axial imaging for lymph node drainage territory; Figure 3.1B 
Obtaining oblique axial imaging ensured coverage of draining nodes and tumour deposits, 
which can extend above the superior edge of tumour. 
 
Third sequence in coronal plane for low rectal cancers. Figure 3.1C 
Relying on oblique axial imaging alone can be limiting at the level of the anorectal 
junction.  At this level the rectal wall changes in diameter and distance to the neighbouring 
tissues is smaller. The images may not show the rectal wall in its entirety and overstaging 
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may result from partial volume artefact. Therefore high resolution coronal imaging was 
useful for lower third rectal tumours, which showed the relationship between the rectal wall 
and the levator muscles, the anal sphincter complex and the intersphincteric plane. 
 
Table 3.1 Imaging sequences for rectal imaging using Siemens‘ 1.5 T MR System 
NSA= Number of signal averages. 
TSE= Turbo spin echo. 
  
Sequence 
 
 
FOV 
mm 
 
 
TR/ 
TE 
 
Slice  
mm 
 
Matrix 
 
NSA 
 
Time 
mins 
Sagittal T2  
From one pelvic 
sidewall to other 
TSE/ 23 354 5478/ 
128 
3 
interleaved 
276 x 
512 
3 3.22 
 
Axial T2 
Iliac crest to pelvic 
floor 
TSE/ 23 354 5478/ 
128 
5  
interleaved 
322 x 
512 
3 3.55 
 
 
Axial T2 
Perpendicular to 
the rectum 
Oblique Axial T2 
To cover lymph 
node territory 
TSE/ 23 185 5383/ 
128 
3 
(0.1 gap) 
230 x 
256 
3 4.23 
Coronal T2 
Low tumours 
parallel to anal 
canal 
TSE/ 23 185 5383/ 
128 
3  
(0.1gap) 
230 x 
256 
3 4.23 
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Table 3.2 Imaging sequences for rectal imaging using Philips‘ 1.5T Integra System 
NSA= Number of signal averages. 
TSE= Turbo spin echo. 
SENSE= Sensitivity encoding for fast MRI. 
  
Sequence 
 
 
FOV 
mm 
 
 
TR/ 
TE 
 
Slice  
mm 
 
Matrix 
 
NSA 
 
Time 
mins 
Sagittal T2  
From one pelvic 
sidewall to other 
TSE/ 23 250 3500/ 
125 
3 
interleaved 
304 x 
512 
4 6.36 
 
Axial T2 
Iliac crest to pelvic 
floor 
TSE/ 22 420 3500/ 
80 
5  
interleaved 
352 x 
512 
1 1.38 
SENSE 
2 
 
 
Axial T2 
Perpendicular to 
the rectum 
Oblique Axial T2 
To cover lymph 
node territory 
TSE/ 16 160 3500/ 
120 
3 
interleaved 
256 x 
512 
6 5.36 
 
Coronal T2 
Low tumours 
parallel to anal 
canal 
TSE/ 16 160 3500/ 
120 
3  
interleaved 
256 x 
512 
6 5.36 
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Figure 3.1. Imaging sequences for rectal cancer imaging 
A)    B)             C) 
 
The tumour is indicated by arrowheads.  
 
A) Planned high resolution block (black box) axial to the plane of the tumour and rectal 
wall. Images are acquired perpendicular to the long-axis of the rectum. 
B) Oblique axial block (black box) to cover lymph node drainage territory- which can 
extend above the superior edge of tumour. 
C) Block in coronal plane (black box) for low rectal cancers. This shows the relationship 
between the rectal wall and the levator muscles, the anal sphincter complex and the 
intersphincteric plane. 
 
3.2.1.3 Diffusion weighted imaging protocol 
 
Axial Diffusion Weighted (DW)  MR images were obtained by using a DW MR echo-
planar sequence on both Philips and Siemens MRI scanners. Imaging parameters are 
detailed in Table 3.3. DW MR Images and ADC maps were acquired by using b values of 
0, 350 and 750 sec/ mm. All DW MR imaging was performed during free breathing with fat 
suppression. Both the high resolution T2 and diffusion weighted imaging was performed in 
the same plane.  
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Table 3.3. Small field of view Diffusion weighted imaging parameters 
SPAIR= Spectral attenuated inversion recovery. 
Parameter Philips Siemens 
Field of view (cm) 280 220 
Matrix size 112X256 138X256 
TR 2500 3100 
TE 66 71 
Echo planar imaging factor 75 112 
Parallel imaging factor 2 2 
No. signals averaged 4 8 
Section thickness (mm) 5 5 
Direction of motion probing 
gradients 
3 scan trace 3 scan trace 
Fat suppression SPAIR  SPAIR 
b factors (s/mm2) 0,350,750 0,350,750 
 
3.2.1.4 Additional MR techniques 
3 Tesla MR Systems are increasingly available in radiology departments. Such systems 
shorten the examination time as 3 dimensional image acquisitions remove the need for 
multiplanar 2D images. Improved spatial resolution and signal to noise ratio has also been 
reported (Kim, Lim et al. 2010). Studies comparing 2D with multiplanar reconstruction and 
3D T2 weighted imaging protocols in staging rectal cancer patients have shown no 
significant differences in T and N staging accuracy (Futterer, Yakar et al. 2008; Maas, 
Lambregts et al. 2012). These studies did not investigate the accuracy of 3D T2 weighted 
imaging in restaging rectal cancer post chemoradiation. This thesis presents images 
acquired using a 1.5-T whole-body MR imager with a pelvic phased-array coil.   
Dynamic contrast-enhanced MRI (DCE-MRI) has been evaluated in the restaging of rectal 
cancer post CRT. Derives et al (n=17) (Devries, Griebel et al. 2001)  showed DCE-MRI 
perfusion index values before chemoradiation correlated with T downstaging. Diner et al 
(n=33) (Dinter, Horisberger et al. 2009) showed the slope of the contrast media 
enhancement curve helped to identify responders to chemoradiation. Overall, given the 
absence of published evidence regarding the accuracy, reproducibility and DCE-MRI‘s 
comparative value versus high resolution T2 scanning we did not use this sequence in the 
restaging of rectal cancer.  
 
3.2.2 MRI Quality Assurance 
The centres participating in the trials detailed in this thesis conducted regular quality 
assurance to detect any changes in machinery performance which could adversely affect 
images obtained.  The schedule of quality assurance was conducted in line with the 
individual institution‟s standard operating procedures. The method of assurance involved 
conducting a series of test measurements on a body phantom supplied by the relevant MRI 
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manufacturer. The measurements where then compared with published acceptable limits.  
The measurements and reference limits have been described fully elsewhere (Firbank, 
Harrison et al. 2000).  In the event of a substantial deviation from the accepted limit the 
machine was not used. 
 
To ensure the standard protocol described in section 3.2 was used by all centres in the 
MERCURY, CORE and GEMCAD trials an imaging workshop was conducted prior to 
patient recruitment. All patients in the deferral of surgery study are imaged at The Royal 
Marsden Hospital.  
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3.3 Image interpretation software- Diffusion View 
Diffusion View™ is a program developed at The Royal Marsden Hospital for quantitative 
image interpretation. The program requires selected slices to be imported into its image 
viewer to be in a DICOM format.  A freehand region of interest (ROI) is then drawn on the 
required area of the imported slices. The program calculates the signal for each pixel of the 
ROI.  For the deferral of surgery study small field of view ADC map images were imported 
into Diffusion View. 
 
3.4 Histopathology 
3.4.1 Overview 
Pathological endpoints were recorded for each of the four available patient datasets. The 
exact pathological specimen handling and definitions used are detailed in the relevant 
chapter. 
 
TNM 5 definitions are used in this thesis, as noted in 1.2.7, some pathologists disagree with 
the definition of tumour microdeposits in TNM 6 and 7. Extramural depth of tumour 
invasion and presence of tumour microdeposits were recorded separately in each patient 
database to enable calculation of TNM stage by version 6 or 7 criteria. 
 
MERCURY dataset;  ypT (with T3 substaging) and ypN assessed according to TNM 5 and 
circumferential margin status. 
 
CORE dataset; ypT (with T3 substaging) assessed according to TNM 5 and pTRG assessed 
by 5 point system (0-4). 
 
GEMCAD dataset; assessed according to TNM 5 and pTRG assessed by 5 point system (0-
4) and circumferential margin status (pCRM).  
 
Deferral of surgery; ypT (with T3 substaging) and ypN stage (according to TNM 5) and 
circumferential margin status. 
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4 Post treatment High Resolution MRI correlation with pathology 
4.1 Introduction 
The precise role, importance and validity of restaging rectal cancers after preoperative 
therapy is uncertain (Kim, Kim et al. 2010). As discussed previously, refinements in T,N 
and CRM assessment post treatment have been proposed as well as the novel MRI based 
tumour regression grading system (Brown, Chau et al. 2003). These proposals remain 
unvalidated in large numbers of patients in a multicentre trial. 
 
This study matched pathological slides to post treatment MRI images with the aim of 
characterising the MRI appearances of; 
Treatment response- fibrosis and acellular mucin,  
Residual tumour-mucin and non mucinous and  
Treatment effects- desmoplastic reaction and oedema.  
 
Additionally, the accuracy of MRI tumour regression (mrTRG), T staging (ymrT), N 
staging and CRM (ymrCRM) was assessed against with pathological endpoints (ypT, ypN, 
pCRM). 
 
4.2 Methods & Materials 
4.2.1 Patients 
Patients were enrolled into the original MERCURY prospective study evaluating diagnostic 
accuracy of MRI staging of rectal cancer between February 2002 and October 2003. The 90 
patients treated with preoperative chemoradiotherapy or long course radiotherapy with 
evaluable post treatment MRI and pathology were evaluated for this study.  
 
4.2.2 Inclusion and exclusion criteria  
Inclusion Criteria 
 
Biopsy proven rectal cancer. 
 
Considered by individual centre multidisciplinary team as high risk and requiring 
preoperative therapy for downstaging or downsizing of the primary tumour. The uniform 
criterion used by all centres was potential CRM involvement on MRI.  Most centres also 
offered CRT to advanced T3c, T3d or T4 tumours. 
 
One hundred and eleven of 374 patients underwent preoperative chemoradiotherapy/ long 
course preoperative radiotherapy. 
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Exclusion criteria 
 
Patients with distant metastatic disease on body computed tomography (CT).  
Patients having contraindications to MRI.   
Patients undergoing primary surgery or surgery following short course preoperative 
radiotherapy.  
 
Figure 4.1. MERCURY trial progress flowchart 
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4.2.3 Preoperative treatment 
Radiotherapy consisted of 45-54Gy delivered to the primary tumour and pelvic lymph 
nodes at risk.  Fifty eight patients and 53 patients received long course radiotherapy or 
concurrent chemoradiotherapy with a fluoropyrimidine respectively. MRI scans were 
performed following completion of radiotherapy at an interval of 4 to 6 weeks and surgery 
was undertaken at 6-8 weeks after chemoradiotherapy. 
 
4.2.4 Surgery 
Surgical options included standard TME plane surgery or extended TME (TME with 
adjacent visceral resection) with or without sphincter preservation according to a 
standardised technique. The units‘ policies were to offer postoperative single agent 
chemotherapy for AJCC stage III disease. No patient received postoperative radiotherapy. 
 
4.2.5 Histopathological assessment 
Following TME, the specimen was opened along its anterior surface proximal to the tumour 
and fixed in formalin for a minimum of 72 hours. After painting the entire mesorectal 
surface with marker inks the whole tumour and mesorectum was serially sliced axially at 3-
5 mm intervals in order to produce tissue slices that corresponded precisely with the MR 
slices.  
 
A clear pCRM was defined as greater than, or equal to, 1 mm between the tumour and the 
resection margin. Eighteen pathologists, with 5-25 years experience in gastrointestinal 
pathology, evaluated specimens for the post treatment T (ypT), N (ypN) stage, and 
circumferential margin status (pCRM).  
 
4.2.6 Matching MRI images with pathology 
MRI was carried out according to standardised protocol detailed in chapter 3.2.1.  
 
Pathological slides were matched to post treatment MR images using a subset of the 
MERCURY dataset to have undergone post treatment imaging. Baseline MRI images were 
also used for information regarding to original anatomical location of the tumour. 
Observational pathological findings were divided into: 1) Treatment response -Collagen/ 
Fibrosis and Acellular mucinous, 2) Residual tumour 3) Treatment related effects-
Submucosal oedema and desmoplastic reaction. Spatial correlation between pathological 
slices and post treatment MRI images was achieved by identifying anatomical and 
morphological landmarks (lymph nodes, blood vessels and the bowel contour, tumour 
contour) visible on the pathological specimen and then respectively on the MR images. 
This was undertaken by two radiologists (GB &UP) in consensus with 15 and 5 years 
experience in GI imaging.  
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4.2.7 MRI assessment 
A one day imaging workshop for specialist gastrointestinal radiologists participating in the 
study was held prior to recruitment in 2002 to ensure standardisation of scan acquisition 
techniques (section 3.2.1) and image interpretation prior to the study using previously 
published criteria (Brown, Richards et al. 1999; Brown, Radcliffe et al. 2003; Brown, 
Davies et al. 2004). All scans were single read by each investigating centre radiologist, with 
5-15 years GI radiology experience.  
 
T staging of tumour post treatment (ymrT) was based on interpretation of local extent of 
persistent tumour signal intensity relative to the layers of bowel wall on T2 weighted 
images. High resolution scans were used to enable accurate delineation of residual tumour 
signal versus low signal fibrosis and to depict the area of treated tumour. 
 
A T1 tumour was classified if tumour was confined to the submucosal layer. If tumour 
signal had extended into, but not through the muscle layer a T2 tumour was classified. A T3 
tumour was characterised by tumour extension through the muscularis propria. An early 
T3a tumour extended less than 1mm beyond the border of the muscularis propria. A T3b 
tumour extended between 1-5mm.  More advanced T3 tumours, T3c and T3d, extended 5-
15mm or greater than 15mm beyond the muscularis propria. 
 
Nodal stage post treatment was based on interpretation of lymph node border characteristics 
and signal intensity (Koh, Chau et al. 2008). A node was regarded as positive if either an 
irregular border or mixed signal intensity was demonstrated.  
 
Post treatment MRI scans were also evaluated for predicted circumferential resection 
margin status (ymrCRM). A predicted clear circumferential resection margin was recorded 
if the distance of intermediate signal tumour to the mesorectal fascia was greater than or 
equal to 1 mm on MRI. For lower third rectal tumours, the definition of predicted ymrCRM 
involvement was tumour within 1 mm of the levator muscle. If the tumour was present at or 
below the level of the puborectalis sling, the ymrCRM was predicted involved if there was 
invasion into the intersphincteric plane or beyond. 
 
4.2.7.1 MRI tumour regression grading 
 
Of 111 patients undergoing preoperative therapy, 90 also underwent post treatment MRI 
before surgery.  Sixty six of 90 (73%) pre and post treatment scans were available for MRI 
TRG grading.  MRI scans were anonymised and centrally reviewed by a radiologist with 
14(GB) years experience in MRI assessment of rectal cancers using previously defined 
criteria (Brown, Chau et al. 2003).  
 
MRI TRG is based on similar principles to the pathological TRG originally described by 
Dworak. Scans were reviewed to determine the degree of tumour replacement by fibrotic 
stroma (Dworak, Keilholz et al. 1997) (Table 1.6). 
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4.3 Statistics 
4.3.1 Receiver Operating Curve and Kappa Analysis 
Based on known histopathological outcomes according to ypT stage, ―good‖ ypT stage was 
defined as stages T0, T1, T2 and T3a with ―poor‖ defined as ypT stages T3b,T3c,T3d or 
T4. Stage T3a and T2 tumours have similar outcomes and were therefore classified as 
―good‖(Hermanek P 1993; Willett, Badizadegan et al. 1999).   Binary pathological outcome 
enabled a cut-off between favourable and unfavourable mrTRG groups to be derived using 
ROC analysis. This also enabled calculation of the diagnostic accuracy of the mrTRG using 
the area under the curve (AUC). The AUC is classified as follows: 0.9-1=excellent, 0.8-
0.9=good, 0.7-0.8=fair, 0.6-0.7=poor, 0.5-0.6=fail.     
 
Cohen‘s Kappa was used to analyse the association between ymrT and pathological T 
stage,  ymrN and ypN, as well as  ymrCRM and pCRM. Kappa was used as the same 
criteria were used by both radiologists and pathologists in looking at post treatment MRI 
and pathology samples respectively. Kappa was classified as follows, κ < 0, poor 
agreement;κ =0–0.20, slight agreement; κ =0.21–0.40, fair agreement; κ =0.41–0.60, 
moderate agreement; κ =0.61–0.80, substantial agreement; and κ =0.81–1.00, almost 
perfect agreement. 
 
4.3.2 Univariate logistic regression 
Based on known histopathological outcomes according to ypT (Willett, Badizadegan et al. 
1999), favourable regression was defined as stages ymrT0,1,2, and 3a, while unfavourable 
grading was defined as ymrT3b,c,d and 4.  Favourable and unfavourable mrTRG was 
defined according to ROC analysis as detailed in 4.3.1. 
 
MR predicted involvement of CRM or pCRM involved were defined as ―poor‖, while clear 
pCRM/ymrCRM were classified as ―good‖. Likewise MR predicted nodal positivity or ypN 
involved were defined as ―poor‖, while node negative ypN/ymrN were classified as ―good‖.  
 
Univariate logistic regression analysis was used to analyse the association between MRI 
parameters (mrTRG, ymrT, ymrN and ymrCRM) and pathologic tumour response (in terms 
of ypT,ypN and pCRM). This enabled calculation of odds ratios for the probability of an 
unfavourable pathological outcome.  
 
P values of less than 0.05 were considered significant. 
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4.4 Results  
4.4.1 Demographics 
Of the 111 patients who underwent preoperative treatment 49 were <65 and 62 were ≥65. 
Sixty nine patients were male and 42 were female. Fifty nine patients had mid/high rectal 
cancers, with 52 patients having low rectal cancers. 
 
4.4.2 Observations 
4.4.2.1 Treatment response- Fibrosis and acellular mucin 
 
Pathologically fibrotic stroma consisted predominantly of fibrosis as well as cells 
responsible for fibrosis development such as fibroblasts and histiocytes. Areas of 
pathological fibrosis were correlated with very low signal on T2 MRI weighted images (as 
seen on figure 4.2), while residual tumour was intermediate signal.  The signal intensity of 
fibrosis was similar to that of muscularis propria, while residual tumour was of similar 
signal as baseline tumour. Careful review of high resolution images enabled detection of 
small foci of intermediate signal intensity tumour within areas of low signal fibrosis. 
Varying degrees of residual fibrosis and tumour were observed both between patients and 
within the same patient at different levels of the tumour.  
 
Figure 4.2. Correlating fibrosis on pathology with imaging 
 
A) Axial T2 weighted image showing intermediate signal semi-annular tumour between   
12‘o‘clock-6‘o‘clock (outlined).  
B) Post treatment axial T2 weighted image shows a residual low signal intensity crescentic 
area (white arrow). 
C) Corresponding photomicrograph (Original magnification X 0.4, H&E stain). The low 
signal area of on T2 correlates with an area of fibrosis (black arrow). 
 
A)                                          B)                                            C) 
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Final pathology showed an acellular mucinous response in two scenarios;  
 
1) In a tumour that on baseline MRI appeared mucinous.  
Such tumours pathologically consisted of pools or lakes of extracellular mucin, lined by 
columns of malignant cells, cords and vessels. Cellular mucin on T2 imaging was 
hyperintense, but upon close matching with pathology, contained areas of more 
intermediate signal corresponding to the histologically demonstrated malignant cells, cords 
and vessels. After treatment, the necrosis of these viable nests/cords of tumour could result 
in the formation of acellular mucin - namely pools of featureless high signal intensity fluid-
like signal on the T2 weighted images which when compared with pre-treatment scans 
contain no or minimal intermediate signal intensity, this is seen in figures 4.3 and 4.4. 
 
2) In a tumour/lymph node that on baseline MRI appeared  non-mucinous i.e. on baseline 
imaging the tumour was of entirely intermediate signal intensity. Matching post 
chemoradiation MRI images with pathological slides it was found that acellular mucin 
pathologically correlated with very high signal intensity pools within the previously 
documented intermediate signal intensity tumour stroma. This is seen in figures 4.5 and 4.6.
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Figure 4.3. Mucinous response with imaging and pathology correlation-Example 1 
 
A) Axial T2 weighted image showing intermediate signal semi-annular tumour between   
3‘o‘clock-10‘o‘clock (white arrow).The tumour shows an high signal mucinous extramural 
component (white arrowhead)- this has intermediate signal components (black arrowhead) 
consistent with tumour.  
 
B) Post treatment axial T2 weighted image shows a high signal intensity extramural area 
(white arrowhead).Previous intermediate signal components are less visible (black 
arrowhead), in keeping with response. 
 
C) Corresponding wholemount pathological specimen. Pathological mucin is identified 
extramurally (black arrowheads). 
 
D) & E) Corresponding photomicrographs (Magnification X 0.4, and 0.8 respectively, 
haematoxylin-eosin (H-E) stain). The high signal extramural area on T2 correlates with 
areas of acellular mucin (black arrowheads). 
 
A)                                            B)                                           C) 
 
 
D)                                           E)                            
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Figure 4.4. Mucinous response with imaging and pathology correlation-Example 2 
 
A) Sagittal T2 baseline image shows large tumour with high signal compatible with mucin. 
There are intermediate solid cellular components noted within the tumour (arrows).  
 
B) Sagittal T2 post treatment image. There has been formation of acellular mucin indicated 
by featureless areas of high signal (arrowhead). Areas of intermediate signal residual 
tumour (arrow) remain. 
 
A)                                                          B) 
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Figure 4.5. Mucinous degeneration post treatment in a non mucinous tumour at 
baseline  
A) Coronal baseline T2 weighted image showing a semiannular tumour as intermediate 
signal intensity in the rectal wall between 12 ‘o‘clock-9‘o‘clock   (arrow). 
B) Coronal post treatment T2 image shows high signal areas of mucinous degeneration 
(arrow). This was correlated with acellular mucin pathologically (not shown). 
 
A)                                                         B) 
 
 
Figure 4.6. Mucinous change in lymph node post chemoradiation 
 
A) Baseline T2-weighted image showing a heterogeneous lymph node in the left 
mesorectum (arrow).  
B) Following chemoradiation treatment, the node now returns high signal intensity, 
indicating mucinous change (arrow).  
 
A)                                                          B) 
 
 84 
4.4.2.2 Residual tumour 
 
Several mucinous tumours at baseline remained unchanged post chemoradiation. 
Pathologically persistent columns of malignant cells and cords were shown, On MRI this 
was seen on baseline as tumours containing high signal with intermediate signal intensity 
components which remained on post treatment imaging.  Pathological non mucinous 
residual tumour correlated with intermediate signal on post treatment MRI, often with a 
similar appearance as baseline. 
 
4.4.2.3 Treatment effects, desmoplastic reaction and oedema 
 
Pathologically desmoplastic reaction corresponded to the deposition of collagen as a 
stromal response. Several cases where observed were anatomical distortion was caused as a 
result. Pathologically desmoplastic reaction did not contain tumour. Figure 4.7 illustrates 
this. 
 
On both baseline and post CRT MR imaging desmoplastic reaction corresponded to low-
intensity spicules or strands in the perirectal fat radiating from the residual tumour. 
Conversely the pathological appearance of an advancing tumour margin was correlated to a 
more nodular, intermediate signal intensity appearance on imaging. Figure 4.8 illustrates 
this. 
 
Figure 4.7. Desmoplastic reaction 
 
A) Axial T2 post treatment image shows a semi-annular tumour between  12‘o‘clock-
4‘o‘clock (arrow). Low-intensity spicules in the perirectal fat radiating from the residual 
tumour (arrowheads) represent desmoplastic reaction. 
B) Corresponding photomicrograph (Original magnification X 0.4, haematoxylin-eosin (H-
E) stain) showing desmoplastic reaction (arrowheads). 
 
A)                                                             B) 
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Figure 4.8. Nodular invasive margin  
 
A) Axial T2 post treatment image shows a semi-annular tumour between  6‘o‘clock-
12‘o‘clock (arrow). Nodular intermediate signal radiating into the perirectal fat represents 
tumour  (white arrowhead). 
B) Corresponding photomicrograph (Magnification X 0.4, haematoxylin-eosin (H-E) stain) 
showing extramural tumour invasion (black arrowhead). 
 
A)                                                           B) 
 
 
It was observed that on both baseline imaging and pathology rectal carcinoma often grows 
circumferentially eventually leading to annular stenosis of the bowel wall. Certain tumours 
showed central indentation with rolled everted edges and invasion/ulceration at their base, 
with the remaining rectal mucosa and submucosa appearing heaped up into the lumen.  
 
In some cases this appearance became exaggerated after treatment. The original tumour 
become fibrotic, low signal and less bulky, which resulted in near normal thickness of 
treated rectal wall, while the unaffected intermediate signal intensity submucosa became 
oedematous and thickened. This appearance is important as it can lead to the oedematous 
submucosa being incorrectly interpreted as tumour (figure 4.9). 
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Figure 4.9. Pseudotumour 
 
A) Baseline T2 weighted axial MR image shows a semi-annular tumour (curved black 
arrow) the unaffected portion of rectal wall is in the posterior midline at the 6‘o‘ clock 
position (arrowhead). 
B) Images of the same tumour after CRT, and C) Corresponding wholemount pathological 
specimen. The tumour is at the 12‘o‘clock position (curved black arrow), with the 
pseudotumour at the 6 ‘o‘ clock position (arrowhead), due to treatment related oedema of 
mucosa and submucosa.   
 
A)                                             B)                                            C) 
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4.4.3 MRI correlation with pathology 
 
4.4.3.1 mrTRG results 
 
Using mrTRG; 5/111 cases were classified as mrTRG1, 15/111 cases were classified as 
mrTRG2, 12/111 cases were classified as mrTRG3, 22/111 cases were classified as 
mrTRG4, 12/111 cases were classified as mrTRG5 and 45 patients were either not 
reimaged or had missing scans.  
 
Pathology, 5/111 cases were classified as ypT0 (complete response), 2/111 ypT1, 25/111 
ypT2, 9/111 ypT3a, 20/111 ypT3b, 30/111 ypT3c, 4/111 ypT3d and 16/111 were ypT4.  
Table 4.1 shows the raw data.   
 
Table 4.1.  mrTRG and pathological T stage  
  Pathology T stage  
 pT0 pT1 pT2 pT3a pT3b pT3c pT3d pT4 Total 
mrTRG 1 1 0 1 0 2 1 0 0 5 
2 3 2 6 2 1 1 0 0 15 
3 0 0 4 3 3 1 0 1 12 
4 0 0 1 1 6 9 1 4 22 
5 0 0 0 0 1 4 1 6 12 
Missing 
MRI 
1 0 13 3 7 14 2 5 45 
Total 5 2 25 9 20 30 4 16 111 
 
4.4.3.2 mrTRG Receiver operator curve (ROC) analysis 
Figure 4.10 shows the number of patients in each of the five mrTRG categories using 
binary favourable and unfavourable pathology to group the data.   ROC analysis was 
undertaken to calculate the area under the curve (AUC) as well as propose a cut-off 
between favourable and unfavourable mrTRG. Figure 4.11 shows the ROC analysis. The 
area under the ROC curve (AUC) is 0.85, indicating mrTRG has a good diagnostic 
accuracy for T stage pathology.  
 
Table 4.2 illustrates the sensitivity and specificity for the different mrTRG group cut-offs. 
Grouping mrTRG groups 1-3 as favourable and mrTRG 4&5 as unfavourable gives a 
sensitivity of 76% and a specificity of 83% against T stage pathology. Matched examples 
of mrTRG 1-5 are shown in figures 4.12-4.17. 
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Figure 4.10. Histogram showing pathological T stage and mrTRG  
 
Figure 4.11. Receiver Operating curve showing illustrating the performance of 
mrTRG against the binary outcome of favourable and unfavourable T stage 
pathology 
 
The area under the curve is 0.85, 95% confidence interval (0.76-0.95). 
 
Table 4.2. The sensitivity and specificity of different mrTRG cut-offs vs. pathological T stage 
Proposed mrTRG cut-offs Sensitivity (%) Specificity (%) 
mrTRG1 vs. mrTRG 2-5 92.9 8.3 
mrTRG1&2 vs. mrTRG 3-5 88.1 62.5 
mrTRG1-3 vs. mrTRG 4&5 76.2 83.0 
mrTRG1-4 vs. mrTRG 5 28.6 91.7 
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Figure 4.12. mrTRG1 
 
A) Axial T2 weighted MR image shows a semiannular infiltrating tumour (arrow). 
B) Axial post treatment image shows a fibrotic low signal scar at 7‟o‟clock-8‟o‟clock 
(arrowhead), absence of any tumour signal indicates an mrTRG1. 
C) Photomicrograph (Original magnification X 0.4, haematoxylin-eosin (H-E) stain) shows 
fibrosis (arrowhead) extending beyond the muscularis propria. 
 
A)                                                                 B)                                         
 
 
C) 
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Figure 4.13. mrTRG 2 
 
A) Axial T2 weighted MR image shows a semiannular tumour between the 10‗o‘clock and 
5‗o‘ clock positions (arrow). 
B) Axial T2 post treatment image shows tumour regression within the rectal wall, with 
fibrotic low signal scar (arrowheads). Small foci of residual intermediate signal indicating 
tumour is noted at the 12‗o‘ clock position (arrow). Overall this is compatible with MRI 
tumour regression grade 2. 
C) Photomicrograph (Original magnification X 0.4, haematoxylin-eosin (H-E) stain) shows 
fibrosis (arrowhead) extending beyond the muscularis propria. 
 
A)                                                            B)                                               
 
C) 
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Figure 4.14. mrTRG2, example 2 
 
A) Axial T2 weighted post treatment image shows a predominantly low signal area of 
fibrosis with small intermediate signal areas (arrow). This is in keeping with mrTRG 2. 
B) Corresponding photomicrograph (Magnification X 0.4, haematoxylin-eosin (H-E) stain) 
demonstrating foci of extramural viable tumour (arrowheads), within the area of fibrosis.  
 
A)                                                   B) 
 
 
Figure 4.15. mrTRG3 
 
A) Axial baseline T2 image shows tumour centred at the 3‗o‘clock position, infiltrating 
through the rectal wall (arrow). 
B) Axial post treatment T2 image shows a mixed area; part low signal fibrosis and part 
intermediate signal intensity indicating mrTRG 3 (arrow).  
 
A)                                                     B) 
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Figure 4.16. mrTRG4 
 
A) Axial T2 weighted MR image shows a semi annular infiltrating tumour between 
1‘o‘clock-5‘o‘clock (arrow). 
B) Axial post treatment image shows a fibrotic low signal extramural rim (arrowheads), 
however there is dominant residual intermediate signal tumour (arrow). Overall this is 
consistent with mrTRG4. 
C) Photomicrograph (Original magnification X 0.4, haematoxylin-eosin (H-E) stain) shows 
extramural fibrosis (arrowhead) with residual tumour between 1‘o‘clock-5‘o‘clock (arrow). 
 
A)                                                       B)                                       
 
C) 
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Figure 4.17. mrTRG5 
 
A) Coronal T2 weighted baseline images showing a semiannular tumour as intermediate 
signal intensity in the rectal wall between the 11‘o‘ clock to 4‘o‘clock position (arrow). 
B) Coronal T2 weighted post treatment image shows little response compared with the 
baseline scan.  
 
 A)                                                  B) 
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4.4.3.3 MRI T stage post treatment 
 
Using the refined ymrT criteria, tumour downstaging was observed between baseline and 
post treatment MRI. Baseline MRI T stage of the 111 evaluable patients was mrT1:1, 
mrT2:9, mrT3a:8, mrT3b:11, mrT3c:29, mrT3d:16, mrT4:37. Post treatment T stage was 
ymrT0:6, ymrT1:1, ymrT2:12, ymrT3a:3, ymrT3b:14, ymrT3c:24, ymrT3d:8 ymrT4:22, 
Missing/not re imaged:21. Table 4.3 shows the raw data. 
 
Table 4.3. Pathological T stage and ymrT 
  Pathology T stage  
 pT0 pT1 pT2 pT3a pT3b pT3c pT3d pT4 Total 
ymrT T0 2 1 2 0 0 1 0 0 6 
T1 0 0 1 0 0 0 0 0 1 
T2 1 1 7 1 2 0 0 0 12 
T3a 0 0 1 0 1 1 0 0 3 
T3b 1 0 4 2 6 1 0 0 14 
T3c 0 0 2 3 6 11 1 1 24 
T3d 0 0 1 1 0 5 0 1 8 
T4 0 0 1 1 3 4 1 12 22 
 Missing 
MRI 
1 0 6 1 2 7 2 2 21 
  5 2 25 9 20 30 4 16 111 
 
Observations showed that often low signal fibrosis can extend extramurally with 
intermediate signal residual tumour present only in the bowel wall. Figure 4.18 illustrates 
an example of residual tumour and fibrosis at differing extramural depths. Cohen‘s kappa 
analysis showed a fair level of agreement between ymrT and pathological T stage with 
K=0.449, standard error 0.053. 
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Figure 4.18. Post treatment MRI T stage 
 
A) Axial T2 weighted MR image shows a semiannular infiltrating tumour (arrowhead) a 
nodule of intermediate signal is seen in a medium sided vein at 3‗o‘clock (arrow). 
B) Axial post treatment image shows tumour regression within the rectal wall, with fibrotic 
low signal scar between  9‘o‘clock-4‘o‘clock (arrowhead). A focus of residual disease 
remains in a vein at 3‗o‘clock (large arrow).  The residual venous disease is 6mm beyond 
the muscularis propria indicating ymrT3c (double headed arrow).  
 
A)                                                       B) 
 
 
4.4.3.4 MRI N stage and MRI CRM status post treatment 
Forty cases were recorded as ymrN positive (N1 or N2) and 50 cases ymrN negative (N0). 
Sixty seven/111 cases were pathological node negative (ypN0), while 44/111 were 
pathological node positive (ypN1/2).The raw data is shown in table 4.4. 
 
The predictive value for MRI identified node negative disease was 76%, while the ability to 
of MRI to identify positive lymph nodes was 60%.  An example of an involved lymph node 
with corresponding pathology is shown in figure 4.19. Cohen‘s kappa analysis showed a 
slight level of agreement with between post treatment MRI Node negative cases and 
pathological node negative cases with a Kappa=0.364, standard error=0.099. 
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Table 4.4. Raw data for Nodal status and CRM status 
 ypN0 ypN1-2 
ymrN   
Negative 38 12 
Positive 16 24 
Missing 13 8 
 
 pCRM Clear pCRM Involved 
ymrCRM   
Clear 54 1 
Involved 19 18 
Missing 15 4 
 
Eighty eight/111 cases were CRM pathologically clear while 23/111 were CRM 
pathologically involved.  The predictive value for MRI CRM clear was 98% while the 
ability of MRI to predict a potentially involved CRM was 49%. Cohen‘s kappa analysis 
showed a fair level of agreement between post treatment MRI CRM status and pathological 
CRM status with kappa=0.48, Standard Error=0.083. 
 
Examples of a potentially clear CRM are seen in figure  4.20 and 4.21 , with spiculation 
and fibrosis seen at the CRM on MRI identified pathologically.  Of the 19 patients with 
ymrCRM potentially involved but pathological CRM clear, 15/19 had locally advanced 
T3b-T4 tumours, Thirteen/19 patients were observed to have small areas of intermediate 
single within more dense areas of fibrosis at the margin, but were pCRM negative.  Figure 
4.22 shows an example of this scenario. 
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Figure 4.19. Nodal restaging following chemoradiation treatment 
 
A)  Axial T2 weighted MR image shows a lymph node in the right lower mesorectum 
(arrow). Malignancy is indicated by signal heterogeneity  
B) Images after CRT, The node continues to have an irregular edge, and signal 
heterogeneity indicating malignancy (arrow). 
C) Corresponding photomicrograph (Original magnification X 0.7, haematoxylin-eosin (H-
E) stain) shows widespread tumour deposition in the lymph node. Since there is minimal 
normal nodal tissue it is indistinguishable from an extra nodal deposit. 
 
A)                                                B)                                        
 
 
C) 
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Figure 4.20. Spiculation at the circumferential resection margin 
 
A) T2 weighted image shows a residual area of mural fibrosis (arrow), with spiculations 
(white arrowhead) extending to the CRM (black arrowhead).  
B) Corresponding photomicrograph shows fibrosis (star) extending to the CRM (black 
arrowheads). 
 
A)                                                           B) 
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Figure 4.21. Fibrosis at the potential circumferential resection margin 
 
A) Baseline T2-weighted image showing a bulky tumour with invasive at the 3‘o‘clock 
position. There is intermediate signal at the circumferential resection margin (arrowhead). 
B) Following chemoradiation treatment, the tumour is now a combination of fibrosis (black 
arrow), which extends to the CRM (white arrowhead). Mucinous degeneration is also seen 
(dashed white arrow). Residual intermediate signal tumour remains at the 6‘o‘ clock 
position (white arrow). The overall mrTRG grade is 3.  
 
A)                                                        B) 
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Figure 4.22. Example of incorrect CRM assessment by MRI 
 
A) Post chemoradiation axial T2 weighted image shows apparent intermediate signal 
tumour (arrow) at the CRM (arrowhead) 
B) Corresponding H&E stained section showed only inflammation (arrow) at the CRM.  
The residual tumour was staged at T3c, with 6mm extramural invasion. 
 
A)                                                        B) 
 
 
 
4.4.3.5 Univariate logistic regression analysis 
 
The data for univariate logistic regression analysis was grouped as section 4.3.2. Using data 
from ROC analysis of mrTRG, Favourable mrTRG was defined as 1-3, unfavourable 
mrTRG 4-5.  Table 4.5 shows univariate logistic regression results. 
 
Patients with mrTRG stage 4-5 were significantly associated with unfavourable pathology 
(32/34), compared with mrTRG stage 1-3 (10/32); p=0.0001; OR 35.2.  
 
ymrT stages T3b-4 were significantly associated with unfavourable pathology (52/67), 
compared with ymrT stage T0-T3a (5/23); p=0.001; OR 11.05.  
 
Post treatment MRI node positive cases stages were significantly associated with node 
positive   pathology (24/40), compared with node negative MRI (12/50); p=0.001; OR 4.75. 
 
Cases identified as having a potentially involved CRM on Post treatment MRI  were 
significantly associated with    pathological CRM involvement  (18/37), compared with 
case with a potentially clear CRM on Post treatment MRI (1/55); p=0.001; OR 45.9. 
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Table 4.5. Pathological endpoints by MRI parameters 
 
 
 
ypT0-
T3a 
 
ypT3b-4 
 
Positive (PPV) and 
Negative predictive 
(NPV) value 
OR (95% CI) 
p value 
mrTRG  
1-3 
4-5 
Missing n=45 
 
22 
2 
 
10 
32 
 
PPV=70% 
NPV=94% 
 
35.20 
(7.02-176.5) 
p=0.0001 
ymrT  
T0-T3a 
T3b-4 
Missing n=21 
 
18 
15 
 
5 
52 
 
PPV=78% 
NPV=78% 
 
11.05 
(3.52-34.68) 
p=0.001 
 ypN0 ypN1-2   
ymrN  
Negative 
Positive 
Missing n=21 
 
38 
16 
 
12 
24 
 
NPV=76% 
PPV=60% 
 
 
4.75 
(1.91-11.75) 
p=0.001 
 pCRM  
Clear 
pCRM 
Involved 
  
ymrCRM  
Clear 
Involved 
Missing n=19 
 
54 
19 
 
1 
18 
 
NPV=98% 
PPV=49% 
 
 
45.90 
(5.72-367.78) 
p=0.001 
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4.5 Discussion 
4.5.1 Observations on MRI post chemoradiation 
 
This study has confirmed that low signal on T2 represents fibrosis, intermediate signal- 
tumour, high signal with intermediate components-mucinous tumour and uniform high 
signal mucinous response. Such changes can be heterogeneous- It is possible for small foci 
of intermediate signal tumour to persist in areas of low signal fibrosis. 
 
Treatment related effects such as spiculation- linear low signal strands often radiating from 
areas of mural fibrosis, are important to appreciate as misinterpretation of desmoplastic 
reaction for residual tumour can lead to overstaging, as the spiculated areas are presumed to 
represent tumour rather than reaction.  Likewise the inflammatory pseudotumour pitfall can 
be avoided by direct comparison of the pre-treatment scans and documenting the invasive 
and rolled edge of tumour as well as the portion of the rectal wall circumference that has 
not been involved by tumour. Other signs such as desmoplastic reaction from the tumour 
were also found to be helpful. 
 
4.5.2 ymrT and mrTRG assessment on MRI post chemoradiation 
 
The mrTRG system is based on the degree of fibrosis/acellular mucinous response versus 
intermediate signal tumour/mucinous tumour.   ymrT assesses the extent of residual tumour 
in relation to the bowel wall.  
 
The diagnostic accuracy of mrTRG calculated by area under the ROC curve was good, but 
not excellent at 0.85. Using ROC analysis mrTRG groups 1-3 were classed as favourable, 
with mrTRG 4&5 unfavourable. Using this grouping for univariate logistic regression 
analysis mrTRG showed a significant relationship with T stage pathology. 
 
Post treatment MRI T stage showed a showed a fair level of agreement between ymrT and 
pathological T stage with Kappa=0.45. When ymrT was grouped as favourable and 
unfavourable for univariate logistic regression a statistically significant relationship was 
observed. 
 
From the observations and data presented it is suggested that the extent of fibrosis can be 
documented and recorded as a separate entity to the extent of tumour signal since fibrosis 
may or may not contain viable tumour and maybe managed differently.   
 
Our grouped ymrT data is similar to studies published from other centres while this thesis 
was being undertaken. For example, Barbaro et al (n=53) analysed the correlation between 
pathological T stage and MR T stage in 53 rectal cancer patients after chemoradiotherapy. 
This study grouped pathological and radiological T stage into T0-T2 (responders) and T3-
T4 (non responders). Of the 36 MR T stage responders, 30 were pathological responders, 
while of the 17 MR T stage non-responders, 12 were pathological nonresponders. The 
overall accuracy of MR was 79%.  Likewise Dresen et al, using the same radiological and 
pathological grouping between T0-T2 tumours versus T3-T4 tumours found of the 11 yMR 
T0-T2 staged patients, 10 were pathological ypT0-T2, while of the 56 yMR T3-4 staged 
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patients, 42 were pathologically staged as yp3-4.  (Barbaro, Fiorucci et al. 2009; Dresen, 
Beets et al. 2009).  
 
The correlation between restaging MRI T stage and pathology T stage is better in these 
studies than previous investigations. This maybe partly due to recent studies (Barbaro, 
Fiorucci et al. 2009; Dresen, Beets et al. 2009) used a 3mm slice thickness high resolution 
protocol, similar to section 3.2. This is likely to have enabled higher quality images 
compared to previous studies using  4mm (Chen, Lee et al. 2005) and 5mm slice thickness 
(Kuo, Chern et al. 2005). Thus, more subtle appearances can be appreciated than on low-
resolution techniques used by earlier studies.  
 
It is important to note that more recent investigations (Barbaro, Fiorucci et al. 2009; 
Dresen, Beets et al. 2009)  did not state if any refinements were made to MRI T staging 
criteria post treatment. Nevertheless a greater appreciation of the reactive changes that 
occur after chemo radiotherapy, meaning morphological changes such as desmoplastic 
reaction were not misinterpreted as tumour, is likely to have contributed to the improved 
reported results. i.e., although not explicitly stated is likely only residual tumour was re T 
staged according to baseline MRI criteria.  
 
Both mrTRG and ymrT showed good ability to identify those with pathological complete 
response (ypT0, n=5)/ near compete response (ypT1 n=2). All 7 patients in this group were 
TRG1/2 and 6/7 were ymrT 1/2. These assessments may therefore be useful as entry 
criteria in a deferral of surgery approach. 
 
4.5.3 CRM and node assessment on MRI post chemoradiation 
 
While the predictive value for MRI identified node negative disease and potential CRM 
clearance was relatively high at 76% and 98% respectively, the ability to of MRI to identify 
positive lymph nodes and potentially involved CRM was lower at 60% and 49% 
respectively. As a result, a fair degree of agreement between MRI CRM potential 
involvement and pathological CRM involvement was observed. 
 
In this analysis of the 19 cases of where the ymrCRM was reported as potentially involved 
in but pathological was CRM clear, 15 had locally advanced ypT3b-T3d tumours extending 
close to the margin. These patients are likely to remain in a poor prognostic group due to 
locally advanced ypT despite being pCRM clear. Therefore correlation of MRI and 
pathological parameters against survival outcomes is warranted. Thirteen/19 patients were 
observed to have small areas of intermediate signal within more dense areas of fibrosis at 
the margin, but were pCRM negative.  
 
Two further studies have supported this chapter‘s data on the difficulty in predicting a 
potentially involved CRM on MRI post CRT. Vliegen et al suggested the development of a 
fat pad larger than 2 mm between a residual tumour mass and the CRM on MRI as a 
definitive sign of the CRM being clear, while the presence of an iso/hyperintense mass 
infiltrating into or beyond the CRM was considered a definitive sign of tumour invasion. 
This study found the prediction of a CRM clear of tumour by MRI was 100% (11/11), 
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while the ability of MRI to predict an involved margin was 57% (30/53). (Vliegen, Beets et 
al. 2008).  Barbaro et al‘s found similar results; of the 7 patients classified as having MRI  
CRM involvement, only 3 had histologic findings of CRM involvement. While 100% (46 
/46) cases with a clear CRM on MRI had a clear pathological CRM (Barbaro, Fiorucci et al. 
2009).  Overall, the data suggests that any surgery should remove fibrotic stroma regardless 
of whether residual tumour signal can be seen.  
 
The ability to predict node positive and negative disease on MRI in this analysis was lower 
than that previously demonstrated by Koh et al. This study showed a negative predictive 
value of 90% (18/20 patients) and a positive predictive value  of 80% (4/5 patients) (Koh, 
Chau et al. 2008). The reason for this difference may be due to this study using data from 
multiple local radiologists rather than two central radiologists. However if involved lymph 
nodes are removed by careful TME dissection they may not influence survival. This is 
further discussed in chapter 6. 
 
4.6 Conclusion 
 
This study shown the novel MRI based tumour regression grading system has a good 
diagnostic accuracy vs. T stage pathology. Using this relatively small data set mrTRG1-3 
appear favourable categories, while mrTRG 4 and 5 appear unfavourable.  
 
Individual post treatment MRI T staging showed only a fair level of agreement with 
pathology. However regression analysis grouping post treatment T stage into favourable 
and unfavourable categories demonstrated a statistically significant relationship with 
pathology.  
 
The ability of post treatment MRI to predict node negative pathology and a potentially 
pathologically clear circumferential resection margin was high. However identifying 
pathologically involved nodes and an involved CRM on MRI was difficult. 
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5 Comparison of different MRI response assessment methods and 
histopathological end points in locally advanced rectal cancer post 
chemoradiotherapy  
5.1 Introduction 
High resolution pelvic magnetic resonance imaging (MRI) is a valuable preoperative 
staging tool for rectal cancer (MERCURY 2007).  Most centres offer preoperative chemo-
radiotherapy (CRT) to patients with locally advanced, T3, T4 rectal adenocarcinoma and 
those threatening the potential anatomical planes of resection. Preoperative CRT has been 
shown to be beneficial in reducing local recurrence rates, and has become a standard of care 
for locally advanced rectal cancer (Sauer, Becker et al. 2004). Accurate preoperative 
assessment of response to therapy may permit the clinical teams to modify conventional 
surgical treatment (Habr-Gama, Perez et al. 2004; O'Neill, Brown et al. 2007).  
 
A number of different methods have been proposed for assessing response of rectal cancer 
to CRT on MRI.  For example MRI tumour regression grading (mrTRG) - investigated in 
chapter 4 using the MERCURY database, showed good diagnostic accuracy correlation 
pathological T stage.  
 
Other proposed methods to assess treatment response involve tumour volume reduction 
estimation and tumour length reduction on MRI. For example Dresden et al examined the 
relationship between tumour volume and pathological T stage. The tumour volume 
reduction rate (TVRR) was significantly higher in ypT0-2 tumours compared to ypT3-4 
tumours.  This study suggested the following criteria to predict an ypT0-2 tumour:   
Tumour volume of <50cm3, a volume reduction rate of >75%, a normal two layered bowel 
wall pattern, and any residual tumour surrounded by a hypodense line corresponding with 
an intact muscular bowel wall (Dresen, Beets et al. 2009). Yeo et al also investigated 
tumour volume reduction using a work station based method of volume calculation in 405 
patients. In this study the tumour volume reduction ratio significantly correlated with both 
ypT and TRG pathological grading as well with complete response. When the TVRR was 
categorised into three groups (<60%, 60–80%, and >80%), the rates of ypT0-T2 and ypN0 
were significantly greater for patients with a TVRR of >60%, as was the favourable TRG 
regression rate (pTRG 3-4) for patients with a TVRR >80% (p <0.05) (Yeo, Kim et al. 
2009).    
 
There is no published evidence for the superiority of a workstation based volume 
assessment compared with conventional three dimensional estimation of tumour volume in 
rectal cancer.  Similar work in cervical cancer did not find the workstation method to be 
substantially different to conventional volume measurements (Mayr, Yuh et al. 2006).  
Therefore investigation of tumour response using the less time intensive single slice 
technique appears the preferred option. 
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Change in maximum tumour length between baseline and post treatment sagittal images 
(modified RECIST) may also be useful in assessment in tumour response. As previously 
discussed, 68/70 patients enrolled in the  EXPERT study showed a decrease in maximum 
tumour length post treatment and correlation with survival, but the correlation between the 
change in tumour length and pathology was not presented (Chau, Brown et al. 2006).   
 
5.2 Aims 
The usefulness of ymrT and mrTRG in the reassessment of rectal cancer post CRT was 
assessed in chapter 4. This analysis used a single pathological outcome (ypT) and did not 
use MRI to assess change in tumour volume or length.  
 
The aim of this study was to compare which of the available imaging methods- post 
treatment T staging (ymrT), tumour regression grading (mrTRG), volume reduction post 
treatment, and modified RECIST length measurement;  can identify good vs. poor 
responders to CRT compared with the histopathological reference standards of ypT and 
pTRG.  
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5.3 Methods & Materials 
5.3.1 Patients 
This analysis was performed in the context of a prospective phase II trial treating patients 
with MRI defined locally advanced rectal cancer with Oxaliplatin, Capecitabine and 
concomitant pelvic radiotherapy. Eighty Six patients were enrolled between July 2003-
December 2004. The local scientific and research ethics committees of each institution 
approved the trial.
 
Eighty three patients had evaluable imaging and 78 had final pathology 
(5 did not undergo surgery). This is summarised in Figure 5.1. 
Figure 5.1. Trial progress flowchart 
 
 
 
 
 
 
 
 
 
 
 
Evaluable Imaging and 
pathology n=78 
 
Received Preoperative 
Chemoradiation  n=86 
 
Restaging MRI scan n=83 
 
Surgery n=78 
 
Not restaged  n=3: 
        Death n=2 
        Emergency surgery=1 
 
Not operated  n=5: 
       Death n=1 
       Disease Progression=3 
       Refusal=1 
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5.3.2 Eligibility 
 
The treatment group comprised only patients that were considered at risk of circumferential 
resection margin (CRM) involvement based on baseline preoperative MRI staging. This 
was defined as tumour within 2 mm of the mesorectal fascia, or any mrT3/T4 tumour 
arising at <5 cm from the anal verge. Patients with distant metastatic disease on clinical
 
examination and computed tomography (CT) of chest, abdomen,
 
and pelvis were excluded.  
Patients were also excluded if they had
 
a history of pelvic malignancy, pelvic radiotherapy, 
or pelvic
 
floor surgery for faecal incontinence or rectal prolapse. 
 
5.3.3 Preoperative treatment 
 
Patients received preoperative treatment with Oxaliplatin, Capecitabine, and radiotherapy 
(XELOX-RT). Chemoradiation therapy comprised 45 Gy RT (1.8 Gy/dose) 5 days/wk for 5 
wks, weekly Oxaliplatin 50 mg/m
2
, and twice-daily Capecitabine 825 mg/m
2
 on each day 
of RT.   Patients were restaged using high resolution pelvic MRI 6-8 weeks post 
chemoradiation therapy.  
 
5.3.4 MRI technique 
 
MRI was performed with 1.5 T whole body MR image systems with a pelvic phased array coil 
according to chapter 3. 
 
5.3.5 MRI image analysis 
 
The terms ymrT (T stage on MRI images obtained after CRT), mrTRG (tumour regression 
grade on MRI images obtained after CRT), mrRECIST (modified RECIST based on 
tumour length on baseline and MRI images obtained after CRT), ypT (T stage on post 
treatment histopathological examination of the resection specimen) and pTRG (tumour 
regression grade on post treatment histopathological examination of the resection 
specimen) are used to describe the data.  
 
Images were prospectively read by central and local investigators for mrRECIST and ymrT. 
Percentage Volume reduction and mrTRG were retrospectively read by the central and 
second reviewer. 
 
5.3.5.1 T stage post CRT 
 
ymrT assessment was based on identification of persistent tumour signal intensity relative 
to the layers of bowel wall on T2 weighted images. Comparison was made with the pre-
treatment images. Tumour response manifested as either replacement of tumour signal by 
low signal intensity fibrosis or the development of high signal intensity mucin pools -such 
areas where not considered as tumour and did not contribute to T stage. ymrT staging 
criteria was the same as baseline MRI T staging (this was detailed in section 4.2.7).  
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Based on known histopathological outcomes according to ypT stage and along similar lines 
to other studies, ymrT stage was divided into favourable and unfavourable response to 
enable binary comparison. Favourable regression was defined as stages ymrT0,1,2, and 3a, 
while unfavourable grading was defined as ymrT3b,c,d and 4 (Willett, Badizadegan et al. 
1999). 
 
5.3.5.2  MRI tumour regression grading 
 
The MRI scans were anonymised and separately reviewed by two radiologists with 14 (GB) 
and 5 (UBP) years experience in MRI assessment of rectal cancers using the previously 
defined criteria in Table 1.6.  Figure 5.2 illustrates the MR tumour regression system. 
 
Good MRI tumour regression grade was defined as grades 1,2 and 3 with poor defined as 
stages 4 and 5.  This binary division was chosen as per chapter 4 results.  
 
Figure 5.2. mrTRG1-5 
 
mrTRG1 
A) Axial baseline images showing a semiannular tumour as intermediate signal intensity in 
the posterior rectal wall between the 3‘o‘ clock to 9‘o‘clock position. 
B) Axial post treatment image shows a fibrotic low signal scar at 6‘o‘clock, there is high 
signal intensity submucosal oedema, absence of any tumour signal indicates an mrTRG1. 
 
A)                                                          B) 
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mrTRG2 
C) Coronal baseline images show a semiannular tumour centered at the 9‘o‘clock position 
(arrow). 
D) Coronal post treatment image shows a fibrotic low signal scar at 9‘o‘clock. A small 
amount of residual tumour remains inferior to the scar (white arrow), therefore there is 
predominant scar signal intensity post treatment with minimal residual tumour indicating 
mrTRG2. 
 
C)                                                           D)    
 
 
 
mrTRG3 
E) Axial baseline image shows tumour centred at the 12‘o‘clock position (arrows), 
infiltrating through the anterior rectal wall. 
F) Axial post treatment image show mixed areas of low signal fibrosis and intermediate 
signal intensity indicating mrTRG 3 (arrow). 
 
E)                       F) 
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mrTRG4 
G) Axial baseline images show an annular infiltrating tumour (black arrows). 
H) Axial post treatment images shows persistent intermediate signal intensity tumour with 
minimal low signal fibrosis (white arrow), therefore tumour signal intensity predominates 
in keeping with mrTRG 4. 
 
G)                                           H) 
 
 
 
mrTRG5 
I) Axial baseline images show an annular tumour (black arrow), with extramural extension 
at the 3‘o‘clock position (white arrow). 
J) Axial post treatment images show little response compared with the baseline scan, MR 
TRG5 
 
I)                             J) 
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5.3.5.3 MRI modified RECIST 
 
Maximum tumour length was measured on sagittal images pre and post treatment. 
Percentage change in tumour length was classified using RECIST criteria with complete 
disappearance of tumour being defined as complete response. Partial response to treatment 
was defined as at least a 30% decrease in tumour length, taking as reference the baseline 
tumour length. Progression of disease was defined as at least a 20% increase in tumour 
length, stable disease was defined as neither sufficient shrinkage to qualify for partial 
response nor sufficient increase to qualify for progression of disease (Therasse, Arbuck et 
al. 2000). For the analysis partial response was categorised as favourable, while stable 
disease or progression of disease was unfavourable. 
 
5.3.5.4 MRI volumetric analysis 
 
MRI scans were assessed using previously defined criteria; (Barbaro, Fiorucci et al. 2009) 
an axial slice was selected where the tumour had maximal dimensions. The length and 
width of the tumour was measured on this slice. Maximal height was measured on a sagittal 
section. Tumour volume was obtained by multiplying tumour length, width and height. 
Percentage volume reduction, was defined as 100* [(Volume baseline-Volume post 
CRT)/Volume baseline)]. Volume reduction rates were categorised into three groups 
(≤60%, 60–80%, and ≥80%), according to previous criteria (Yeo, Kim et al. 2010). 
 
5.3.6 Surgery 
 
Total mesorectal excision with or without abdominoperineal excision was performed 6-8 
weeks after the completion of CRT. This time is based on the only randomised controlled 
trial to investigate timing of surgery post CRT (Francois, Nemoz et al. 1999). 
 
5.3.7 Histopathological assessment 
 
After surgical resection, the specimen was fixed in formalin for 48 hours, cross sectioned 
into 3-5 mm slices and histologically sampled. There was a defined a pathologic protocol to 
classify pCR; Firstly the whole area of the tumour was embedded, and at least ﬁve blocks 
were sampled including at least one large block. If tumour cells could not be found on  
initial examination, three levels were taken and examined from each tumour block. If after 
these assessments no tumour cells were indentured then the tumour was considered to have 
undergone a complete pathologic response.  
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5.4  Statistics 
5.4.1 Grouping of pathological  endpoints 
As well as grading and staging by the 5 point pTRG (Dworak, Keilholz et al. 1997) and 
ypTNM version 5 systems, a simplified pathological grading of favourable and 
unfavourable pathology was also undertaken. Favourable pathology was defined as ypT 
stages 0, 1, 2 and 3a or pTRG stages 3 and 4, while unfavourable pathology was defined as 
ypT stages 3b, c, d and 4 or pTRG stages 0,1,and 2. ypT3a was included in the favourable 
group as these tumours have been shown to have a similar prognostic outcome as ypT2 
tumours (Willett, Badizadegan et al. 1999). 
 
The area under the ROC was used to indicate the diagnostic accuracy of MRI parameters 
(details below) and was classified as follows: 0.9-1=excellent, 0.8-0.9=good, 0.7-0.8=fair, 
0.6-0.7=poor, 0.5-0.6=fail.    
 
Kappa analysis was also used and defined as follows; κ < 0, poor agreement; κ =0–0.20, 
slight agreement; κ =0.21–0.40, fair agreement; κ =0.41–0.60, moderate agreement; κ 
=0.61–0.80, substantial agreement; and κ =0.81–1.00, almost perfect agreement. 
 
Central reviewer data was used for analysis. Agreement between the two observers grading 
categorical variables (ymrT, mrTRG, change in volume and mrRECIST) was also 
determined by kappa calculation. Calculations were performed using Statistical Package for 
Social Sciences program, version 15.0 (SPSS, Chicago, Illinois, USA). P values of less than 
0.05 were considered significant.  
 
5.4.2 mrTRG analysis 
ROC analysis was used to calculate the diagnostic accuracy of the mrTRG with the binary 
pathological outcome measure of favourable and unfavourable T stage pathology. ROC 
analysis was also used to assess any relationship between mrTRG and favourable and 
unfavourable TRG. 
 
5.4.3 ymrT analysis 
Cohen‘s Kappa was used to analyse the association between ymrT and pathological T 
stage.  ROC analysis was also used to assess any relationship between ymrT and favourable 
and unfavourable TRG  
 
5.4.4 MRI modified RECIST and MRI Volumetric Analysis. 
The Mann-Whitney U test was used to assess if there was a significant difference between 
the Sum of Ranks of favourable and unfavourable mrRECIST scores. Similarly the Kruskal 
Wallis one way analysis variance test was used to assess if there was a significant 
difference between the three volume reduction rates distributions.  
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5.4.5 Univariate logistic regression 
Univariate logistic regression analysis was undertaken to analyse the association between 
demographic variables (patient age and sex), type of operation, MRI parameters divided 
into favourable and unfavourable groups (ymrT, mrTRG, change in volume, mrRECIST) 
and pathologic tumour response (in terms of ypT and pTRG). This enabled calculation of 
odds ratios for the probability of an unfavourable pathological outcome.  
 
5.5 Results 
Table 5.1 shows the baseline demographics of the patients who were eligible for this study. 
The mean baseline tumour length was 5.32cm; standard deviation (SD) 1.83cm. The mean 
baseline tumour volume was 58.13 (SD 80.03cm
3
). The mean post treatment tumour length 
was 3.55 (SD 1.37cm
3
) and the mean post treatment tumour volume was 17.43 (SD 
19.92cm
3
). The mean tumour length change was -31.57% (SD 20.95%) and the mean 
tumour volume reduction rate was -62.76% (SD 34.39%). 
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Table 5.1. Patient characteristics of patients with full imaging and pathology n=78 
 
  No of patients 
Age:  <65 years 52 
 ≥65 years 26 
Sex: Male 58 
 Female 20 
Height of primary 
tumour  
(from anal verge): 
Low        (0-5 cm) 51 
Medium/High  (≥5-10 
cm) 
27 
Tumour stage at 
baseline on  
MR:  
T2 11 
T3a 6 
T3b 15 
 T3c 21 
 T3d 16 
 T4 6 
 Poor image quality 3 
Tumour stage post 
CRT on MR (ymrT) 
Central r/v:  
T0 9 
T1 3 
T2 10 
 T3a 8 
 T3b 13 
 T3c 21 
 T3d 4 
 T4 5 
 Missing  5 
Tumour regression 
grade on MR 
(mrTRG) Central r/v: 
TRG1 6 
TRG2 27 
TRG3 14 
 TRG4 20 
 TRG5 2 
 Missing 9 
Modified MR 
RECIST 
Central r/v: 
Partial response 46 
Stable disease 26 
Progression 0 
 Missing  6 
Volume change 
Central r/v: 
>-80% to 100% 20 
≥- 60% to ≤-80% 25 
 ≥0% to <-60% 23 
 Missing 10 
Post operative T stage 
pathology (ypT):  
n=78 
T0  11 
T1 4 
T2 13 
 T3a 6 
 T3b-d 40 
 T4 4 
Post operative TRG Favourable 27 
 Unfavourable 51 
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5.5.1 mrTRG results  
 
Table 5.2 shows the ypT histopathology status of patients by individual mrTRG grade. 
Table 5.3 shows simplified ypTRG status by individual mrTRG grade. ROC analysis was 
undertaken to calculate the area under the ROC curve (AUC). Figure 5.3 shows the ROC 
analysis for mrTRG vs. both T stage pathology and pathological TRG. The AUC is 0.82 for 
ypT, indicating mrTRG has a good diagnostic accuracy for T stage pathology. The AUC for 
mrTRG vs. TRG pathology was 0.77 indicating a fair diagnostic accuracy. Section 5.8 
shows raw data tables indicating grouping mrTRG stages 1-3 as favourable and mrTRG 
stages 4&5 as unfavourable gives the highest possible sensitivity and specificity for both 
pathological endpoints. 
 
Table 5.2. Histopathological T stage by individual mrTRG grade 
  Pathological T stage 
  T0 T1 T2 T3a T3b-d T4 
mrTRG 1 1  2  3  
2 8 4 9 2 4  
3   1 2 11  
4    2 17 1 
5     2  
Missing 2 0 1 0 3 3 
 
 
Table 5.3.  mrTRG vs. Pathological Tumour Regression Grade 
  
pTRG favourable 
(pTRG3&pTRG4) 
pTRG unfavourable 
(pTRG0, 1& 2) 
mrTRG 1  3 3 
 2 17 10 
 3 1 13 
 4 1 19 
 5 1 1 
  Missing n=9  
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Figure 5.3. mrTRG ROC analysis   
 
A, mrTRG vs. Pathological T stage 
B, mrTRG vs. Pathological TRG 
   
  A         B 
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5.5.2 Post CRT  ymrT results 
 
Cohen‘s kappa analysis showed a fair level of agreement between ymrT and pathological T 
stage with Cohen‘s kappa=0.33, standard error 0.069. Table 5.4 shows the raw data used 
for this calculation. 
 
Table 5.4 Histopathological T stage by individual ymrT stage 
  Pathological T stage 
   T0 T1 T2 T3a T3b-d T4 
ymrT ymrT0 3 1 3  2  
ymrT1  1 2    
ymrT2 3 1 2 2 2  
ymrT3a 1  3 2 2  
ymrT3b 1  2  10  
ymrT3c 2    17 2 
ymrT3d     4  
ymr4  1  2 1 1 
Missing 1 0 1 0 2 1 
 
ROC analysis was undertaken to assess the relationship between ymrT and pathological 
tumour regression grade. Figure 5.4 shows the ROC analysis, Table 5.5 shows the raw data. 
The area under the ROC curve (AUC) is 0.78, 95% confidence limits (0.65-0.91),  
indicating ymrT has a fair diagnostic accuracy for TRG pathology.  
 
Figure 5.4.  ROC analysis of ymrT vs. Binary Pathological Regression Grade 
Table 5.5. ymrT Vs. Pathological Tumour Regression Grade 
 
Missing n=5 
  
pTRG 
good 
(pTRG3 
pTRG4) 
pTRG 
poor 
(pTRG0 
pTRG1 
pTRG2) 
ymrT ymrT0 7 2 
 ymrT1 3  
 ymrT2 5 5 
 ymrT3a 3 5 
 ymrT3b 2 11 
 ymrT3c 2 19 
 ymrT3d  4 
 ymr4 2 3 
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5.5.3 MRI modified RECIST analysis 
Table 5.6 shows the distribution of  MRI RECIST scores across the different pathological T 
stages. Figure 5.5 graphically displays the same data, with individual pathological T stages 
as the y axis and frequency as the x axis. The blue bars show those with a MRI RECIST 
partial response, while the green bars show MRI RECIST stable disease/progression. The 
figure shows the data to be distributed non-parametrically.   
 
Table 5.6.  MRI RECIST  vs. Pathological T stage 
 Pathological T stage 
   T0 T1 T2 T3a T3b-d T4 
MR 
RECIST 
Partial 
Response 
 7 3 12 3 20 1 
Stable/ 
Progression 
 3 1 0 3 17 2 
Missing n=6 
 
Figure 5.5 Histogram showing distribution of MRI RECIST data by T stage pathology 
 
The Mann-Whitney U test calculation was performed to assess if there was a difference 
between the Sum of Ranks between the Partial Response MRI group and the Stable Disease 
MRI group.  A significant difference (p=0.025) was found between the MRI partial 
response group and the MRI Stable disease group. This is shown in table 5.7. 
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Table 5.7. Mann-Whitney U test results for MRI RECIST and T stage pathology 
Modified MRI RECIST n Mean Rank Sum of Ranks Test Statistic 
Partial response 46 32.64 1501.50 p=0.025 
Stable disease/Progression 26 43.33 1126.50  
 
5.5.4 MRI Volumetric Analysis 
Table 5.8 shows the distribution of data between the three MRI Volume groups and 
different pathological T stages. Group 1 80% to 100% volume reduction, Group 2  60% to 
80% volume reduction , Group 3 no change in volume up to 60% volume reduction). 
Figure 5.6 graphically displays the same data, with individual pathological T stages as the x 
axis and frequency as the y axis.  
 
Table 5.8.  MRI Volume Change vs. Pathological T stage 
  Pathological T Stage 
   T0 T1 T2 T3a T3b-d T4 
MRI 
Volume 
change 
>-80% to 100% 
 2 2 7 1 8  
≥- 60% to ≤-80% 
 6 2 3 2 11 1 
≥0% to <-60% 1  2 3 17  
Missing n=10 
Figure 5.6 MRI Volume Groups and Pathological T stage 
 
 
Blue = 80% to 100% volume reduction group, Green = 60% to 80% volume reduction group 
Beige = No change in volume to 60% volume reduction group 
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The Kruskal Wallis One-Way Analysis of Variance was used as the data was distributed in 
a non-parametrically. A borderline significant difference (p=0.05) was found between the 
Mean Ranks  between the three MRI volume change groups. This is shown in table 5.9. 
 
Table 5.9.  Kruskal Wallis Analysis of MRI Volume Change vs. T stage pathology 
 
  n 
Mean 
Rank  
Test 
Statistic 
Volume change >-80% to 100% 
 20 29.70 p=0.05 
≥- 60% to ≤-80% 
 25 31.24  
≥0% to <-60% 23 42.22  
 
5.5.5 Univariate binary logistic regression results 
 
Table 5.10 shows the ypT histopathology status of patients by age, sex, operation, mrTRG, 
ymrT, mrRECIST, and volume change. Patients with mrTRG stage 4-5 were significantly 
associated with unfavourable pathology (20/22), compared with mrTRG stage 1-3 (18/47); 
p=0.001; OR 16.11 (3.36-77.29). Furthermore, ymrT stage T3b-4 was significantly 
associated with unfavourable pathology (35/43), compared with ymrT stage T0-T3a (6/30); 
p=0.001; OR 17.50 (95% CI 5.38-56.89).  
 
mrRECIST stable disease/progression was significantly associated with unfavourable 
pathology (19/26), compared with partial response (21/46); p=0.028; OR 3.23 (95% CI 
1.14-9.17).  No change to a 60% decrease in volume was significantly associated with 
unfavourable ypT (17/23), compared with an 80-100% decrease in volume (8/20); p=0.028; 
OR 4.25 (95% CI 0.92-15.45).  
 
Table 5.11 shows the TRG histopathology status of patients by age, sex, operation, mrTRG, 
ymrT, mrRECIST and volume change. As with ypT significantly more patients with 
mrTRG stage 4-5 had unfavourable pathology (20/22), compared with mrTRG stage  1-3 
(26/47); p=0.009; OR 7.98 (95% CI 1.66-38.29). Furthermore, significantly more patients 
with ymrT stage T3b-4 had unfavourable pathology (37/43), compared with ymrT stage 
T0-T3a  (12/30); p=0.001; OR 9.25 (95% CI 3.00-28.64). Borderline statistical significance 
was seen for age. No significant relationship was shown for either mrRECIST or volume 
change and pathological TRG.  
 
5.5.6 Interobserver agreement 
 
There was a moderate level of agreement for mrTRG (49 cases reviewed κ =0.55 SE=0.11). 
A moderate level of agreement was also calculated for ymrT (76 cases κ =0.41 SE=0.11). 
For ymrT and mrTRG disagreements between the central reviewer and second reviewer 
were in the identification of favourable responders, with the central reviewer classifying 
more patients as good responders (see Table 5.12). There was fair agreement for change in 
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tumour volume on MRI (64 cases reviewed κ =0.27 SE=0.08). There was slight agreement 
for mrRECIST (64 cases reviewed κ = 0.13 SE=0.12).  
 
Table 5.10.  ypT pathology status by clinical and MRI parameters 
 
 ypT0-
T3a 
 
ypT3b-
4 
 
OR (95% CI) P value 
Age 
<65 years 
≥65 years 
 
20 
14 
 
32 
12 
 
1.00 
0.54 (0.21-1.39) 
 
0.19 
Sex 
Male 
Female 
 
27 
7 
 
31 
13 
 
1.00 
1.62(0.56-4.64) 
 
0.37 
Operation  
TME 
APR 
 
22 
12 
 
34 
10 
 
1.00 
0.54(0.19-1.46) 
 
0.22 
mrTRG Central r/v 
1-3 
4-5 
Missing n=9 
 
29 
2 
 
 
18 
20 
 
1.00 
16.11 (3.36-77.29) 
 
0.001 
ymrT Central r/v 
T0-T3a 
T3b-4 
Missing n=5 
 
24 
8 
 
6 
35 
 
1.00 
17.50 (5.38-56.89) 
 
0.001 
mrRECIST 
Partial Response 
Stable/ Progression 
Missing n=6 
 
25 
7 
 
21 
19 
 
1.00 
3.23 (1.14-9.17) 
 
0.028 
Volume change 
>-80% to 100% 
≥- 60% to ≤-80% 
≥0% to <-60% 
Missing n=10 
 
12 
13 
6 
 
8 
12 
17 
 
1.00 
1.39 (0.42-4.55) 
4.25 (0.92-15.45) 
 
 
0.59 
0.028 
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Table 5.11.  TRG pathology status by clinical and MRI parameters 
 
 TRG  
good 
(3,4) 
TRG 
poor 
(0,1,2) 
OR (95% CI) P value 
Age 
<65 years 
≥65 years 
 
14 
13 
 
38 
13 
 
1.00 
0.37 (0.14-0.99) 
 
0.047 
Sex 
Male 
Female 
 
23 
4 
 
35 
16 
 
1.00 
2.63 (0.78-8.86) 
 
0.12 
Operation  
TME 
APR 
 
20 
7 
 
36 
15 
 
1.00 
1.19 (0.42-3.40) 
 
 
0.75 
mrTRG Central r/v 
1-3 
4-5 
Missing n=9 
 
21 
2 
 
26 
20 
 
1.00 
7.98 (1.66-38.29) 
 
0.009 
ymrT Central r/v  
T0-T3a 
T3b-4 
Missing n=5 
 
18 
6 
 
12 
37 
 
1.00 
9.25 (3.00-28.64) 
 
0.001 
mrRECIST 
Partial Response 
Stable/ Progression 
Missing n=6 
 
18 
6 
 
28 
20 
 
1.00 
2.23 (0.78-6.38) 
 
0.14 
Volume change 
>-80% to -100% 
≥-60% to ≤-80% 
≥0% to <-60% 
Missing n=10 
 
8 
10 
5 
 
12 
15 
18 
 
1.00 
1.09 (0.33-3.67) 
2.33 (0.60-9.02) 
 
 
0.89 
0.22 
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Table 5.12.  Interobserver agreement of MRI parameters 
Table 5.4A. mrTRG agreement 
 Central r/v 
2
nd
 reader r/v  Favourable Unfavourable 
Favourable 24 0 
Unfavourable 11 14 
κ =0.55,  SE=0.11,  n=49. 
 
Table 5.4B. ymrT agreement 
 Central r/v 
Local  reader r/v  Favourable Unfavourable 
Favourable 15 5 
Unfavourable 16 40 
κ =0.41, SE=0.11, n=76. 
 
Table 5.4C. mrRECIST agreement 
 Central r/v 
Local  reader r/v  Favourable Unfavourable 
Favourable 25 13 
Unfavourable 15 13 
κ =0.13, SE=0.12, n=66. 
 
Table 5.4D. Volumetric analysis agreement 
 Central r/v 
Local  
reader r/v 
 >80% 
reduction 
60-80% 
reduction 
<60% 
reduction/ 
unchanged 
>80% reduction 16 15 4 
60-80% reduction 1 3 5 
<60% 
reduction/unchanged 
2 5 13 
κ =0.27, SE=0.08, n=64. 
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5.6 Discussion 
This study assessed the relationship between ymrT staging, mrTRG, change in volume and 
modified RECIST agreement with the pathology standards of ypT and pTRG. 
 
Using ROC analysis mrTRG had a good diagnostic accuracy for T stage pathology and a 
fair diagnostic accuracy for TRG pathology. A combination of ROC and kappa analysis 
showed ymrT had a good diagnostic accuracy for TRG pathology and a fair level of 
agreement with pathological T stage. Binary logistic regression analysis showed that 
grouped ymrT and mrTRG assessment showed a statistically significant relationship with 
both histopathological parameters. 
 
The Mann-Whitney U test showed a significant difference between the Sum of Ranks for 
the MRI partial response group and the MRI Stable disease group, while a borderline 
significant difference was found between MRI volume change groups using the Kruskal 
Wallis test. Binary logistic regression analysis showed both RECIST measurements and 
volume reduction of >80% had odds ratios of 3.23 and 4.25 respectively for a good ypT 
score, however no relationship was observed with histopathological TRG. Furthermore, the 
interobserver agreement for RECIST and MRI volume measurements was only slight and 
fair compared with better, moderate interobserver agreement for mrTRG and ymrT staging.  
 
The binary logistic regression analysis suggests the strength of the relationship of mrTRG 
and ymrT with histopathology is stronger than RECIST and volume measurements.  No 
previous studies investigating volume measurement and final pathology have formally 
compared these endpoints against other MRI parameters such as ymrT and mrTRG 
assessment (Yeo, Kim et al. 2010),(Dresen, Beets et al. 2009),(Kang, Kim et al. 2010), this 
is an important area for future research. 
 
A potential limitation of the present study is that tumours were not outlined slice-by-slice 
on a workstation to calculate volume. However, as previously noted, there is no published 
evidence for the superiority of a workstation based volume assessment compared with 
conventional three dimensional estimation of tumour volume in rectal cancer.  A further 
possible limitation is that not all MR parameters were measured for all 78 patients, 
nevertheless 87 % (68/78) had complete data indicating that our results are likely to be 
representative of the population studied. 
 
5.7 Conclusion 
Overall mrTRG and ymrT staging showed fair/good levels of diagnostic accuracy 
compared to MRI length and volume assessment. MR RECIST analysis also showed a 
significant difference between the MRI partial response group and the MRI Stable disease 
group. These parameters appear useful in response assessment although the level of 
agreement with pathological endpoints is fair/good rather than excellent. 
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5.8 Raw data tables 
Table 1.  mrTRG cut-off for T stage pathology 
mrTRG Sensitivity(%) Specificity(%) 
mrTRG1 vs. mrTRG 2-5 92.1 9.7 
mrTRG1&2 vs. mrTRG 3-5 85.5 60.0 
mrTRG1-3 vs. mrTRG 4&5 81.6 83.9 
mrTRG1-4 vs. mrTRG 5 52.6 93.5 
 
Table 2. mrTRG cut-off for Tumour regression grade 
pathology 
mrTRG Sensitivity(%) Specificity(%) 
mrTRG1 vs. mrTRG 2-5 93.5 13.0 
mrTRG1&2 vs. mrTRG 3-5 87.3 58.6 
mrTRG1-3 vs. mrTRG 4&5 71.7 87.0 
mrTRG1-4 vs. mrTRG 5 43.5 91.3 
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6 MRI detected tumour response for locally advanced rectal cancer 
and survival outcomes 
6.1 Introduction 
In rectal cancer, long course radiotherapy or preoperative combination chemoradiotherapy 
together with total mesorectal excision surgery (TME) surgery has been associated with 
improved curative surgery rates and reduced local recurrence (Kapiteijn, Marijnen et al. 
2001). As discussed in 1.54-1.57 MRI enables appropriate selection of patients based on 
assessment of locally advanced disease and the relationship of tumour to the potential 
resection margin (Brown, Richards et al. 1999). 
 
Assessment of treatment efficacy normally relies on histopathology after the tumour has 
been resected. Pathology studies have shown that in assessment of irradiated specimens, 
post treatment T and N stage (ypT and ypN) can predict local recurrence, disease free 
survival and overall survival (Capirci, Valentini et al. 2008). The pathological Dworak 
tumour regression grading system (pTRG) (Dworak, Keilholz et al. 1997; Wheeler, Warren 
et al. 2002) has also been shown to predict overall survival and is considered to be an 
important prognostic predictor for disease free survival (Vecchio, Valentini et al. 2005).  
 
High resolution MRI has been used to assess tumour response prior to surgical resection. 
To date all studies have compared MRI assessment with pathology, the relevance of post 
treatment MRI assessment in predicting survival outcomes has not been investigated.  
Furthermore, by applying the principles of histopathology grading and exploiting the 
characteristic MRI low signal intensity appearances of fibrosis, it has been possible to 
develop a similar MRI based tumour regression grading system as well as refinement of T 
and N staging and CRM assessment post chemoradiation (Chapter 4).   
 
In 2002, the MERCURY prospective study evaluated the diagnostic accuracy MRI staging 
in a consecutive series of patients with biopsy proven rectal cancer undergoing TME 
surgery with histopathology as the reference standard. The 5 year follow-up of this cohort 
was completed in December 2008. This chapter reports a planned subgroup analysis of post 
treatment MRI scan parameters and survival outcomes of patients enrolled in this study 
(MERCURY 2006). 
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6.2 Aims 
In chapters 4 and 5, it was observed that grouped MRI based tumour regression grading 
system as well as grouped post treatment MRI T staging showed statistically significant 
correlation with pathological endpoints. Favourable correlation between node negative MRI 
and node negative pathology as well as circumferential resection margin clearance and 
pathology was also observed. Overall diagnostic performance of mrTRG and ymrT was 
good and fair respectively, with neither factor showing an excellent diagnostic accuracy vs. 
pathology.  
 
Therefore, the aim of this analysis was to evaluate the prognostic relevance, as judged by 
overall survival, disease free survival and local recurrence of post neoadjuvant therapy MRI 
assessment of tumour stage, nodal status, CRM and MRI tumour regression grading system 
in patients undergoing neoadjuvant therapy and TME surgery in the MERCURY study. 
Assessment of pathological, N and CRM involvement against outcome was also 
investigated. 
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6.3 Methods & Materials 
6.3.1 Patients, recruitment, preoperative treatment and surgery 
The background of the study was detailed in section 4.2: 
Recruitment- including inclusion and exclusion criteria is summarised in section 4.2.2 and 
figure 4.1 (Trial progress flowchart). 
Preoperative treatment and surgery details were also described in sections 4.2.3 and 4.2.4. 
 
6.3.2 MRI assessment 
A one day imaging workshop for specialist gastrointestinal radiologists participating in the 
study was held prior to recruitment in 2002 to ensure standardisation of scan acquisition 
techniques (section 3.2.1) and image interpretation prior to the study according to published 
criteria (Brown, Richards et al. 1999; Brown, Radcliffe et al. 2003; Brown, Davies et al. 
2004). All scans were single-read by each investigating centre radiologist, with 5-15 years 
GI radiology experience.  
 
T staging of tumour post treatment (ymrT) was based on interpretation of local extent of 
persistent tumour signal intensity relative to the layers of bowel wall on T2 weighted 
images as discussed in section 4.3.5. 
 
Nodal stage post treatment was based on interpretation of lymph node border characteristics 
and signal intensity (Koh, Chau et al. 2008). A node was regarded as positive if either an 
irregular border or mixed signal intensity was demonstrated.  
 
Post treatment MRI scans were also evaluated for predicted circumferential resection 
margin status (ymrCRM). A predicted clear circumferential resection margin was defined if 
the distance of intermediate signal tumour to the mesorectal fascia was greater than or equal 
to 1 mm on MRI, as discussed in section 4.2.7. For lower third rectal tumours, the 
definition of predicted ymrCRM involvement was tumour within 1mm of the levator 
muscle. If the tumour was present at or below the level of the puborectalis sling, the 
ymrCRM was predicted involved if there was invasion into the intersphincteric plane or 
beyond. The ymrCRM status was recorded prospectively in the study by each participating 
radiologist. When a post-treatment scan was not performed, the CRM at baseline was 
entered as CRM status. All MRI-assessed T, N, and CRM staging data were obtained 
prospectively by workshop trained radiologists. 
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6.3.2.1 MRI tumour regression grading 
 
Of 111 patients undergoing preoperative therapy, 90 also underwent post treatment MRI 
before surgery.  Sixty–six of 90 (73%) pre and post treatment scans were available for MRI 
TRG grading.  MRI scans were anonymised and centrally reviewed by a radiologist with 
14(GB) years experience in MRI assessment of rectal cancers using previously defined 
criteria (Brown, Chau et al. 2003). 
 
In order to assess the reproducibility of the MRI TRG system, pre and post treatment scans 
were reviewed independently by 2 radiologists (CDG and HE) with 5-15 years experience 
in MRI staging of rectal cancers and compared with the central reviewer. 
 
6.3.3 Histopathological assessment 
After TME, the specimen was axially sectioned into 3-5 mm slices, as described by Quirke 
et al (Quirke, Durdey et al. 1986). A clear pCRM was defined as greater than, or equal to, 1 
mm between the tumour and the resection margin. Eighteen pathologists, with 5-25 years 
experience in gastrointestinal pathology, evaluated specimens for the post treatment T and 
N stage ypT, ypN and circumferential margin status (pCRM).  
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6.4 Statistics 
6.4.1  Grouping of data 
Tumours were categorised into ―good‖ and ―poor‖ responders to enable binary comparison 
by multivariate analysis.  mrTRG, ymrT, ymrN and ymrCRM as well as ypT, ypN and   
pCRM were grouped as discussed in section 4.1.1. 
 
6.4.2 Follow-up 
Patients were followed according to local protocols, typically this comprised outpatient 
assessment at three-monthly intervals for two years then six monthly for five years. Clinical 
follow up comprised physical examination, routine blood tests and yearly CT of the thorax, 
abdomen and pelvis. Histopathological confirmation of local and distant recurrences was 
sought when feasible.   Surgical data included; date of operation, procedure performed and 
quality of the specimen. Date of enrolment, last follow-up, date of disease progression, date 
and cause of death were also prospectively collected. The presence of distant metastatic 
disease or local recurrence at the time of death was recorded as a rectal cancer specific 
death. 
 
6.4.3 Analysis 
Local recurrence was measured from date of original trial enrolment until local progression; 
disease free survival was measured from date of enrolment until progression at any site or 
death from any cause; patients who were alive and disease free were censored at last 
follow-up or death.  
 
Cox proportional hazard models were used to analyse the effect on local recurrence, disease 
free and overall survival by preoperative MRI staging variables (ymrT, ymrN, ymrCRM 
and mrTRG) and pathological variables (ypT, ypN, pCRM). Other potential factors age, 
sex, type of surgery (Total mesorectal excision or Abdominoperineal resection with TME 
approach), tumour height (≤5cm or >5cm) and treatment (chemoradiation or long course 
radiation) were included in the multivariate analysis for each MRI/pathology staging 
variable. Survival curves were calculated using the Kaplan Meier product limit method and 
differences between survival curves were tested using the Univariate Log-rank test. 
 
Agreement between the two observers grading mrTRG was determined by the kappa 
statistic. (κ < 0, poor agreement; κ = 0–0.20, slight agreement; κ = 0.21–0.40, fair 
agreement; κ = 0.41–0.60, moderate agreement; κ = 0.61–0.80, substantial agreement; and 
κ = 0.81–1.00, almost perfect agreement).  
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6.5 Results 
Eighty-one of 111 patients (73%) were considered to have potential ymrCRM involvement 
prior to neoadjuvant therapy, this reduced to 47/111 (42%) after treatment. The number of 
mrT3c, T3d and T4 tumours reduced from 82/111 to 53/111. Table 6.1 shows demographic 
characteristics and survival outcomes of 111 patients included in the analysis. As of 
December 2008, surviving patients had been followed for a median of 50 months (range: 
0.6-71 months). All 111 patients had evaluable post operative pathology and complete 
follow-up data. During the follow-up period 54 patients died, 40 died of cancer related 
causes, 5 non cancer deaths, 4 peri/post operative and in 3 patients the cause of death was 
unknown. Fifty patients had disease progression, 42 patients recurred with metastatic 
disease and 8 relapsed with local recurrence only.   
 
Table 6.2 summarises the results of multivariate analysis of known clinical variables: age, 
sex, height of tumour from anal verge, type of preoperative treatment, and type of 
operation, according to each of the MRI preoperative staging variables and survival 
outcomes. mrTRG was significant for overall survival and disease free survival; hazard 
ratios were 4.40  (95% CI 1.65-11.7) and 3.28 (95% CI 1.22-8.80) respectively.  
 
Overall survival at five years for poor mrTRG patients was 27% (95% CI 8-47%) compared 
with 72% (95% CI 56-88%) for good mrTRG patients (p=0.001 Univariate log-rank 
analysis). Disease free survival at five years for poor mrTRG patients was 31% (95% CI 
13-49%) compared with 64% (95% CI 47-82%) for good mrTRG patients (p=0.007 
Univariate log-rank analysis). This is illustrated in figures 6.1 and 6.2. 
 
On multivariate analysis post treatment prediction of ymrCRM was significant for local 
recurrence. The hazard ratio for predicted involved ymrCRM and local recurrence was 4.25 
(95% CI 1.45-12.51). The local recurrence rate at five years for predicted involved 
ymrCRM patients was 28% (95% CI 13-44%) compared with 12% (95% CI 3-22%) for 
predicted clear ymrCRM patients (p=0.013 univariate log-rank analysis). 
 
On multivariate analysis post treatment prediction of ymrN showed borderline statistical 
significance for overall and disease free survival but was not significant for local 
recurrence; hazard ratios were 1.89 (95% CI 1.006-3.58) and 2.09 (95% CI 1.06-4.15) for 
OS and DFS respectively. 
 
Table 6.3 summarises multivariate analysis results of the association between overall 
survival, disease free survival and time to local recurrence of known clinical variables: age, 
sex, height of tumour from anal verge, type of preoperative treatment, and type of 
operation, according to each of the histopathology staging variables. On multivariate 
analysis, ypT remained significant for overall survival, disease free survival and local 
recurrence;  hazard ratios for poor ypT  and OS, DFS and local recurrence were 4.59 (95% 
CI 2.16-9.78), 5.63 (95% CI 2.45- 12.9) and 9.78 (95% CI 2.29- 41.8) respectively. Kaplan 
Meier survival curves according to ypT stage are shown in figures 6.3 and 6.4. 
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The 5 year overall survival for patients with poor ypT was 39% (95% CI 26-51%) 
compared with 76% (95% CI 62-89%) for good ypT response (p=0.0001 Univariate log-
rank analysis). The 5 year disease free survival for patients with poor ypT was 38% (95% 
CI 25-51%) compared with 84% (95% CI 72-96%) good ypT response (p=0.0001 
Univariate log-rank analysis). The 5 year local recurrence rate was 27% (95% CI 14-40%) 
for patients with poor ypT compared with 6% (95% CI 0-15%) for good ypT response 
(p=0.018 Univariate log-rank analysis).  
 
On multivariate analysis pCRM was significant for overall, disease free survival and local 
recurrence; hazard ratios were 2.99 (95% CI 1.64-5.47), 2.17 (95% CI 1.14- 4.13) and 8.80 
(95% CI 2.99- 25.91) respectively.  
 
The five year overall survival for pCRM involved patients was 30% (95% CI 10-49%) 
compared with 59% (95% CI 49-70%) for pCRM clear (p=0.001 Univariate log-rank 
analysis). The five year disease free survival for patients with involved pCRM was 28% 
(95% CI 7-50%) compared with 62% (95% CI 51-73%) for clear pCRM (p=0.023 
Univariate log-rank analysis). The five year local recurrence rate was 56% (95% CI 30-
83%) for patients with involved pCRM compared with 10% (95% CI 3-18%) for clear 
pCRM (p=0.0001 Univariate log-rank analysis).  
 
ypN did not predict for any of the survival outcomes. The linear kappa between radiologists 
GB and CDG, was 0.65 (0.44-0.86), indicating moderate- to substantial agreement. The 
linear kappa between radiologists GB and HE was 0.6 (0.31-0.89), indicating moderate 
agreement.  
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Table 6.1. Patient demographics and survival outcomes in 111 patients  undergoing preoperative 
therapy in the MERCURY study 
  Frequency  OS, (95% CI) DFS, (95% CI) LR, (95% CI) 
Age (years) <65 49 58(43-72) 51(36-66) 21(8-35) 
 ≥65 62 49(36-62) 60(47-73) 16(6-27) 
Sex Male 69 49(37-62) 48(35-61) 
p=0.04 
21(9-33) 
 Female 42 59(44-74) 68(53-83) 
p=0.04 
16(4-28) 
Treatment Long course 58 53(39-66) 53(39-67) 19(8-31) 
 Chemo & RT 53 54(40-68) 58(44-72) 18(5-30) 
Tumour height > 5cm 59 49(35-62) 52(37-66) 17(5-30) 
 ≤ 5cm 52 57(44-71) 60(46-74) 21(8-33) 
Operation TMEAnterior 
resection  
62 50(37-63) 51(37-64) 14(4-25) 
 TME+AP 
excision 
49 56(42-70) 62(47-76) 24(10-38) 
Baseline MRI 
T stage 
T1/T2 10 78(58-97) 
p=0.048 
72(51-93) 13(0-31) 
T3a 8 
 T3b 11 49(38-60) 
p=0.048 
51(40-63) 19(10-29) 
 T3c 29 
 T3d 16 
 T4 37 
MR Node stage N0 68 52(36-69) 56(38-73) 22(7-38) 
 N1/N2 41 54(42-66) 54(42-66) 17(7-27) 
 Missing 2    
yMR T stage  T0 6 73(54-92) 72(52-91) 20(2-38) 
 T1/T2 13 
 T3a 3 
 T3b 14 48(35-60) 50(37-64) 16(6-27) 
 T3c 24 
 T3d 8 
 T4 22 
 No post Tx MRI 21    
yMR Node 
stage 
N0 50 61(47-76) 63(49-78) 
p=0.027 
18(5-33) 
 N1/N2 40 45(29-61) 46(29-63) 
p=0.027 
17(3-32) 
 Missing 21    
CRM baseline CRM clear 30 N/A   
 CRM involved 81    
ymrCRM CRM clear 55 59(46-71) 58(46-71) 12(3-22) 
p=0.013  CRM clear 
baseline only 
9 
 CRM involved 37 46(31-61) 51(35-67) 28(13-44) 
p=0.013  CRM involved 
baseline only 
10 
MRI TRG MRTRG good 32 72(56-88) 
p=0.001 
64(47-82) 
p=0.007 
14(1-27) 
 MRTRG poor 34 27(8-47) 
p=0.001 
31(13-49) 
p=0.007 
29(8-49) 
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 Missing 45    
ypT stage T0 5 76(62-89) 
p=0.0001 
84(72-96) 
p=0.0001 
6(0-15) p=0.023 
 T1 2 
 T2 25 
 T3a 9 
 T3b 20 39(26-51) 
p=0.0001 
38(25-51) 
p=0.0001 
27(14-40) 
p=0.023  T3c 30 
 T3d 4 
 T4 16 
ypN stage N0 67 56(43-68) 64(52-77) 16(6-26) 
 N1/N2 44 48(33-64) 42(26-58) 77(61-93) 
Pathology 
CRM 
Clear 88 59(48-70) 
p=0.001 
62(51-73) 
p=0.023 
10(3-18) 
p=0.0001 
 CRM Involved 23 30(10-49) 
p=0.001 
28(7-50) 
p=0.023 
56(30-83) 
p=0.0001 
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Table 6.2. Multivariate analysis preoperative factors, Data presented as Hazard ratios 
 
*** p=0.003  §p=0.048 ††† p=0.009  
* p=0.019  §§p=0.033  †p=0.022   
 
 Post Rx 
mr T stage 
  Post Rx 
mr Node stage 
 mrTRG stage 
Post Rx  
ymr CRM 
  OS DFS LR  OS DFS LR  OS DFS LR  OS DFS LR 
MRI 
Variable 
ymrT 
good 
1 1 1 
MR N- 
1 1 1 MRTRG 
good 
1 1 1 yMR 
CRM- 
1 1 1 
 ymrT poor 
2.27 1.82 0.91 
MR N+ 
1.89 
§ 
(1.006
-3.58) 
2.09 
§§ 
(1.06- 
4.15) 
1.08 
MRTRG 
Poor 
4.40 
*** 
(1.65-
11.7) 
3.28 
* 
(1.22- 
8.80) 
3.71 
yMR 
CRM+ 
1.76 
 
1.08 4.25 
††† 
(1.45-
12.51) 
Age <65 years  1 1 1 <65 years  1 1 1 <65 years  1 1 1 <65 years  1 1 1 
 ≥65 years 1.48 0.88 0.59 ≥65 years 1.58 1.01 0.61 ≥65 years 1.46 0.98 0.65 ≥65 years 1.57 0.93 1.10 
Sex Male 1 1 1 Male 1 1 1 Male 1 1 1 Male 1 1 1 
 Female 
0.88 0.59 0.931 
Female 
0.78 0.53 0.92 
Female 
0.70 0.67 0.80 
Female 
0.76 0.46† 
(0.24-
0.89) 
1.16 
Treatment 
Chemo & 
RT  
1 1 1 Chemo & 
RT  
1 1 1 Chemo & 
RT  
1 1 1 Chemo & 
RT  
1 1 1 
 LCRT 0.98 0.93 0.99 LCRT 1.20 1.07 0.94 LCRT 0.69 0.69 0.41 LCRT 0.86 0.89 0.51 
Operation 
Anterior 
Resection 
1 1 1 Anterior 
Resection 
1 1 1 Anterior 
Resection 
1 1 1 Anterior 
Resection 
1 1 1 
 
AP 
excision 
1.36 0.85 2.69 AP 
excision 
1.24 0.83 2.75 
AP excision 
0.81 0.58 1.69 AP 
excision 
0.99 0.56 2.05 
Height from 
anal verge 
>5cm  1 1 1 >5cm  1 1 1 >5cm  1 1 1 >5cm  1 1 1 
≤5cm 0.92 1.37 0.95 ≤5cm 0.88 1.26 0.97 ≤5cm 1.05 1.19 0.99 ≤5cm 0.73 1.30 1.08 
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Table 6.3. Multivariate analysis histopathologic factors, Data presented as Hazard ratios 
 Pathology T stage Pathology N stage Pathology CRM 
  OS DFS LR  OS DFS LR  OS DFS LR 
Pathology 
Variable 
yp T good 
1 1 1 
ypN - 
1 1 1 
pCRM - 
1 1 1 
 yp T poor 
4.59*** 
(2.16-
9.78) 
5.63*** 
(2.45- 
12.9) 
9.78*** 
(2.29- 
41.8) 
ypN + 
1.53 1.71 1.49 
pCRM + 
2.99*** 
(1.64-
5.47) 
2.17†† 
(1.14-
4.13) 
8.80*** 
(2.99-
25.91) 
Age <65 years  1 1 1 <65 years  1 1 1 <65 years  1 1 1 
 ≥65 years 
1.98†† 
(1.12-
3.52) 
1.32 1.37 
≥65 years 
1.49 0.97 0.91 
≥65 years 
1.74 0.98 1.65 
Sex Male 1 1 1 Male 1 1 1 Male 1 1 1 
 Female 
0.87 0.58 1.18 
Female 
0.68 0.44§§ 
(0.23-
0.85) 
0.82 
Female 
0.67 0.44†† 
(0.23-
0.85) 
0.85 
Treatment 
Chemo & 
RT  
1 1 1 Chemo & 
RT  
1 1 1 Chemo & 
RT  
1 1 1 
 LCRT 
0.67 0.49† 
(0.26-
0.94) 
0.31§ 
(0.55-
6.70) 
LCRT 
1.06 0.99 0.73 
LCRT 
0.93 0.87 0.61 
Operation 
Anterior 
Resection 
1 1 1 Anterior 
Resection 
1 1 1 Anterior 
Resection 
1 1 1 
 
AP 
excision 
1.04 0.63 1.91 AP 
excision 
1.05 0.62 1.91 AP 
excision 
0.86 0.51 1.48 
Height from 
anal verge 
>5cm 1 1 1 >5cm  1 1 1 >5cm  1 1 1 
≤5cm 1.41 2.02 2.62 ≤5cm 0.92 1.37 1.33 ≤5cm 1.02 1.42 1.65 
 
*** p=0.001 §§ p=0.01 † p=0.03 
§  p=0.04 †† p=0.02 
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Figure 6.1. mrTRG and overall survival 
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Figure 6.2. mrTRG and disease free survival 
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Figure 6.3. ypT and overall survival 
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Figure 6.4. ypT and disease free survival. 
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6.6 Discussion 
This study has shown that MRI assessment of tumour regression grade after preoperative 
therapy predicts disease free survival and overall survival and thus patient prognosis prior 
to definitive surgery. Post treatment MRI prediction of circumferential resection margin 
involvement also gives important prognostic information regarding the risk of local 
recurrence.  
  
There are several  pathology TRG systems (such as those proposed by Dworak,(Dworak, 
Keilholz et al. 1997) and Mandard(Vecchio, Valentini et al. 2005)),  each based on the 
relative proportion of fibrosis present in the resected specimen. The relationship between 
pathological tumour regression grade and outcome has been considered important in 
previous studies (Rodel, Martus et al. 2005; Suarez, Vera et al. 2008), with for example 
pathology TRG predicting overall survival and seeming to be an important prognostic 
predictor for disease free survival (Vecchio, Valentini et al. 2005).
 
Applying similar 
principles using MRI we have now shown that it is possible to assess tumour regression 
prior to surgery. 
 
It is notable that neither histopathological nor MRI assessment of nodal status following 
radiotherapy or chemoradiotherapy predicted local recurrence. This differs from previously 
published studies (Moran, James et al. 1992; Bujko, Michalski et al. 2007).  Studies from 
the pre TME era convincingly demonstrate the strong relationship between node positivity 
and pelvic recurrence which has been attributed to mesorectal tissue containing nodes and 
deposits left behind in the pelvis (Gunderson, Jessup et al. 2010). However, incomplete 
TME specimens are also associated with 20% pelvic recurrence rates for node positive 
patients compared with only 6% for complete TME specimens (Shihab, Moran et al. 2009). 
In the MERCURY study, the TME specimen quality was audited and an incomplete rate of 
only 5% was observed which is significantly better than previously published series 
(Nagtegaal, van de Velde et al. 2002; MERCURY 2006; Shihab, Moran et al. 2009). This 
may explain the observed lack of an effect on outcome by involved lymph nodes after 
preoperative therapy.  
 
The strengths of this study are that it represents high quality radiological, pathological and 
surgical data ensured by training workshops. The prospective nature of the study also 
represents a large series of patients who have undergone baseline and post CRT MR 
imaging as well as outcome data.  However, there are potential limitations of this study, 
Firstly, 73% (66/90) post treatment MRI scans were available for a retrospective review of 
mrTRG. Despite this, a representative sample were reviewed and interobserver agreement 
was moderate to substantial (κ=0.6 and κ=0.65), indicating that this technique is 
reproducible. A further limitation was the lack of standardisation of neoadjuvant therapy 
and the use of both CRT/RT treatment approaches. This could have influenced outcomes as 
it would be expected that patients receiving long course radiotherapy would have responded 
less well. However, on multivariate analysis the type of treatment did not materially 
influence the outcomes and the prognostic importance of mrTRG and ypT are independent 
of the type of treatment received.  
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This is the first time that a prospective study has demonstrated a correlation between 
radiologically determined tumour response and long term outcomes. The fact that this is 
achieved prior to surgical resection provides evidence for the design of future studies that 
could alter patient therapy based on response assessment. It also allows the identification of 
good and poor responding patient groups and different approaches that could be adopted 
after completion of CRT. For example, the role of systemic non cross resistant 
chemotherapy could be tested in poor responding patients in a randomised controlled trial 
against the current surgical standard of care. On the other hand, the evaluation of the timing 
or even deferral of surgical resection could be investigated in patients with a good response 
(mrTRG1 and 2) (O'Neill, Brown et al. 2007). 
 
6.7 Conclusion 
Post treatment MRI tumour regression grading and CRM evaluation gives the 
multidisciplinary team a window of opportunity to refine treatment plans prior to definitive 
surgical treatment. 
 
6.8 Supplementary analysis 
6.8.1 Histopathological and post treatment MRI factors vs. survival 
Table 6.4 summarises multivariate analysis assessing the association between significant 
histopathological & MRI preoperative staging variables with overall survival, disease free 
survival and time to local recurrence.  
 
Pathological post treatment Circumferential Resection Margin Status (pCRM) was 
significant for overall survival, disease free survival and local recurrence;  hazard ratios for 
involved pCRM for OS, DFS and local recurrence were 4.19 (95% CI 1.49-11.8), 2.43 
(95% CI 1.01- 7.75) and 4.6 (95% CI 1.03- 20.54) respectively.  Post treatment 
pathological T stage and pathological nodal status were not statistically significant. 
 
MRI tumour regression grade (mrTRG) was significant for overall survival with a hazard 
ratio of 4.46  (95% CI 1.3-15.27). Post treatment MRI Nodal status and MRI 
Circumferential resection margin status were not significant. 
 
6.8.2 Discussion 
Histopathological T stage and CRM involvement both predicted overall survival, disease 
free survival and local recurrence on initial analysis in table 6.3. In this further analysis of 
significant post treatment MRI and histopathological factors pCRM was the only 
significant pathological factor. 
 
pCRM has previously been described as a crucial prognostic factor after treatment 
(Nagtegaal, Gosens et al. 2007).   The data shows of the 23/111 patients that had a positive 
CRM on histopathology, 21/23 (91%) were also staged as ypT poor (>ypT3a). Thus, the 
two variables are highly interdependent with nearly all those patients with involved 
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resection margins part of the larger poor prognosis group (n=70) with more advanced 
pathological T stage. This may explain the absence of a significant effect for ypT in this 
analysis. 
 
Of the 66 patients scored for post treatment mrTRG, 34 had unfavourable grades 4 and 5. 
The majority (20/34), 58% also had a potentially involved circumferential resection margin 
on post treatment MRI.   Therefore, these two variables appear to partly overlap and may 
explain the absence of a significant effect for post treatment MRI CRM in this analysis. 
 
mrTRG appears to be the imaging parameter with the strongest relationship to outcome.  As 
mrTRG can be assessed preoperatively this gives an opportunity for the multi-disciplinary 
team (MDT) to modify treatment prior to surgery. 
 
Table 6.4. Multivariate analysis MRI and histopathologic factors, Data presented as Hazard ratios 
 
 
Overall Survival, 
n=63 
Disease Free 
Survival,  n=63 
Local Recurrence, 
n=63 
ypT Good 1 Good 1 Good 1 
 Poor 1.3 Poor 2.37 Poor 17.45 
ypN Good 1 Good 1 Good 1 
 Poor 1.80 Poor 1.77 Poor 0.25 
pCRM Negative 1 Negative 1 Negative 1 
 Positive 
4.19 
(1,49-
11.80)*** 
Positive 
2.43 
(1.01-
7.75) “ 
Positive 
4.60 
(1.03-
20.54)
$ 
MRTRG Good 1 Good 1 Good 1 
 Poor 
4.46 
(1.30-
15.27)** 
Poor 
2.01 
Poor 
0.33 
ymrN Good 1 Good 1 Good 1 
 Poor 1.55 Poor 1.71 Poor 0.41 
ymrCRM Negative 1 Negative 1 Negative 1 
 Positive 0.38 Positive 0.54 Positive 0.93 
 
***=0.007 
**=0.017 
*=0.049 
$=0.045 
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7 Comparison ymrT and mrTRG to histopathological response to 
chemotherapy in ‗intermediate risk‘ rectal cancer 
7.1 Introduction 
Most centres worldwide offer preoperative chemo-radiotherapy (CRT) to patients with 
locally advanced, T3, T4 rectal adenocarcinoma threatening the potential anatomical planes 
of resection. Preoperative CRT has been shown to be beneficial in reducing local 
recurrence rates, and has become a standard of care for locally advanced rectal cancer. 
However, preoperative CRT has not been shown to improve overall survival rates (Sauer, 
Becker et al. 2004). This is presumably due to the preoperative CRT not controlling distant 
disease development (Glynne-Jones, Anyamene et al. 2012). 
 
It is well established that baseline MRI staging can identify potential CRM involvement 
therefore enabling selection of patients at high risk of local recurrence and candidates for 
CRT (MERCURY 2006). More recently it has been found that baseline MRI  also enables 
the risk  of distant failure to be assessed; with the presence of advanced T and N stage as 
well as extramural venous invasion identified as increasing the probability of distant 
metastasis (Smith 2008; Smith, Barbachano et al. 2008).  
 
Systemic chemotherapy has been shown to be an effective treatment of both the primary 
colorectal tumour as well as secondary liver metastasis. For example Gervaz et al reported 
the results of 29 patients with colorectal cancer and synchronous liver metastases. Patients 
received neoadjuvant chemotherapy prior to liver surgery and resection of the primary 
tumour. Histopathological tumour regression grading showed complete or predominant 
fibrosis in 10/29 colorectal samples and 11/29 liver specimens (Gervaz, Rubbia-Brandt et 
al. 2010). 
 
A study by Chau et al showed a high primary tumour response rate to systemic induction 
chemotherapy, followed by chemoradiotherapy and TME in MRI defined high risk patients. 
MR restaging using change in tumour length showed no patients with progressive disease, 
84% with a MRI partial response, 12% with MRI stable disease, and 4% with MRI 
complete response  (Chau, Brown et al. 2006). 
 
Three recent small studies have investigated the use of chemotherapy alone in the treatment 
of rectal cancer (Table 7.1). The studies have shown systemic chemotherapy can provide 
primary tumour control as judged by pathological complete response and pathological clear 
margin rates. Only Schrag et al restaged tumours, using endoscopic ultrasound, with 
regression observed in all 27 patients that had completed chemotherapy (Schrag 2010).  
 
Therefore in a subgroup of patients with baseline MRI markers for increased risk of distant 
disease but low risk for local recurrence initial neoadjuvant systemic chemotherapy maybe 
useful in treating both the primary tumour and preventing distant metastasis. 
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Table 7.1.  Chemotherapy alone in the treatment of rectal cancer 
 Eligibility Imaging Pathology R0 
Ishii  
(Ishii, 
Hasegawa 
et al. 
2010) 
 
n=26 
T3/T4 N0-2 MRI for baseline 
staging. No 
restaging 
pCR =1/26 
T downstaging 
12/26 
N downstaging 
13/26 
Not stated 
Schrag 
(Schrag 
2010) 
 
 
n=31 
Clinical stage II-
III 
EUS used to re-
stage post 
chemotherapy  
2 patients 
withdrawn 
pCR= 8/29 
All patients 
showed 
regression. 
100% 
(29/29) 
Cerek 
(Cercek 
2010) 
 
n=26 
RT 
contraindicated 
or metastatic 
disease 
Not stated pCR=9/26  Not stated 
 
Tumour regression grading has been considered important as tumour predominating in the 
stoma is considered unfavourable pathological tumour regression (Dworak 0&1) and is 
associated with poor survival, while fibrosis predominating in the stoma, favourable tumour 
regression (Dworak 2,3,4),  is associated with good survival. Rodel et al showed 63% 
disease free survival (DFS)  for TRG0+1,  75% DFS for intermediate TRG groups 2+3 and 
86% DFS for favourable  TRG 4 . 
 
Several methods/criteria for assessing response on MRI post chemoradiotherapy have been 
investigated by this thesis.  These include post treatment T staging (ymrT), tumour 
regression grading (mrTRG) and length change assessment.  The accuracy of these criteria 
in restaging rectal cancer post chemotherapy alone is uncertain. 
 
7.2 Aims 
The aim of this study was to compare which of the available MRI imaging methods can 
identify good vs. poor responders to neoadjuvant chemotherapy compared with the 
histopathological reference standard of pTRG.  The reproducibility of ymrT, mrTRG and 
length change assessment across 7 observers was also investigated. 
 
This analysis takes place in the context of a prospective phase II non randomised 
multicentre clinical trial investigating the use of neoadjuvant systemic chemotherapy 
(Oxaliplatin, Capecitabine and Bevacizumab) in patients with MRI defined ‗intermediate‘ 
risk rectal cancer – low risk of local recurrence but high risk of distant failure.  
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7.3 Methods & Materials 
7.3.1 Patients 
This prospective study was approved by the institutional review board, and informed 
consent was obtained from all patients. Patients who were scheduled to undergo 
preoperative chemoradiotherapy were eligible to be included in this study. Enrolment was 
between July 2009-May 2011. Eleven centres from 1 country took part in the study. Twenty 
eight patients underwent combination neoadjuvant chemotherapy prior to surgery.  
 
Eligibility 
 
Inclusion criteria: 
 
All enrolled patients had biopsy proven rectal cancer and were candidates for complete 
surgical resection (R0) with sphincter preservation surgery, prior to the administration of 
any therapy. 
 
Baseline MRI showed: 
A tumour ≥ 1 mm from the mesorectal fascia and 
Either: 
 T3 stage or the presence of extramural venous invasion. 
 
Exclusion criteria: 
 
Patients with Stage T4 or a tumour with an intraperitoneal distal edge, metastatic disease. 
Tumour presenting initially in a low location and judged, prior to any treatment, to require 
abdominoperineal resection. Previous chemotherapy for colorectal cancer, incomplete 
recovery from previous major surgery and patients who had received previous pelvic 
radiotherapy. 
 
7.3.2 Treatment 
XELOX (Oxaliplatin and Capecitabine) /Bevacizumab were administered for 3 cycles, each 
lasting 3 weeks, for a total of 9 weeks. XELOX without Bevacizumab was then 
administered during an additional 3 week cycle.   
 
The XELOX regimen consisted of intravenous Oxaliplatin, 130 mg/m2 (day 1 of each cycle 
for a total of 4 cycles), followed by oral Capecitabine, 1000 mg/m2 twice a day (from the 
afternoon of day 1 until the morning of day 15). Bevacizumab was administered at a dose 
of 7.5 mg/kg during 30 minutes on day 1 of each 3-week cycle, during 3 cycles.  
 
Restaging MRI was undertaken after the conclusion of the 4
th
 cycle of XELOX.  
 
Responders/Stable disease by MRI RECIST length analysis proceeded to surgical resection. 
Those with MRI RECIST length progression proceeded to chemoradiotherapy. The total 
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radiation dose was 52.5 Gy administered in two series. In the first series, a dose of up to 45 
Gy, was distributed into 25 daily sessions of 180 cGY (5 sessions per week during 5 weeks 
for a total of 25 sessions), The second series (concomitant boost) was administered during 
the last 5 days of treatment at a rate of 1.5 Gy x 5 days, up to a dose of 750 cGY. 
Capecitabine 825 mg/m2/12 hrs a day was administered for the duration of radiotherapy 
according to a regimen of administration of 2 daily doses, 7 days a week. 
 
7.3.3 Surgery 
Surgery was performed in the week after the period of recovery from neoadjuvant therapy 
ended. This period was 3-4 weeks after neoadjuvant chemotherapy or 6-8 weeks after 
neoadjuvant chemotherapy and radiation, depending on the case.  
 
Surgical options included standard total mesorectal excision (TME) plane surgery or 
extended TME (TME with adjacent visceral resection) with or without sphincter 
preservation according to a standardised technique.  
 
After recovering from surgery, patients were evaluated by their oncologist for consideration 
of postoperative treatment. The regimen used was at the discretion of the oncologist, 
although 4 additional cycles of XELOX was recommended. 
 
7.3.4 MRI imaging technique and image interpretation 
Each centre in the trial employed the imaging protocol described in 3.2.1 
Two imaging workshops for the gastrointestinal radiologists participating in the study were 
held to ensure standardisation of image interpretation. All MR images were analysed 
independently by each of the seven experienced radiologists. Three of the seven readers had 
>10 years experience in gastrointestinal MR imaging. The remaining 4 readers had at least 
10 years experience in cross-sectional imaging 
 
T stage post CRT, MRI tumour regression grading and MRI length assessment was 
undertaken. Baseline and Post treatment MRI scans were also evaluated for predicted 
circumferential resection margin status. A predicted clear circumferential resection margin 
was defined if the distance of tumour to the mesorectal fascia is greater than or equal to 1 
mm on MRI (MERCURY 2006). Extramural venous invasion was defined on both baseline 
and post treatment MRI as the
 
presence of intermediate signal intensity within vessels with  
accompanying nodular expansion of the vessel or irregular vessel contour (Smith 2008; 
Smith, Shihab et al. 2008). 
 
7.3.4.1 T stage post CRT 
 
ymrT was based determined by the extent of persistent tumour signal intensity relative to 
the layers of bowel wall on T2 weighted images. Comparison was made with pre-treatment 
images. Tumour response manifested as either replacement of tumour signal by low signal 
intensity fibrosis (dark stroma) or the development of high signal intensity mucin pools -
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such areas where not considered as tumour as did not contribute to T stage. ymrT staging 
criteria was the same as baseline MRI T staging (section 4.2.7).   
 
Based on known histopathological outcomes according to ypT stage and along the same 
lines to other chapters in this thesis, the patient‘s ymrT was divided into favourable and 
unfavourable response to enable binary comparison. Favourable regression was defined as 
stages ymrT0,1,2, and 3a, while unfavourable grading was defined as ymrT3b,c,d and 4 
(Willett, Badizadegan et al. 1999). 
 
7.3.4.2  MRI tumour regression grading 
 
The MRI scans were anonymised and separately reviewed by two radiologists with 14 (GB) 
and 5 (UBP) years experience in MRI assessment of rectal cancers using the previously 
defined criteria in Table 1.6.   
 
Good MRI tumour regression grade was defined as grades 1, 2 and 3 with poor defined as 
stages 4 and 5. This binary division was chosen as per the chapter 4.  
 
7.3.4.3 MRI modified RECIST 
 
Maximum tumour length was measured on sagittal images pre and post treatment. 
Complete disappearance of tumour was defined as a complete response.  Percentage change 
in tumour length was classified using RECIST criteria with complete disappearance of 
tumour being defined as complete response. Partial response to treatment was defined as at 
least a 30% decrease in tumour length, taking as reference the baseline tumour length. 
Progression of disease was defined as at least a 20% increase in tumour length, stable 
disease was defined as neither sufficient shrinkage to qualify for partial response nor 
sufficient increase to qualify for progression of disease (Therasse, Arbuck et al. 2000). For 
the analysis partial response was categorised as favourable, while stable or progression of 
disease was unfavourable. 
 
7.3.5 Histopathology 
After surgical resection, the specimen was fixed and sampled as described in 4.2.5. Each 
specimen was graded by degree of tumour regression, according to the Dworak system 
(Dworak, Keilholz et al. 1997). A clear pCRM was defined as greater than, or equal to, 1 
mm between the tumour and the resection margin.  
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7.4 Statistics 
7.4.1 ROC analysis 
As well as grading and staging by the 5 point pTRG (Dworak, Keilholz et al. 1997) a 
simplified pathological grading of favourable and unfavourable pathology was also 
undertaken. Favourable pathology was defined as pTRG stages 3 and 4, while unfavourable 
pathology was defined as pTRG stages 0, 1, and 2.  
 
The area under the ROC was used in two analyses; the first assessed the diagnostic 
accuracy of mrTRG against the favourable and unfavourable pathological TRG 
classification above.  The second analysed the diagnostic accuracy of ymrT against 
favourable and unfavourable pathological TRG. The area under the ROC curve was 
classified as follows: 0.9-1=excellent, 0.8-0.9=good, 0.7-0.8=fair, 0.6-0.7=poor, 0.5-
0.6=fail.    
 
Calculations were performed using Statistical Package for Social Sciences program, version 
15.0 (SPSS, Chicago, Illinois, USA). P values of less than 0.05 were considered significant.  
 
7.4.2 MRI modified RECIST Analysis 
The Mann-Whitney U test was used to assess if there was a significant difference between 
the Sum of Ranks of favourable and unfavourable mrRECIST scores. 
 
7.4.3 Univariate logistic regression 
Univariate logistic regression analysis was used to analyse the association between MRI 
parameters (ymrT, mrTRG and tumour length assessment) and pathologic TRG. This 
enabled calculation of odds ratios for the probability of unfavourable pathological outcome. 
   
7.4.4 Intra-observer agreement 
Agreement between the seven observers grading MR variables was determined by 
Krippendorff's alpha calculation. (α < 0, poor agreement; α = 0–0.20, slight agreement; α = 
0.21–0.40, fair agreement; α = 0.41–0.60, moderate agreement; α = 0.61–0.80, substantial 
agreement; and α = 0.81–1.00, almost perfect agreement).  
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7.5 Results 
Twenty four patients had evaluable imaging and 27 had final pathology (3 did not undergo 
restaging MRI and 1 died during the trial). All patients showed response or stable disease 
by post treatment MRI length assessment, therefore no patients were referred for 
preoperative chemoradiation. This is summarised in Figure 7.1. 
 
Figure 7.1. Trial progress flowchart 
 
 
 
Table 7.2 shows the baseline demographics of the 28 patients who were eligible for this 
study. The mean baseline tumour length was 4.4cm, standard deviation 1.08 cm. The mean 
post treatment tumour length was 2.05cm, standard deviation 2.05 cm. The mean tumour 
length change was -54.06% (standard deviation 22.45%). T stage downstaging was 
observed; at baseline 27/28 patients had ≥T3b stage, while post treatment 12/24 patients 
were re-staged as ≥T3b. 
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Table 7.2. Patient characteristics of patients with full imaging and pathology 
*Includes pathology of 4 patients that did not complete neoadjuvant treatment and undergo MRI restaging.  
 
 
  No of patients. 
Age: <65 years 9 
 ≥65 years 19 
Sex Male 18 
 Female 10 
Tumour stage at baseline on  
MR Central r/v:  
mrT3a 1 
mrT3b 18 
 mrT3c 7 
 mrT3d 2 
Extra mural vascular invasion 
on baseline MR: 
None 8 
Minimal 7 
Intermediate 7 
 Severe/ Large vessel 3 
 Not assessed 4 
Tumour stage post CRT on 
MR (ymrT)  
Central r/v: 
ymrT0 2 
ymrT1 2 
ymrT2 4 
 ymrT3a 4 
 ymrT3b 9 
 ymrT3c 2 
 ymrT3d 1 
 Not restaged  4 
Tumour regression grade on 
MR (mrTRG)  
Central r/v: 
mrTRG1 0 
mrTRG2 13 
mrTRG3 6 
 mrTRG4 5 
 mrTRG5 0 
Extra mural vascular invasion 
on post treatment MR: 
None 13 
Minimal 9 
Intermediate 2 
 Severe/ Large vessel 0 
 Not restaged 4 
CRM on post treatment MR: Potentially clear 24 
Potentially involved 0 
Modified MR RECIST 
Central r/v: 
Partial response 20 
Stable disease 4 
Progression 0 
 Not restaged 4 
Pathological TRG:* pTRG 0 3 
 pTRG 1 5 
 pTRG 2 6 
 pTRG 3 6 
 pTRG 4 4 
Pathological CRM Clear 23 
Involved 1 
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7.5.1 Correlation of MRI parameters and pathological TRG 
7.5.1.1 MRI tumour regression grade post CRT 
Table 7.3 shows the histopathological tumour regression grade of the patient by individual 
mrTRG grade. ROC analysis was undertaken to calculate the area under the curve (AUC) 
and is illustrated in figure 7.2. The area under the ROC curve (AUC) is 0.84; indicating 
mrTRG has a good diagnostic accuracy for TRG pathology. 
 
Table 7.3. Raw data table for mrTRG vs. pathological TRG 
 Pathological TRG  
0 1 2 3 4 5 Total 
mrTRG 1        
2  1 5 3 4  13 
3 1 2 1 2 0  6 
4 2 2 0 1 0  5 
5        
 Total 3 5 6 6 4  24 
 
Figure 7.2. mrTRG vs. pathological TRG 
 
 
 
 
 
 
 
 
Area Std. Error 95% Confidence Interval 
.848 .090 .672 1.023 
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7.5.1.2 MRI T stage post CRT 
Table 7.4 shows the histopathological tumour regression grade of the patient by individual 
ymrT stage. ROC analysis was undertaken to calculate the area under the curve (AUC) and 
is illustrated in figure 7.3. The area under the ROC curve (AUC) is 0.77; indicating ymrT 
has a fair diagnostic accuracy for TRG pathology. 
 
Table 7.4.  Raw data table for ymrT vs. pathological TRG 
 Pathological TRG 
0 1 2 3 4 Total 
ymrT 0 0 0 1 1 0 2 
1 0 0 1 0 1 2 
2 0 0 1 2 1 4 
3.1 1 0 1 1 1 4 
3.2 2 4 2 1 0 9 
3.3 0 1 0 1 0 2 
3.4 0 0 0 0 1 1 
 Total 3 5 6 6 4 24 
 
Figure 7.3.  ROC analysis for ymrT vs.  pathological TRG 
 
 
 
 
 
 
 
 
Area Std. Error 95% Confidence Interval 
.773 .096 .586 .961 
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7.5.1.3 MRI RECIST post CRT 
The Mann-Whitney U test calculation was performed to assess if there was a difference 
between the Sum of Ranks between the Partial Response MRI group and the Stable Disease 
MRI group.  No significant difference (p=0.17) was found between the MRI partial 
response group and the MRI Stable disease group. The raw data is shown in table 7.5; the 
Mann-Whitney U test is shown in table 7.6 
 
Table 7.5.  MRI RECIST vs. Pathological TRG  
 Pathological Tumour Regression Grade 
   0 1 2 3 4 Total 
MR 
RECIST 
Partial 
Response 
 1 5 5 5 4 20 
Stable/ 
Progression 
 2 0 1 1 0 4 
 
Table 7.6. Mann-Whitney U test results for MRI RECIST and TRG pathology 
Modified MRI RECIST N Mean Rank Sum of Ranks Test Statistic 
Partial response 20 13.35 267.00 p=0.178 
Stable disease/Progression 4 8.25 33.00  
 
7.5.1.4 Univariate logistic regression 
Table 7.7 shows the TRG histopathology status of patients by mrTRG, ymrT and 
mrRECIST. Significantly more patients with mrTRG stage 1-3 had favourable pathology 
(15/19), compared with mrTRG stage 4&5 (1/5); p=0.03; OR 15.00 (95% CI 1.3-174.3). 
Furthermore, significantly more patients with ymrT stage T0-T3a had favourable pathology 
(11/12), compared with ymrT stage T3b-4 (5/12); p=0.022; OR 15.4 (95% CI 1.5-160.9). 
No significant relationship was shown for MRI length analysis and pathology TRG.  
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Table 7.7.  TRG pathology status by MRI parameters 
 
 pTRG  
good 
(3,4) 
pTRG 
poor 
(0,1,2) 
OR (95% CI) P value 
mrTRG Central r/v 
1-3 
4-5 
Not restaged n=4 
 
15 
1 
 
4 
4 
 
1.00 
15.00  
(1.3-174.3) 
 
0.03 
ymrT Central r/v  
T0-T3a 
T3b-4 
Not restaged n=4 
 
11 
5 
 
1 
7 
 
1.00 
15.4 (1.5-160.9) 
  
0.022 
MRI length analysis 
Partial Response 
Stable/ Progression 
Not restaged n=4 
 
14 
2 
 
6 
2 
 
1.00 
2.33(0.3-20.7) 
 
0.45 
 pCRM  
clear 
pCRM  
involved 
  
MRI CRM clear 
MRI CRM involved 
Not restaged n=4 
23 
0 
1 
0 
  
 
7.5.1.5 Interobserver agreement 
Interobserver agreement was calculated between the 7 radiologists.  
 
324 pairs of observations were used for mrTRG.  There was a moderate level of agreement 
for mrTRG Krippendorff's α=0.41.  
 
335 pairs of observations were used for ymrT. There was a fair level of agreement for ymrT 
Krippendorff's α=0.25. 
 
381 pairs of observations were used for tumour length assessment. There was a slight level 
of agreement for tumour length assessment Krippendorff's α=0.13. 
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7.5.2 Examples of treatment response 
 
Both acellular mucinous change (figure 7.4) and fibrosis (figure 7.5) were observed. 
 
Figure 7.4. Acellular mucinous response post neoadjuvant chemotherapy 
A) Axial T2 weighted post treatment image shows a high signal mucinous area (Circled) 
with no intermediate signal within it. This was interpreted as treatment response. 
B) Corresponding photomicrograph (H&E strain) shows multiple areas of acellular mucin 
(black stars).  
 
A)                                               B) 
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Figure 7.5. Fibrosis post neoadjuvant chemotherapy 
A)  Axial baseline T2 weighted image shows a semiannular intermediate signal tumour 
between the 9‗o‘clock to 3‗o‘ clock positions. 
B) Axial post treatment image shows a low signal area between the 12‗o‘clock to 2 
‗o‘clock position, (Circled).  
C) Corresponding photomicrograph (H&E strain) shows area of mural fibrosis (arrow).  
Star indicates extramural fat.  
 
A)                                                      B) 
 
 
C) 
 
  159 
7.5.3 CRM positive case 
 
One case in this study had pathological CRM involvement. This was due to an involved 
lymph node at the mesorectal fascia. This is illustrated in figure 7.6. This patient underwent 
adjuvant chemoradiation. 
 
Figure 7.6. Coronal T2 weighted MRI image showing involved lymph node (black 
arrowhead), at the potential CRM (white arrows). 
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7.6 Discussion 
This multicentre multiobserver study has afforded the opportunity to evaluate a number of 
imaging measures of primary tumour response to chemotherapy. Of these mrTRG 
assessment gave a good diagnostic accuracy as indicated by the area under the ROC curve. 
ymrT showed a fair diagnostic accuracy on ROC analysis, with logistic regression analysis 
showing a statistically significant relationship with histopathological tumour regression 
grade for both parameters. No significant relationship was shown for MRI length analysis  
and pathological TRG.  
The level of reproducibility between 7 radiologists for each MRI parameter was also 
assessed, mrTRG was the most reproducible parameter, ( =0.41), ymrT was less 
reproducible in this analysis at α=0.25, with slight agreement for length measurement at 
α=0.13.  
This is the first study to use MRI to select a subgroup of ‗intermediate risk‘ rectal tumours 
(MRI CRM clear, EMVI + or T3 tumour) (Smith, Barbachano et al. 2008), at high risk of 
distant relapse but relatively low risk of local recurrence.  In many American centres T3 
tumours are treated with preoperative chemoradiation (Minsky 2011); while in the UK 
short course radiation or chemoradiation is considered by most centres (NICE 2011). The 
approach used in this study has potential advantages over these regimes as possible distant 
micrometastases are treated by systemic chemotherapy- decreasing the risk of distant 
relapse and the morbidity of pelvic radiation is avoided- as the risk of local recurrence is 
low. 
One patient in this trial had pathological CRM involvement due to an involved 
encapsulated lymph node at the mesorectal fascia. There has been debate regarding if such 
cases constitute an involved margin, with some proposing a pathologically involved node 
within 1 mm of the CRM (pCRM+ by definition) is unlikely to result in tumour recurrence 
due to the protective effect of the nodal capsule and intact mesorectal fascia (Cecil, Sexton 
et al. 2004). A recent study by Shihab et al supports this view, 31 of the 396 patients in this 
study had suspicious nodes on MRI 1 mm or less from the CRM. Subsequently none of 
these patients had a positive CRM owing to nodal involvement. Therefore caution is needed 
when recommending neoadjuvant/adjuvant therapy based solely on a suspicious MRI 
detected involved lymph node close to the potential circumferential resection margin 
(Shihab, Quirke et al. 2010). 
Pathological observations such as fibrosis and acellular mucin seen in this study are in line 
to those observed in rectal cancer treated with chemoradiation (Puppa, Sonzogni et al. 
2010). The results are also in agreement with Poultsides et al, who described pathologic 
fibrosis and  acellular mucin in colorectal liver metastases resected post chemotherapy 
(Poultsides, Bao et al. 2012). Furthermore, oesophageal and stomach adenocarcinoma are 
often treated with chemotherapy alone prior to surgery, with the Mandard pathological 
tumour regression system, based on the degree of fibrosis versus tumour, used by 
pathologists to assess response (Mandard, Dalibard et al. 1994). The Mandard system is 
similar to the Dworak pathological system used in this analysis (Dworak, Keilholz et al. 
1997).  
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It is known that one of the key cellular mediators of fibrosis is the myofibroblast, which 
when activated serves as the primary collagen producing cell. Myofibroblasts are activated 
by a variety of mechanisms, such as paracrine signals derived from lymphocytes and 
macrophages and autocrine factors secreted by myofibroblasts themselves (Wynn 2008). 
Whether the immunological/histological pathways of fibrosis development differ between 
chemoradiation and chemotherapy treatment is unclear, however from this analysis it 
appears that fibrosis development is a common endpoint from both treatment pathways. 
The mechanism of chemotherapy induced fibrosis versus radiotherapy induced fibrosis 
remains poorly understood and topic for future study. 
 
Although the pathological CRM positive rate suggests patients in this study have a low risk 
of local recurrence, long term follow-up data is needed to confirm this. Further follow-up of 
this cohort is also needed to evaluate the rate of distant failure. However this study suggests 
radiotherapy can potentially be avoided in a group of patients carefully selected by MRI. 
This will need to be confirmed in a future phase three trial. 
 
7.7 Conclusions 
A subgroup of MRI defined intermediate risk patients- at higher risk of distant metastasis 
and low risk of local recurrence are likely to benefit from neoadjuvant chemotherapy and 
avoid morbidity associated with radiotherapy. mrTRG has a good diagnostic accuracy and 
ymrT has a fair diagnostic accuracy for the post chemotherapy assessment of rectal 
tumours.  
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8 Serial ADC Measurements in Rectal Cancer Patients Deferring 
Surgery Following Chemoradiotherapy—Detecting Residual 
Disease, Complete Response and Tumour Regrowth 
8.1 Introduction 
Preoperative long course chemoradiotherapy is used to downstage locally advanced rectal 
tumours prior to surgery (Sauer, Becker et al. 2004). Up to 25%  of patients show an 
excellent response to CRT, with no tumour found on post operative pathology- a 
pathological complete response (Hartley, Ho et al. 2005). Such rates of complete 
pathological response have prompted patients and clinical teams to seek the option of 
avoiding surgery, particularly when this can lead to avoidance of a permanent stoma, but 
only if complete response to treatment can be safely identified and monitored.   
 
Previously published observational data has indicated that patients with clinical complete 
response may avoid surgery (Habr-Gama, Perez et al. 2004). However, identifying and 
monitoring such patients is a challenge as it may be difficult to determine when it is 
appropriate to biopsy and how predictive a small sample of the scar is for overall tumour 
status is uncertain. Moreover, assessment that relies on luminal biopsy or excision of the 
tumour scar inevitably risks underestimating persistent extramural disease. 
 
Based on the initial experience of patients that wished to avoid surgery, The Royal Marsden 
Hospital set up two prospective trials in 2006 to enrol patients with low rectal tumours 
(tumours arising within 5cm of the anal verge or within 1-2 cm of the anorectal junction), 
who wished to avoid a permanent stoma by deferring surgery and undergo monitoring of 
the treated tumour site (Yu, Brown et al. 2011). 
 
For the deferral of surgery trial, high resolution MRI is used for assessment of eligibility 
and surveillance. This technique has the advantage of assessing extramural disease. The 
main parameters used to assess eligibility are MR T stage and tumour regression grade. 
Both these parameters are significantly linked with favourable and unfavourable pathology 
(Chapters 4&5 analysis) and in the case of mrTRG with survival outcomes (Chapter 6).  
Furthermore, we have observed that if post treatment MR imaging shows predominant low 
signal intensity fibrosis with no visible or minimal intermediate signal intensity (mrTRG1 
or 2) at the treated tumour site, this is strongly associated with complete or near complete 
regression of tumour on histology. For example in Chapter 4, 7 cases of ypT0/1 were 
graded as mrTRG 1/2, such patients would be eligible for consideration for deferral of 
surgery.  
 
In addition to the signal and morphological characteristics seen on high resolution T2 
weighted MRI, it is also possible to use MRI to quantify the structural composition of 
treated tumour using diffusion weighted imaging (Gu, Khong et al. 2011; Reischauer, Wilm 
et al. 2011).  The technique measures movement of water molecules using different 
magnetic field gradients. The degree of movement is dependent on tissue structure and has 
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been exploited to distinguish malignant from non malignant tissue (Gu, Khong et al. 2011; 
Reischauer, Wilm et al. 2011). A particular region of interest can be quantified for 
diffusivity as the apparent diffusion coefficient value(ADC). Although ADC measurements 
have been shown to identify complete responders at the end of chemoradiotherapy (Kim, 
Lee et al. 2009), its usefulness in the setting of surveillance after an apparent complete has 
never been tested. 
 
8.2 Aims 
The aims for this study of patients undergoing deferral of surgery with MR imaging 
surveillance were: 
 
1) To determine whether ADC values differ between patients with residual/recurrent 
tumour and those patients in clinical, radiological and biopsy confirmed complete response. 
 
2) To identify an ADC threshold for the optimal sensitivity and specificity for predicting 
residual tumour/tumour re-growth on an individual patient basis.   
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8.3 Materials and methods 
8.3.1 Patients 
Patients were enrolled into one of two studies: the deferral of surgery or alternative deferral 
of surgery studies which were both approved by our institutional review board. Informed 
consent was obtained from all patients. 
 
Eligibility criteria for both studies were determined following completion of 
chemoradiotherapy (CRT) and were as follows: 
 
Group 1- Deferral of surgery study: 
 
Patients were enrolled if they had either: 
 
1)  MRI defined complete response: low signal intensity fibrotic scar tissue only and no 
visible disease in the mesorectum seen at MRI performed 4 weeks after long-course CRT, 
confirmed at 8-12 week MRI. 
2) MRI defined incremental response; evidence of fibrosis predominating over residual 
tumour signal at 4-6 weeks following CRT MRI which continued to show an incremental 
response at 8-12 week MRI. 
 
Group 2 – Alternative deferral of surgery trial.  
 
All patients in this group had MRI defined good response, as there was evidence of fibrosis 
predominating over residual tumour signal, but without a complete or near complete 
radiological response. The indication for surveillance in the alternative deferral of surgery 
group was to monitor disease control in the rectum/mesorectum in patients that had no 
plans for immediate surgery because of: 
 
Synchronous metastasis at presentation. 
Refusal of surgery on completion of CRT. 
Medical comorbidity and therefore unsuitable for aggressive treatment. 
Those with incomplete local tumour excision and subsequent CRT. 
 
8.3.2 Treatment 
All patients had received preoperative treatment with radiotherapy prior to entry into the 
study.  The majority of patients received neo-adjuvant chemotherapy in combination with 
radiotherapy. The majority of patients received radiation therapy at a dose of at least 50Gy 
to the primary rectal tumour in two phases: 1. Pelvis: 45 Gy in 25 fractions at 1.8Gy per 
fraction. 2. Boost: 5.4-9 Gy in 3-5 fractions at 1.8 Gy per fraction (the smaller dose was 
administered if there was concern about the volume of small bowel included in the boost 
field). Patients with co-morbidities received a radiation dose of at least 45Gy with or 
without concomitant chemotherapy. The date of completion of radiotherapy was recorded 
in relation to the MRI scan timing. Any patient with MRI defined node positive disease at 
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baseline was offered adjuvant 5FU based combination chemotherapy upon entering the 
deferral study. 
 
8.3.3 Surveillance schedule 
Both groups were followed according to protocol as detailed in table 8.1.  
 
Patients in both groups were considered for surgery if there was evidence of tumour growth 
or regrowth on surveillance. If the patient was unsuitable/refused surgery then further 
palliative treatment was offered. 
 
The following imaging characteristics were documented for all baseline and surveillance 
MRIs: ymrT substage, ymrN stage, mrTRG, potential resection margin status. 
 
At the time of each surveillance MRI scan, disease status based on clinical and T2 imaging 
findings was recorded as residual tumour or absence of tumour. 
 
MRI based TRG (mrTRG) was used to assess imaging. As described in chapter 4, the entire 
tumour was assessed to determine whether fibrous signal intensity or tumour signal 
intensity predominated, mrTRG was graded as described in table 1.6.  
 
Radiological complete response or near complete response was defined mrTRG 1/2. 
Incremental radiological was defined as the regression grade improving to TRG 1/2.  
Tumour regrowth/residual tumour was defined as persistent or new intermediate signal 
intensity either at the site of the treated tumour or as tumour deposits within mesorectum.   
 
8.3.4 MRI Imaging technique  
MRI scans were performed using either of two 1·5-T whole-body MR image systems made 
by Phillips and Siemens.  The scan parameters and sequences are detailed in section 3.2. 
 
Diffusion weighted scans were performed as an additional investigation when patients 
consented into either of the deferral of surgery studies. Therefore scans with diffusion 
weighted imaging were undertaken at variable time points following completion of 
preoperative radiotherapy depending on time of entry into the study.  
 
All MR images were analysed separately by two experienced radiologists (GB and DMK) 
with 15 and 13 years of experience in gastrointestinal MR imaging, respectively. Both 
radiologists were blinded to biopsy results and clinical examination findings.  
 
 
 
 
 
 
  166 
8.3.5 MRI Diffusion weighted imaging analysis 
The T2 axial image slice best showing the tumour or treated tumour was used as a reference 
to select a region of interest (ROI) on an equivalent single slice of the ADC map. The ADC 
map slice, with ROI outlined upon it was imported into Diffusion View™ software to 
generate mean ADC values for each ROI.   
 
8.3.6 Surgical and Pathology assessment 
Biopsies were performed if there was either clinical or radiological suspicion of recurrence. 
Biopsy samples were centrally reviewed for the presence of tumour cells by an experienced 
gastrointestinal pathologist (AW with 15 years experience). Tumour status was recorded at 
the time of biopsy during the course of surveillance.  
 
For patients with tumour regrowth, surgery was performed by standard TME plane surgery 
or extended TME (TME beyond the planes of the mesorectal fascia) with or without 
sphincter preservation.  
 
After surgical resection, the radial cut surface of the surgical specimen was inked, the 
unopened specimen fixed in formalin for a minimum of 48 hours and sectioned into 3-5 
mm slices. The entire area rectum containing the treated tumour was embedded with 
multiple step sections taken.  Tumour was staged according to the Royal College of 
Pathologists Guidelines (TNM version 5) (Sobin 1997).  A clear circumferential resection 
margin (pCRM) was defined as greater than, or equal to, 1 mm between the tumour and the 
inked radial margins. An experienced gastrointestinal pathologist (AW) evaluated 
specimens for the post treatment T and N stage and circumferential margin status.  
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Table 8.1. Trial surveillance protocol 
 
Time from CRT 
completion. 
Clinical exam 
including DRE* 
CEA** Imaging Endoscopy 
4 weeks Y Y MRI  
8 weeks Y Y MRI, PET  
12 weeks Y Y MRI Flexible 
Sigmoidoscopy 
16 weeks Y Y MRI, PET  
6 months Y Y MRI Flexible 
Sigmoidoscopy 
9 months Y Y MRI Flexible 
Sigmoidoscopy 
1 year Y  Y  MRI,PET,CT Colonoscopy 
15 months Y Y   
18 months Y Y MRI Flexible 
Sigmoidoscopy 
21 months Y  Y    
2 years Y Y MRI,CT Flexible 
Sigmoidoscopy 
2.5 years Y Y   
3 years Y Y MRI,CT Flexible 
Sigmoidoscopy 
3.5 years Y  Y    
4 years Y  Y  MRI Flexible 
Sigmoidoscopy 
4.5 years Y Y   
5 years  Y Y MRI Colonoscopy 
6 years Y Y MRI Flexible 
Sigmoidoscopy 
7 years Y Y MRI Flexible 
Sigmoidoscopy 
8 years Y Y MRI  
9 years Y Y MRI  
10 years Y Y MRI Colonoscopy 
*= Digital rectal examination. 
**= Carcinoembryonic antigen. 
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8.4 Statistics 
The ADC data generated from each ROI was categorised into one of two groups (tumour 
present/ tumour absent), based on biopsy results nearest to time of MRI scan and T2 
weighted imaging findings on MRI scan. Linear mixed effects modelling was used to 
investigate if there was a significant difference in ADC values between scans coded as 
showing complete response vs. tumour (Linstrom and Bates 1989).  
 
The mixed effects model employed ADC values as the dependant variable. Independent 
variables were: the patient (classified as a random factor), time (a numeric variable) and 
presence or absence of tumour. The ADC values were regressed as a factor of time, with 
presence or absence of tumour regressed as the independent variable. 
 
Each radiologist‟s data was analysed separately.   
 
Receiver operating curve (ROC) analysis was used to define the mean ADC cut-off value in 
discriminating the tumour group from complete response group and to investigate the level 
of agreement between the two observers. 
 
The Lowess smooth curve of best fit is presented in the figures showing Time of scan 
/Number of days post CRT completion on x axis and ADC value on the y axis. Lowess 
stands for Locally weighted scatterplot smoother. The curve is placed by multiple ―local‖ 
regressions. This approach ensures the subset of observations which lie closest to a given 
evaluation point along the x axis of a graph  have more influence on the placement of the 
local regression line than observations that fall farther away from that local (Jacoby 2000). 
 
P values of less than 0.05 were considered significant. 
All statistical analysis was undertaken using STATA 10 software (StataCorp. 2007. Stata 
Statistical Software: Release 10. College Station, TX: StataCorp LP).  
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8.5 Results 
8.5.1 Patients 
The demographic, baseline and post treatment imaging characteristics are summarised in 
table 8.2. A total of 26 patients were enrolled into the formal deferral of surgery trial and a 
further 15 in the alternate deferral study, 26 of 41 patients were recruited between 2009 and 
2011.  
 
The mean interval between CRT completion and 1
st
 MRI post CRT completion was 40.09 
days (SD 22.29, range 20-146 days).  The mean length of follow-up post CRT completion 
was 686.42 days (SD 20.6, range 2.2-105 months). 
 
At 6 weeks following completion of chemoradiotherapy, there were 16 patients with 
mrTRG 3 or 4, 8 patients showed regression on the subsequent MRI scan and a further 3 
patients showed regression on later scans. Therefore, 11 patients showed incremental 
mrTRG response to CRT on MRI (table 8.2 & figure 8.1). The mean interval between CRT 
completion and complete response (mrTRG1/2) in this group was 81.00 days (SD 52 range 
24-181) with 9 patients in this group showing continued response beyond the conventional 
6 weeks post CRT completion.  
 
Thirty-six patients were monitored after radiological and clinical complete response (initial 
and incremental response) in the alternative and deferral of surgery studies, 10 of these 
patients subsequently showed regrowth of disease. Table 8.3 details the MRI findings at the 
time of regrowth and pathology for each patient.  Eight patients had intramural/submucosal 
tumour regrowth on MRI during the surveillance period. One patient had extramural 
relapse within the mesorectum, which was detected on MRI but not palpable on digital 
rectal examination or visible on sigmoidoscopy. In one case where MRI findings were 
negative for tumour regrowth and recurrent disease was detected clinically. The mean time 
to regrowth was 446.2 days post CRT completion (SD 271.21 range 103-1104 days). 
Figures 8.2 and 8.3 show examples of tumour regrowth. 
 
Five patients in the alternative deferral study had continued follow up with residual tumour 
seen on MRI and were followed for evidence of progressive tumour growth. Three of these 
patients eventually underwent surgery, 2 remained medically unfit to undergo surgery 
despite tumour growth and continued to be followed up.   
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Table 8.2. Baseline, pre-treatment, post treatment and tumour characteristics of 41 patients 
undergoing deferral of surgery following chemoradiotherapy for rectal cancer 
  No (%) 
Age (years) <65 20 (48%) 
 ≥65 21 (51%) 
Sex Male 25 (61%) 
 Female 16 (39%) 
Tumour height ≤ 5cm 36 (88%) 
 > 5cm -10cm 5 (12%) 
 ≥10cm 0 
Adjuvant  
chemotherapy 
 24 (59%) 
5FU/Capecitabine 5 
5FU/Capecitabine+Oxaliplatin 16 
5FU/Capecitabine+Irinotecan 1 
Other 2 
None 17 (41%) 
Deferral of 
surgery trial 
 26 (63%) 
Alternative 
Deferral of 
surgery 
 15 (37%) 
Refused surgery 3 
Medical comorbidity precluding 
radical treatment  
5 
Metastatic disease  3 
Incomplete local excision  4 
  MRI 
baseline 
1
st
 MRI 
post CRT  
2
nd
 MRI 
post CRT  
MRI T stage ymrT0 0 20 31 
 ymrT1 1 4 2 
 ymrT2 9 7 5 
 ymrT3a 5 3 1 
 ymrT3b 11 5 2 
 ymrT3c 8 2 0 
 ymrT3d 4 0 0 
 ymrT4 3 0 0 
MR N stage N0 20 38 40 
 N1/N2 21 3 1 
mrCRM 
involved  
No 15 36 40 
Yes 26 5 1 
mrTRG 1 0 13 16 
 2 0 12 17 
 3 0 14 8*  
 4 0 2 0 
 5 0 0 0 
*3/8 patients with mrTRG3 showed continued response on subsequent MRI scans.   
5/8 patients with mrTRG3 were followed up according to protocol with residual tumour. 
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Table 8.3. Characteristics of 10 patients that relapsed during surveillance 
 
Patient Days 
post 
CRT  
Site of regrowth 
on T2 MRI  
Pathology 
   ypT ypN pCRM 
1 103 Intraluminal/ 
submucosal 
2 0 Negative 
2 232 Submucosal  
 
Medically unfit for surgery. 
3 308 Extramural 
deposit 
3* 0 Negative 
4 330 Intraluminal/ 
submucosal 
2 0 Negative 
5 398 Submucosal  
 
2 0 Negative 
6 414 Intraluminal/ 
submucosal 
2 0 Negative 
7 462 Intraluminal on 
clinical biopsy 
only 
3 0 Negative 
8 503 Submucosal  2 0 Negative 
9 608 Submucosal  
 
2 0 Negative 
10 1104 Submucosal  Medically unfit for surgery. 
*Focus of discontinuous tumour <3mm classified in accordance with TNM version 5 as T3 
rather than N1  
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Figure 8.1. Incremental response to CRT during follow-up 
 
 
 
A: Axial T2 weighted MRI scan 23 days post CRT completion. 
Intermediate signal compatible with tumour (arrow) is noted at the 5‗o‘clock position 
extending extramurally.   
B: Corresponding axial slice of ADC map. Region of interest is outlined.  
ADC= 1.1 X10
-3
/mm
2
/sec. 
C: Axial T2 weighted MRI scan 99 days post CRT completion. 
Extramural area of low signal compatible with fibrosis; mrTRG 2 (arrow) is noted at the 5 
‗o‘clock position. 
D:   Corresponding axial slice of ADC map. Region of interest is outlined.  
ADC= 1.3 X10
-3
/mm
2
/sec. 
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Figure 8.2. Extramural relapse during surveillance 
 
 
A: Axial T2 weighted MRI scan at baseline.  
Intermediate signal within 3 lymph nodes within the mesorectum (arrow) compatible with 
tumour involvement.   
B: Axial T2 weighted MRI scan 154 days post CRT completion. 
One remaining lymph node shows homogenous signal intensity and appears benign 
(arrow).   
C: Axial T2 weighted MRI scan 308 days post CRT completion. 
The previously noted benign lymph node now appears more suspicious with  heterogeneous 
signal (arrow). 
D: Corresponding axial slice of ADC map. Region of interest is outlined.  
ADC= 0.9 X10
-3
/mm
2
/sec. 
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Figure 8.3. Subtle submucosal regrowth during follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Axial T2 weighted MRI scan at baseline.  
Intermediate signal tumour is noted anteriorly between 9 „o‟ clock and 1 „o‟ clock, 
extending extramurally at the 11 „o‟clock position (arrow)   
B: Axial T2 weighted MRI scan 522 days post CRT completion. 
Murally based low signal between the 9„o‟clock and 12„o‟clock position compatible with 
fibrosis (arrow).   
C: Corresponding axial slice of ADC map. Region of interest is outlined. ADC= 1.5 X10
-
3
/mm
2
/sec. 
D: Axial T2 weighted MRI scan 608 days post CRT completion. 
The previously noted mural fibrosis appears similar, with slightly more intermediate signal 
observed (arrow).  
E: Corresponding axial slice of ADC map. Region of interest is outlined. ADC= 1.1 X10
-
3
/mm
2
/sec.    biopsy was undertaken which confirmed submucosal tumour regrowth. 
A 
B C 
D E 
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8.5.2 ADC results 
Both readers evaluated 223 scans from 41 patients in both deferral and alternative deferral 
studies. Sixteen scans from 3 patients were not evaluable due to hip replacement artefact.  
Overall, there were 152 scans coded as complete response and 55 scans coded as tumour.  
 
Using linear mixed effects modelling, a significant difference was found between ADC 
values from those in complete response and those with tumour (Table 8.4). For reader 1 
those in complete response had an ADC value of 1.513 X10
-3
/mm
2
/sec (95% CI 1.404-
1.623) compared to tumour 1.09X10
-3
/mm
2
/sec 95% CI (95% CI 0.976-1.222) in those with 
residual tumour p=0.0001. Similar significant results were seen for reader 2.   
 
Raw ADC data for reader 1 are shown in Table 8.5. Figures 8.4  and 8.5 show serial ADC 
results for patients initially in complete response, ADC results for those initially showing 
incremental response are shown in Figure 8.6, with  patients followed up with tumour 
throughout shown in Figure 8.7. The Lowess smooth curve of best fit is presented in 
relevant figures.  
 
Table 8.4. ADC results 
Reader 1. 
 Number of scans Mean ADC 
X10
-3
/mm
2
/sec 
95% CI p= 
Complete response 152 1.51   (1.40-1.62)  
Tumour 55 1.01   (0.98-1.22) 0.001 
Reader 2. 
 Number of scans Mean ADC 
X10
-3
/mm
2
/sec 
 p= 
Complete response 152 1.47  (1.40-1.55)  
Residual tumour 55 1.10  (1.01-1.19) 0.001 
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Table 8.5  Raw ADC data for reader 1, n=38 
 
Patient and description 
4 
weeks 
8  
weeks 
12  
weeks 
16 
weeks 
6 
months 
9 
months 
1  
yr 
15 
months 
18 
months 
21 
months 
2  
yrs 
2.5 
yrs 
3 
yrs 
3.5  
yrs 
4 
yrs 
4.5 
yrs 
5 
yrs 
6 
yrs 
>7 
yrs 
1 Complete Rx    1.45 1.70 1.44              
2 Complete Rx 1.54  1.42 1.73 1.77 1.28 1.70  1.73  1.21         
3 Complete Rx  1.46   1.33 2.11 1.56 1.64 1.66  1.23 1.85  1.56 1.57     
4 Complete Rx 1.46  1.29    1.52             
5 Complete Rx 1.18  1.33  1.58 1.69 1.38 1.25 1.46  1.92 1.40        
6 Complete Rx    1.17 1.54 1.40 1.69             
7 Complete Rx     1.37 1.94 1.37 1.59 1.31 1.27          
8 Complete Rx                1.43 1.46 1.57 1.39 
9 Complete Rx 1.80  1.81  1.33               
10 Complete Rx         1.76 1.86 1.65 1.64 1.56 1.68 2.04   1.81  
11 Complete Rx            1.28 1.50       
12 Complete Rx      1.65 1.72 1.23 1.66 1.37   1.21 1.39 1.65 1.23    
13 Complete Rx          1.37  1.35        
14 Complete Rx   1.78  1.75               
15 Complete Rx       1.26             
16 Complete Rx     1.47 1.50 1.86             
17 Complete Rx 1.90  1.82 1.84 2.07 1.54 1.47 1.31 1.82           
18 Complete Rx     1.23 1.46              
19 CR->regrowth 1.19  1.19 1.19 1.62 1.22 0.99             
20 CR->regrowth      1.25    0.94          
21 CR->regrowth         1.52 1.14 1.56         
22 CR->regrowth  1.26 1.28 1.59 1.74 1.56 1.40 0.94            
23 Inc. Rx 1.14  1.37 1.26 1.31 1.35 1.21   1.45 1.55         
24 Inc. Rx 0.82 0.62  1.79 1.88 1.85 2.11 1.37  1.33 1.88         
25 Inc. Rx          1.07 1.52 1.45 1.68 1.41 1.55 1.62    
26 Inc. Rx   1.61 1.28 1.61 1.58 1.40 1.42  1.63  1.32        
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Units= 10
3
/mm
2
/sec 
Highlighted= Scans coded as tumour. 
Patient and description 
4 
weeks 
8  
weeks 
12  
weeks 
16 
weeks 
6 
months 
9 
months 
1  
yr 
15 
months 
18 
months 
21 
months 
2  
yrs 
2.5 
yrs 
3 
yrs 
3.5  
yrs 
4 
yrs 
4.5 
yrs 
5 
yrs 
6 
yrs 
>7 
yrs 
                     
27 Inc. Rx 1.27 1.31 1.34 1.54 1.41  1.28 1.38            
28 Inc. Rx 0.82 1.45 1.61 1.51 1.41               
29 
Inc. Rx-
>regrowth 1.01 0.97 1.55 1.58 1.57      1.40 1.44 1.30       
30 
Inc. Rx-
>regrowth        1.03            
31 
Inc. Rx-
>regrowth 1.26  1.29   1.42 1.24 1.20 1.08 1.23          
32 
Inc. Rx-
>regrowth 1.56 1.24  0.88 0.78               
33 
Inc. Rx-
>regrowth 1.20 1.27 1.45 1.81 1.55  1.81 1.48 1.29           
34 Tumour    0.77  0.86 1.07 1.23  1.18 1.50 0.91 0.96        
35 Tumour  1.01 0.44 1.34 1.19 1.33 1.18              
36 Tumour  1.19 1.16 1.24   1.08 1.50 1.08             
37 Tumour  1.26  1.11                 
38 Tumour    1.16 1.35 1.13 1.03 1.08 1.13 1.00 0.75          
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Figures 8.4-8.7. Serial ADC measurements for reader 1, n=38 
 
Key: 
Each coloured line represents an individual patient. 
Red dots= Tumour regrowth. 
Solid red line=Lowess line of best fit 
Dotted black line= Threshold value, ADC= 1.3 X10
-3
/mm
2
/sec.  
 
Figures 8.4 & 8.5. Serial mean ADC measurements in 22 patients with clinical and T2 
MRI complete response initially 
4 patients subsequently had tumour regrowth (black star=1 patient had ADC imaging only at time 
of relapse).  
 
Figure 8.4. 
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Figure 8.5. 
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Figures 8.6. Serial mean ADC measurements in 11 patients with clinical and T2 MRI 
incremental response 
5 patients subsequently had tumour regrowth.  
5 patients had incremental response on T2 imaging but DWI was not carried out at the time. 
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Figure 8.7. Serial mean ADC measurements in 5 patients with clinical and T2 MRI of 
residual tumour throughout the trial 
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8.5.3 Receiver operating characteristic analysis 
A Receiver operating characteristic (ROC) curve was calculated using mean ADC values of 
patients with biopsy confirmed complete response and mean values of patients with 
residual/tumour regrowth. Figure 8.8 shows each reader‘s ROC curve. The area under 
reader 1‘s ROC curve was 95% and reader 2 was 92%. There was no significant difference 
between the two observers ROC curves using the De Long method (DeLong, DeLong et al. 
1988) (p=0.27). 
 
The ADC cut-off calculated from both readers data was 1.281 X10
-3
/mm
2
/sec with 86% 
sensitivity and 87% specificity for tumour presence. Table 8.6 details the accuracy of 
different ADC cut-offs. Of the 152 scans undertaken in patients with sustained complete 
response, 28 scan measurements showed ADC values of less than 1.3X10
-3
/mm
2
/sec 
despite the absence of any residual tumour.  On the other hand, of the 55 scan 
measurements in patients with subsequent biopsy confirmed tumour, ADC values greater 
than 1.3X10
-3
/mm
2
/sec  were observed in 6/55 scans.  
 
Table 8.6. Sensitivity and Specificity for tumour at different ADC pixel values 
ADC pixel value 95% 
CI X10
-3
/mm
2
/sec 
Sensitivity % Specificity % 
1.50   100 0 
1.42 94  65 
1.33  92 77 
1.28  86 87 
1.23  72 91 
1.19   64 95 
1.15   59 96 
1.11  49 97 
1.00  38 98 
0.97   26 99 
0.76  0 100 
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Figure 8.8. ROC curve used to evaluate optimum cut-off between complete response 
and residual/ regrowth of tumour 
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8.6 Discussion 
This analysis has shown that in a patient group being carefully monitored by a combination 
of serial MR imaging, clinical assessment and biopsy, ADC monitoring can provide useful 
additional information that can potentially detect patients with tumour regrowth.  
 
An ADC measurement cut-off of 1.3 X10
-3
/mm
2
/sec gave the optimum sensitivity and 
specificity for detection of tumour, with values of <1.3X10
-3
/mm
2
/sec giving an 86% 
sensitivity for tumour regrowth.  The less than 100% sensitivity and specificity is due to 
inherent fluctuation in ADC values in patients with sustained complete response.  For 
example 18% (28/152) of the scans undertaken in patients with sustained complete 
response showed ADC values of less than 1.3X10
-3
/mm
2
/sec despite the absence of any 
residual tumour.  On the other hand in 11% (6/55) of scans in patients with biopsy 
confirmed tumour regrowth ADC values were above the proposed cut off of 1.3X10
-
3
/mm
2
/sec.  Therefore a consistently elevated ADC value is of reassurance in the context of 
serial monitoring but an ADC value of <1.3X10
-3
/mm
2
/sec should alert the clinical team to 
the possibility of tumour regrowth and consider a biopsy of the lesion.  
 
This study also demonstrates that both mrTRG and ADC values continue to change long 
after completion of radiotherapy. If we had only entered patients that were in definite initial 
complete response, 27% (11/41) patients would not have been enrolled. Therefore our data 
supports the hypothesis that complete response can occur at a variable time period 
following completion of chemoradiotherapy and therefore early biopsy is not helpful in 
predicting eventual complete response (Evans, Tait et al. 2011).  
 
One of the limitations of this study is the variable treatment given and time taken to refer 
the patient to our institution for follow-up. This reflects the inherent delays between 
completion of preoperative therapy and seeking an opinion as an alternative to surgery.  
Furthermore, not all referring centres in this study employed diffusion weighted imaging in 
their initial tumour assessment.  
 
In this study T2-weighted high resolution images were used to identify the site of tumour 
and to guide the placement of region of interest on ADC images, diffusion weighted 
imaging and high resolution T2-weighted scans were not directly compared. However, 
since diffusion weighted imaging is a non anatomical technique it does not permit 
assessment of T and N stage.  Therefore we cannot recommend this DWI to replace 
anatomic staging methods.  The two independent observers in this study used T2 weighted 
imaging to guide ROI placement on ADC maps and achieved similar performance for area 
under ROC curves. Therefore this technique appears reproducible. 
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8.7  Conclusions 
Patients eligible for deferral of surgery approach can be identified using the mrTRG 
grading system. Using incremental mrTRG response as selection criteria enables many 
more patients, who would otherwise have missed the opportunity to avoid surgery, to be 
identified.  This study presents encouraging results using the combination of imaging, 
clinical assessment and biopsy in detecting regrowth. It has been shown that the early 
identification of patients who may have tumour regrowth could be assisted by utilising 
ADC values to alert the clinical team and undertake biopsy accordingly.  
 
Based on the results; in patients with an apparent radiological and clinical complete 
response an ADC measurement of 1.3 X10
-3
/mm
2
/sec or less should prompt a biopsy of the 
region of interest since this was associated with tumour regrowth in 86% of cases. 
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9 Overall discussion 
9.1 Study endpoints 
Many studies referenced in this thesis have focused on the identification of complete 
pathological response (Maretto, Pomerri et al. 2007; Curvo-Semedo, Lambregts et al. 
2011). However, looking only for pCR may underestimate the benefit of treatments as it is 
also clear from chapter 6 that patients with a good response that falls short of pathological 
complete response also have equally good survival outcomes. Pathological pCR maybe a 
controversial endpoint as sampling between studies is not undertaken using a standardised 
protocol.  Therefore this thesis has focused on distinguishing good and poor response rather 
than identifying complete pathological response and also used survival as an endpoint in 
Chapter 5. 
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9.2 Post treatment MRI TRG, T stage, N stage and CRM assessment 
Several approaches to accurately restage residual tumour/fibrosis post CRT  have been 
investigated by this thesis. The background review had shown that the definitions of 
residual tumour, treatment response and treatment effects showed promise, but needed 
further characterisation.  Furthermore, the accuracy of any proposed refined system of T, N 
and CRM assessment had not been assessed against pathology or survival endpoints in a 
multicentre multireader setting. The accuracy of post chemoradiation MRI tumour 
regression system had not been assessed against histopathological or survival endpoints or 
compared against the existing standard of T staging.  
 
9.2.1 Observational findings 
In chapter 4 pathological slides were matched to post treatment MRI images, this confirmed 
several  proposals:  low signal on T2 MRI represents fibrosis, intermediate signal- tumour, 
high signal with intermediate components-mucinous tumour and uniform high signal 
mucinous response.  This observational data characterising fibrosis has subsequently been 
supported by Franklin et al (Franklin, Anderson et al. 2012).  In this retrospective analysis 
of 168 patients treated with neoadjuvant chemoradiation 20 patients had complete 
pathological response. Seven/twenty had no visible tumour on post treatment MRI, in 11 
patients the tumour was replaced by a region of at least 50% low signal on MRI, 8/20 
having >80% low signal, and 3 with 100% low signal.  
 
Degrees of treatment response and residual tumour form the basis of the MRI tumour 
regression grading system, while relation of residual tumour to the bowel wall and CRM 
enable MRI T staging and potential CRM involvement assessment respectively. Nodal 
assessment criteria based on MRI signal heterogeneity and border characteristics had 
already been proposed by Koh et al (Koh, Chau et al. 2008).  
 
9.2.2 mrTRG and ymrT assessment 
9.2.2.1 mrTRG 
mrTRG showed good diagnostic accuracy against T stage pathology in ROC analysis 
conducted in chapters 4, 5 and 7, with the area under the curve in these analyses 0.85, 0.82 
and 0.84 respectively.  Kappa agreement between post MRI T stage and T stage pathology 
in chapters 4 and 5 was fair. Likewise ROC analysis showed a fair degree of diagnostic 
accuracy of post treatment MRI T stage and pathological TRG. When post-treatment T 
stage was broadly grouped into favourable and unfavourable categories, a significant 
relationship was observed using logistic regression analysis.     
 
Overall, mrTRG showed a good, but not excellent, diagnostic accuracy against pathology. 
However, in Chapter 6 when MRI parameters were evaluated against survival; MR 
assessment of TRG predicted survival outcomes for good and poor responders before 
definitive surgery.  Furthermore, mrTRG remained significant in multivariate analysis 
against pathological measures.  
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The reason for mrTRG‘s strong relationship with outcome measures but good relationship 
with pathological endpoints maybe due to pathological sampling. Chetty et al have recently 
suggested sampling as a source of inconsistency in pathological TRG assessment, with the 
authors‘ proposing a cumulative regression score, taking into account all sections from the 
tumour bed, to accurately reflect treatment response (Chetty, Gill et al. 2012). Improving 
pathological sampling may improve radiological-pathological correlation given MR images 
the entire tumour volume. 
 
As discussed in section 1.2.6, difficulties also arise in interpretation and coding of 
pathological appearances particularly with regard to distinguishing extra mural vascular 
invasion from nodal and tumour deposits.  Although all trials in this thesis used TNM 5 
criteria to ensure standardisation, how an extramural nodule should be coded is uncertain 
and may be a source of discrepancy between pathology and survival endpoints.  
 
9.2.2.2 ymrT 
ymrT was not significantly associated with survival outcomes, In chapter 6, more cases 
were assessed as favourable by mrTRG but unfavourable by ymrT and this is likely to have 
made the difference in survival outcomes.  The possible reason for this is small foci of 
extramural tumour within larger areas of fibrosis being assessed as unfavourable by ymrT 
but favourable by mrTRG.  
 
A recent 2012 retrospective study by Nougaret et al investigated the relationship between 
MRI parameters and survival outcomes. This study (n=58) grouped ymrT 0-T3b as 
favourable (n=38) and ymrT3c-4 as unfavourable (n=20). On univariate analysis favourable 
ymrT was associated with improved disease free survival; hazard ratio 5.2 (95% CI 1.60-
11.61); p=0.038, this was not a significant factor on multivariate analysis (Nougaret, 
Rouanet et al. 2012).  Regrouping the MERCURY ymrT data using this classification 
(Appendix 1), shows no significance for outcome measures. These differences may be due 
to the MERCURY ymrT analysis taking place prospectively by each local centres 
radiologist while the Nougaret analysis was retrospective with two central reviewers.  
 
9.2.3 MRI Nodal status and CRM assessment 
Chapter 4 also showed post treatment MRI‘s ability to identify  node negative disease and a 
potentially clear CRM was high, however ability to predict involved nodes and potentially 
involved CRM was lower at 60% and 49% respectively. In chapter 6, a significant 
relationship between MRI nodal status with overall and disease free survival was seen on 
multivariate analysis with hazard ratios of 1.89 and 2.09 respectively. However the lower 
limits of the confidence intervals were 1.006 and 1.06 respectively. Therefore nodal status 
maybe less important as high quality TME surgery removes mesorectal nodes.  
 
Despite MRI showing a relatively low ability to predict a potentially involved CRM post 
CRT in chapter 4, ymrCRM independently predicted local recurrence on multivariate 
analysis in chapter 6.  Nougaret et al reported similar results, with the 49 patients with a 
predicted clear CRM on MRI post CRT  showing improved disease free survival compared 
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to the 9 patients with potentially involved CRM on MRI post treatment [HR 3.9 (95% CI 
1.79-17.56); p=0.003] (Nougaret, Rouanet et al. 2012).  The discrepancy between poor post 
treatment MRI CRM prediction versus pathology but ymrCRM being a significant survival 
factor may again be due to inadequate pathological sampling techniques leading to false 
negative pathological CRM. Future studies matching pathological tumour cell density with 
MRI images may improve interpretation.  
 
9.2.4 Summary 
Across the analysis presented in this thesis mrTRG has shown a good diagnostic accuracy 
verses pathology and is a significant survival parameter. Grouping post treatment T stage 
was significantly associated with pathology but not survival. Overall, as a result of this 
work it is recommended that mrTRG, ymrCRM, ymrT and ymrN parameters are evaluated 
by multivariate analysis in prospective multicentre trials using survival outcomes.  In the 
meantime it is recommended that mrTRG, ymrCRM as well as ymrT are evaluated by 
experienced radiologists in a multidisciplinary team format.  
 
While awaiting further studies mapping MRI fibrosis at resection margins with pathology, 
it is recommended that fibrosis at the potential CRM on MRI, using the criteria defined in 
this thesis, should be fully resected. 
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9.3 MRI volume and length response assessment methods 
As well as ymrT and mrTRG, rectal cancer volume and length reduction post treatment 
have been proposed to assess response. Prior to this thesis there had been no studies 
comparing the diagnostic accuracy of post chemoradiation volume reduction post treatment 
and modified RECIST length measurement with more established techniques such as T 
staging or other proposed approaches such as MRI tumour regression grading. 
For the analysis undertaken in Chapter 5, a single slice method previously described by 
Torkzad and Dresden et al (Torkzad, Lindholm et al. 2007; Dresen, Beets et al. 2009) was 
used to assess tumour volume.   Tumours showing a reduction in length and volume 
assessment were more likely to have a favourable pathological outcome compared to 
tumours showing a lesser reduction/stability. However when MRI length data was assessed 
according to favourable and unfavourable pathological groups, the two distributions 
showed considerable overlap. A similar pattern was also seen for MRI volume data.  
While this thesis was being undertaken, several  groups have published data correlating 
tumour volume change using workstation based techniques against both pathology and 
survival outcomes (tables 9.1 and 9.2).  
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Table 9.1. Studies Correlating workstation calculated tumour volume change against pathology 
 
Authors, 
Patient Number, 
Recruitment 
Dates 
Pathology results.  
 
(Absolute numbers of 
patients). 
Volume vs. pathology results. 
(Yeo, Kim et al. 
2009).    
 
n=405  
 
May 2002-Dec 
2007 
 
 
 
pCR=58 
ypT0–2 =189 
ypT3-4 =216 
 
pTRG3-4=120 
pTRG1-2=285 
Classifications; 
ypT0-T2 vs. ypT3-T4,  
Good regression (TRG 3-4 vs. TRG 1-2),  
Complete regression (TRG 4 vs. TRG 1-3). 
 
Tumour volume reduction ratio (TVRR ) of >60% 
(n=140), was significantly associated with 
favourable ypT0-T2; (p=0.009). 
 
TVRR  of >80% (n=42) was significantly 
associated with favourable pTRG3-4; (p=0.002). 
A tumour volume reduction ratio   >80% (n=25) 
correlated with pathological complete response  
(p = 0.002). 
(Kang, Kim et 
al. 2010).  
 
n=84  
 
May 2002-Dec 
2007  
 
 
pCR=16  
ypT0=18 ,  ypT1=2, 
ypT2=15,  ypT3= 45  
ypT4=4 
 
pTRG1=18,pTRG2=29  
pTRG3=15,pTRG4= 20 
pTRG5= 2 
TVRR>75%  (n=12), correlated with pathological 
complete response (p = 0.01), but not favourable 
ypT or pTRG response.  
(Sun, Zhang et 
al. 2010). 
 
n=37 
 
Dec  2005- Nov 
2008 
 
The end point was tumour 
downstaging; defined as 
pathological T stage lower 
than initial MRI T stage  
 
Downstaged = 17 
Nondownstaged = 20 
The absolute tumour volume in the downstaged 
group was significantly lower than that in the 
nondownstaged group- Presurgery volumes 2.77 
Vs. 6.94 cm
3
 ;(p= 0.022). 
 
The mean percentage rate of tumour volume 
reduction was not significantly different in the 
two groups; (p = 0.276). 
(Lambrecht, 
Vandecaveye et 
al. 2012).  
 
n=20  
 
Recruitment 
dates not stated 
 
 
 
 
 
pCR=6 
ypT0–2 =11 
ypT3-4 =9 
 
TVRR between baseline and mid CRT correlated 
significantly with pathological complete response; 
(p=0.015) and ypT0–2 stage; (p=0.0039),  
 
TVRR of >45% allowed for a prediction of pCR 
with a sensitivity of 83%, a specificity of 71%. 
(Absolute figures not given). 
  
Volume reduction between baseline and CRT 
completion correlated  significantly with 
pathological complete response only (p=0.012). A 
cutoff value of >77%, yielded a sensitivity of 
83%, a specificity of 86%.  
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Table 9.2. Studies Correlating workstation calculated tumour volume change against survival 
 
Authors, 
Patient Number, 
Recruitment 
Dates 
Pathology & Survival 
absolute number of 
patients  
 
 
Volume vs. survival results 
(Nougaret, 
Rouanet et al. 
2012).   
 
n=58 
 
May 2004-May 
2008 
 
ypT0=9,   ypT1/2 =25,  
ypT3 =21,  ypT4 =3 
 
pTRG1=21, pTRG2=13, 
pTRG3=15, pTRG4=9 
 
Mean follow-up 52 
months +/- 20. 
Metastatic disease at 
diagnosis; n=5, lost to 
follow-up; n=2.  
 
Therefore n=51; 
16/51 had local recurrence 
after a median 20 months 
+/- 10.  
Significantly improved disease free survival in 
those with a tumour volume reduction of at least 
70% (n=30/51) vs. those with a TVRR of less 
than 70% (n=21/51) [HR 13.7: 95% CI 3.98-
31.93; (p <0.0001)]. Absolute survival rates not 
given. 
 
TVRR of at least 70% (n=25/58)  was found to be 
significantly associated with good histologic 
regression grade (pTRG3/4); (p <0.0001). 
Correlation against ypt data not stated. 
 
Unclear why number of patients with TVRR of at 
least 70% is 30 for the survival results and 25 for 
the pathology results. 
(Yeo, Kim et al. 
2012). 
 
n=340  
 
May 2002-
March 2008*  
 
ypT0=68, ypTis= 6  
ypT1 =21, ypT2 =112  
ypT3 =208,  ypT4 =15  
 
At 5 years; disease 
recurrence developed in 
99 patients after a median 
18 months (range, 3–77 
months), 55 patients died 
Multivariate analysis results; 
 
Disease free survival was significantly better in 
patients with TVRR ratio of ≥45% (n = 62) than 
in those with total volume reduction ratio of 
<45% (n = 37; p < 0.001). 
 
Overall survival was also significantly better in 
patients with TVRR ≥45% (n = 34) than in those 
with TVRR <45% (n = 21; p < 0.001) 
*Retrospective analysis using some of the same patients as the 2009 study. 
 
Overall workstation based studies have several limitations; firstly no prospective, 
multicentre study has directly compared workstation volume measurement with RECIST 
and other MRI assessment approaches. Secondly the use of a workstation has not been 
proven superior to a single slice based technique. Thirdly some studies enrolled a high 
proportion of T3/4 tumours that at baseline had a relatively low volume. This may affect 
the generalisability of the results into clinical practice. For example in Yeo et al‘s study 
204/408 patients  had a baseline tumour volume of <14cm
3
, while in the chapter 3 dataset, 
baseline tumour volume was 58cm
3
 (Yeo, Kim et al. 2012). Finally, as table 9.1 and 9.2 
show, a variety of cut off values of volume reduction have been proposed by different 
authors.  
  
Given the additional time consumed in manually tracing tumour volumes on workstation 
and varying cut-off values proposed in the literature it is suggested a multivariate analysis 
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is carried out comparing volume with other parameters. Given the level of reproducibility 
of MRI RECIST observed in this thesis, this method of assessment is best used in a trial 
setting with an experienced single central reviewer.  
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9.4 Tumour response for rectal cancer treated with chemotherapy 
MRI‘s ability to identify good and poor responders to chemotherapy, using 
histopathological reference standards, had not been tested at the beginning of this thesis. 
 
In chapter 7 a prospective comparison was undertaken of mrTRG and ymrT and MRI 
RECIST measurements to determine which of these modalities best predicted final 
histopathology following preoperative chemotherapy and which was the most reproducible 
parameter.  ROC analysis showed mrTRG had a good diagnostic accuracy for pathological 
TRG, while ymrT‘s accuracy was fair.   The results are similar to chapters 4&5. No 
association between pathological TRG and MRI RECIST measurement was found.  
This analysis also showed mrTRG to have a moderate level of reproducibility at 0.41 
between the 7 reading radiologists, this is lower than demonstrated in chapter 4 (mrTRG 
κ=0.55). ymrT was less also reproducible in this analysis at 0.25, lower than demonstrated 
in chapter 4 (ymrT κ=0.41). The reasons for the lower level of reproducibility maybe due to 
the relatively small number of patients in this study as well as 4 of the readers not being 
specialist GI radiologists.   
This is the first study to show that ‗intermediate risk‘ rectal tumours can respond to 
chemotherapy alone, and radiotherapy can be selectively used in those with progressive 
disease on MRI.  MRI ymrT and mrTRG can be used to predict pathological response in 
this setting. This approach can be analysed further in phase II trials with MRI defined high 
risk patients and phase III trials with MRI defined intermediate risk patients.   
For example BACCHUS (Bevacizumab and Combination Chemotherapy in Rectal Cancer 
until Surgery) is a randomised phase II study investigating the efficacy, toxicity and 
feasibility of two different chemotherapy regimes in patients with resectable rectal cancer 
where preoperative MRI suggests adverse features such as EMVI, but the CRM is not 
threatened. Radiotherapy is not planned unless the patient has  progressed on restaging  
MRI (Glynne-Jones, Anyamene et al. 2012).  Given the degree of MRI monitored 
downstaging observed in the present study with intermediate risk patients, a future trial by 
the GEMCAD group aims to investigate the efficacy of neoadjuvant chemotherapy in MRI 
defined high risk patients, this study will be the first to use mrTRG to restage, with 
selective use of radiotherapy in those with MRI poor response (figure 9.1). If the efficacy 
and safety of this approach is proven, there will a substantial change in the treatment of 
rectal cancer patients.  
  - 195 - 
Figure 9.1. Neoadjuvant chemotherapy for MRI defined high risk rectal cancer 
 
 
This thesis has shown that rectal tumours can respond to chemotherapy alone, and 
radiotherapy can be selectively used in those with progressive disease on MRI.  The safety 
of this approach can be assessed in phase III trials with MRI defined intermediate risk 
patients. Neoadjuvant chemotherapy‘s ability to provide disease control in MRI defined 
high risk patients can also evaluated in future phase II trials. It is recommended that 
mrTRG, ymrCRM as well as ymrT are evaluated by experienced radiologists in these future 
studies.  
High Risk MRI defined as: 
•Any T3  with CRM +ve 
•T3c  
•T4 operable 
CT/RT 
FOLFOX6 + 
Aflibercept 
 
 
R 
E 
S 
T 
A 
G 
I
N 
G 
 
M
R
I 
 
 
mrTRG 
shows  
good 
response 
and 
CRM-VE 
 
 mrTRG 
shows poor 
response  
and/or 
CRM+VE 
and/or N2 
Surgery 
1º End Point:  Pathological Complete Response. 
2º End Points: mrTRG, % Patients spared radiotherapy, 3 and 5 year Local recurrence, 
toxicity, 3yr disease free survival. 
  
  - 196 - 
9.5 The role of MRI in patients deferring surgery following good 
response to chemoradiation 
 
9.5.1 Clinical considerations 
To date the criteria used to identify patients for entry into a possible deferral of surgery 
program has largely been based on clinical and biopsy assessment at an unspecified time 
after completion of chemoradiotherapy (Habr-Gama, Perez et al. 2004). The role of 
imaging in identifying and monitoring patients had not been explored at the inception of 
this thesis. Futhermore, although diffusion weighted imaging indices appear to change 
during treatment, (Dzik-Jurasz, Domenig et al. 2002) , there had not been any investigation 
of the role for diffusion weighed imaging in surveillance. 
 
The Royal Marsden Hospital deferral of surgery study uses imaging to guide eligibility. 
Given good correlation with pathology, survival and high reproducibility in other analysis, 
mrTRG is used for eligibility assessment. Eligibility is assessed by serial post CRT 
imaging, with those showing incremental tumour response considered. Those with nodal 
disease are also eligible. These criteria enabled 41 patients to be recruited between 2006-
2011; with 11/41 patients showing continued response 6-8 weeks post CRT completion.  
 
Results from a Dutch deferral of surgery cohort have recently been published.  The 
inclusion criteria for this trial included: 1) Substantial tumour downsizing with no residual 
tumour or with fibrosis only on restaging MRI performed 6 to 8 weeks after CRT, 2) No 
suspicious nodes on post CRT MRI, 3) No residual tumour at endoscopy with negative 
biopsies, and 4) No palpable tumour at digital rectal examination when palpable at primary 
presentation. The eligibility criteria for this study are narrower than the Royal Marsden 
Study and has led to a lower rate of patient recruitment, with 21 patients enrolled between 
2004-2010. 
 
The follow up schedules between the cohort enrolled in this thesis and the Dutch study also 
vary, with more frequent use of clinical examination, CEA and MRI for The Royal 
Marsden  group, particularly in the first two years when 90% (9/10 cases) of tumour 
regrowth in was observed.   
 
Due to relatively wide criteria 10 patients showed tumour regrowth in The Royal Marsden 
Group, while 1 patient has relapsed in the Dutch cohort. One patient in The Royal Marsden 
Group had extramural relapse within the mesorectum which was not palpable/visible on 
digital rectal examination or sigmoidoscopy. This pattern of relapse has not been previously 
described and emphasises the importance of combining imaging with clinical surveillance 
in deferral of surgery patients. 
 
The data presented in this thesis is part of an ongoing trial evaluating the safety and 
efficacy of a deferral strategy in patients who are not necessarily in complete response at 
time of recruitment.  The safety and efficacy of this approach will only be known when the 
results of long-term follow-up are available.   When the initial phase II trial of the study is 
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complete, a logical future Phase III trial could investigate eligibility criteria for deferral of 
surgery; patients could be randomised between clinical assessment and selection based on 
negative biopsy versus imaging assessment of mrTRG1-2 and serial imaging. Potential 
endpoints could be overall stoma free survival and the number of patient successfully 
deferred at 3, 5 and 10 years. 
 
9.5.2 Diffusion weighted imaging 
In the chapter 8 analysis, the mean ADC value of scans coded as complete response during 
surveillance was significantly higher than scans showing residual/recurrent tumour. An 
ADC threshold of <1.3 X10
-3
/mm
2
/sec give a high sensitivity and specificity for tumour 
detection.  Several groups have recently published investigations into how rectal cancer 
ADC values change during chemoradiation. These are summarised in table 9.3. 
The data from Sun and Barbaro et al is supportive of the observations of this thesis, with 
favourable pathological responders showing higher mean ADC values/ greater mean 
percentage increase in ADC values than nonresponders (Sun, Zhang et al. 2010; Barbaro, 
Vitale et al. 2012).  The proposed ADC cutoffs presented by Barbaro and Kim et al, in 
cohorts of patients not deferring surgery, are surprisingly consistent and supportive of the 
ADC cut off value of 1.3 X10
-3
/mm
2
/sec proposed in this thesis especially considering the 
differences in parameters and technique used (Kim, Lee et al. 2009; Barbaro, Vitale et al. 
2012).  
However, caution is advised in using pretreatment ADC values/ increases in ADC during 
CRT / applying an ADC threshold to a one-off post treatment MRI scan for the selection of 
patients for surveillance. Instead, as up to 27% of enrolled patients in Chapter 8, show an 
evolving response beyond the conventional 6-8 week window, it is proposed that tumour 
response is monitored, and patient eligibility for deferral of surgery is assessed by serial 
post CRT imaging.  Employing serial monitoring is likely to enable a substantially greater 
rate of recruitment of initially advanced cancers. 
Combining DWI data with mrTRG T2 weighted imaging is likely to be useful in 
determining eligibility for deferral of surgery as  recent studies have shown improvement in 
the ability of radiologists to select pathological complete responders compared with 
standard T2 weighted MRI only (Kim, Lee et al. 2009; Lambregts, Vandecaveye et al. 
2011). This question could not be assessed in this thesis as most referring centres did not 
use diffusion weighted imaging sequences and is a topic for future investigation. 
As shown in chapter 8, fluctuations in ADC values occur during surveillance, it is therefore 
recommended that an ADC value of <1.3X10-3/mm2/sec should alert the clinical team to 
the possibility of tumour regrowth and biopsy of the lesion is considered. The utility of this 
strategy could be employed in future trials investigating deferral of surgery strategies. 
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Table 9.3. Studies investigating tumour ADC change pre and post chemoradiation 
 
Authors, 
Patient Number, 
Scan timing. 
Pathology 
endpoints. 
Results. 
(Kim, Lee et al. 
2009). 
 
n=40 
 
Imaged at 2 
timepoints 
before and after 
CRT. 
pCR=11 
Non pCR=29 
Mean ADC (1.62 +/-0.36X 10
-3
 mm
2
/s) of the pCR 
group (n=11) was significantly higher than that (1.04 
+/- 0.24X10
-3
 mm
2
/s) of the non-CR group (n=29)  
(p=0 .0001). 
 
A cut off ADC value of 1.2X10
-3
/mm
2
/sec after CRT 
had an accuracy of 85% in distinguishing those with 
pCR vs. non pCR. 
(Sun, Zhang et al. 
2010).  
 
n=37  
 
4 timepoints 
Before CRT,  
At the end of the 
1
st
 & 2
nd
 weeks of 
CRT, after CRT  
The end point was 
downstaging; 
defined as 
pathological T stage 
lower than initial 
MRI T stage.  
 
Downstaged = 17 
Nondownstaged=20 
At the end of the 1st week of CRT, the mean tumour 
ADC increased significantly in the downstaged group 
vs. the nondownstaged group  (mean ADC, 1.32X10
-3
 
mm
2
/s  vs. 1.22 10
-3
 mm
2
/s; p=0 .001). 
 
At the end of the 2nd week of CRT, a further increase 
in ADCs was seen in both groups. Before surgery, the 
ADC decreased slightly in both groups. The overall 
mean percentage tumour ADC change was 
significantly different between the two groups 
(p=0.001). 
(Barbaro, Vitale 
et al. 2012). 
 
n=62  
 
 
 
 
Imaged at 3 
timepoints 
Before,  
During (10-14 
days after 
initiation) 
After CRT. 
Histopathologic 
downstaging 
and Mandard 
tumour regression 
grade. 
 
pTRG1/pCR=16 
pTRG2=13 
pTRG3=21 
pTRG4=12 
 
Downstaged=37 
Nondownstaged=25 
Low pretreatment ADCs (<1.0 X10
-3
 mm
2
/s) were 
correlated with pTRG4 (p=0.0011), but not 
downstaging. 
During treatment, the mean percentage increase in 
tumour ADC was significantly higher in those 
downstaged vs. those with stable disease (p < 0.0001). 
The mean percentage ADC increase in the pTRG 1 and 
2 groups was significantly greater than the pTRG 3 and 
4 groups (p= 0.011). 
 
The preoperative ADC was significantly different (p= 
0.0012) between the downstaged group vs. the 
nondownstaged group. A cutoff value of  1.4X10
-3
 
mm
2
/s had a PPV of 79%, a NPV of 62%, and an 
accuracy for response assessment of 68% 
(Lambrecht, 
Vandecaveye et 
al. 2012).  
 
n=20  
 
pCR=6 
 
ypT0–2 =11 
ypT3-4 =9 
 
T downstaging=12 
Nondownstaged=8 
The mean tumour ADC value before treatment was 
significantly lower in patients with pCR vs. no pCR 
(0.94 +/- 0.12 X10
-3
 mm
2
/s and 1.19 +/- 0.22 X 10
-3
 
mm
2
/s, p = 0.003). 
 
Both during and early after CRT a significantly higher 
ADC change was found in patients with pCR compared 
with non pCR patients.  
No significant correlation between ADC and 
pathological T0-T2 or T downstaging. 
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10 Final Conclusions 
This thesis has characterised the imaging appearances of post treatment response and 
residual tumour and validated different MRI assessment methods of response evaluation 
against histopathology and survival outcomes.  From the work presented in this thesis the 
following conclusions can be made; 
 
By matching MRI with pathology slides, pathological fibrosis correlates with low signal on 
MRI and tumour corresponds to intermediate signal. mrTRG was a significant factor in 
overall and disease free survival but in three different datasets mrTRG showed a good, but 
not excellent, diagnostic accuracy for pathological endpoints. This discrepancy maybe due 
to difficulties in accurate pathological sampling and coding.  
 
ymrT showed only a fair level of diagnostic accuracy against pathology, which improved 
with grouping of ymrT into favourable and unfavourable categories, but was not a 
significant factor in survival. 
 
Negative ymrN and potentially clear ymrCRM correlated with negative ypN and negative 
pCRM respectively.  Despite the fair level of agreement between a potentially involved 
margin on MRI and a pathologically involved margin, post chemoradiation MRI CRM was 
an important outcome measure.  Post treatment nodal status was a borderline outcome 
measure. 
 
Length and volume assessment showed less significant correlation with pathology than 
other parameters. However, recent studies have shown tumour volume reduction and ymrT 
to be a significant outcome measures.  
 
Serial MRI based monitoring using diffusion weighted imaging was useful in detecting 
tumour recurrence in patients enrolled into a deferral of surgery trial.  The performance and 
reproducibility  of mrTRG, ymrT, CRM assessment as well as length and volume 
assessment maybe improved by combination with qualitative/quantitative diffusion 
weighted imaging data. 
 
mrTRG and ymrCRM appear to be the most important parameters to evaluate in post 
treatment MRI imaging.  Grouped post treatment T stage may also be useful. Slice by slice 
workstation tumour volume calculation using workstations is time consuming and should 
be compared against other approaches.  Potential improvement in interpretation using 
diffusion weighted imaging can also be investigated in further studies. 
 
Post chemoradiation MRI has an important role in patient management, as assessing 
treatment response prior to surgery gives the multidisciplinary team an opportunity to tailor 
treatment. mrTRG and ymrCRM could be linked with clinical practice by the following 
approach; Patients with mrTRG1/2 and ymrCRM negative, may be offered inclusion into a 
surveillance programme as presented in chapter 8. Intermediate patients (mrTRG3 and 
ymrCRM negative) could proceed to TME plane surgery. Individuals with a potentially 
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involved CRM post treatment and/or more advanced mrTRG grades would be eligible for 
further chemotherapy or exenteration surgery.   
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12 Appendix 1  Regrouping of MERCURY survival data 
Re-Grouping of chapter 6, MERCURY data, with ymrT 0-T3b considered favourable and 
ymrT3c-T4 considered unfavourable as per Nougaret et al (Nougaret, Rouanet et al. 2012). 
Twelve cases were recoded. 
 
No significant difference between favourable and unfavourable ymrT groups by overall 
survival, p=0.63 (figure 1), disease free survival p=0.1 or local recurrence p=0.9. Log rank 
test used. 
 
Figure 1. Recoded ymrT and overall survival 
 
 
 
 
 
